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ABSTRACT 
Respiratory syncytial virus (RSV) is the leading cause of respiratory illness in 
children worldwide.  RSV has a negative sense RNA genome, which is the 
template for viral mRNA transcription and genome replication, and encodes a 
polymerase to carry out viral RNA synthesis.  The promoters for RSV 
transcription and genome replication are found in a 44-nucleotide (nt), 3´-
extragenic region called the leader (Le).  Replication is initiated opposite the first 
nt of the Le, and transcription of the first gene begins at position +45, at a gene 
start (GS) sequence.  However, transcription is also dependent on sequence 
within Le1-12.  Interestingly, Le nucleotides 3-12 bear strong similarity to a GS 
signal.  We hypothesized that this GS-like sequence is the recruitment site for 
transcribing polymerase.  To test this hypothesis, we examined RNA synthesis 
events at the Le promoter.  We identified a previously undescribed RNA initiation 
   x 
site at Le position +3 (Le+3) that was used frequently during RSV infection.  
Initiation at Le+3 led to the production of a small ~25 nt RNA.  Le+3 initiation was 
shown to occur independently of replication initiation at +1, indicating it is a bona 
fide initiation site.  Mutation of Le1-12 to increase similarity to a GS resulted in 
elongation of Le+3 RNA and a decrease in transcription initiation at the GS, 
demonstrating that the Le initiation sequence alters polymerase processivity and 
impacts downstream transcription events.  Preliminary experiments to determine 
the function of the small RNA showed that it increased levels of viral RNA 
replication, suggesting it may be involved in influencing a switch from 
transcription to replication.  These studies suggest a model for RSV transcription 
initiation, whereby the transcribing polymerase enters at the 3´-end of the 
genome, initiates RNA synthesis from Le+3 and generates a small RNA, and is 
then positioned to initiate transcription at the first GS.  The small RNA that is 
generated may act as a feedback molecule to promote RNA replication.  These 
findings provide a greater understanding of polymerase behavior at the promoter 
and may inform rational drug and vaccine design. 
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 1 
Introduction 
 
Respiratory syncytial virus 
 
History 
Respiratory syncytial virus (RSV) was first isolated in 1955 from a chimpanzee at 
the Walter Reed Army Institute of Research during an outbreak in the 
chimpanzee colony (14; 27).  The virus was initially called chimpanzee coryza 
agent, as it produced a cluster of symptoms including sneezing, coughing, and 
mucopurulent nasal discharge, collectively referred to as “coryza”.  The virus was 
later identified in cases of infantile croup, pneumonia and bronchiolitis, and 
serological evidence for RSV proved the virus was common within the pediatric 
population (26; 28).   
 
Clinical significance and Epidemiology 
RSV is now recognized as the leading cause of severe respiratory illness in 
infants and children worldwide, and is increasingly recognized as a significant 
pathogen in the elderly and immunocompromised (52; 58; 93).  Yearly epidemics 
of RSV occur over 4-5 months during winter and spring, and RSV is highly 
contagious and easily spread by contact.  Between 50 and 70 percent of infants 
become infected with RSV during their first year of life, and almost all children 
are infected with RSV by two years of age (76; 101; 121).  Re-infection is 
 2 
frequent during the first few years of life (76).  Mortality due to RSV is low, 
however RSV represents a significant public health burden.  An estimated 2 to 4 
million children receive outpatient treatment, while between 57,000 and 113,000 
children are hospitalized for RSV each year in the United States (95; 140).  Risk 
factors for RSV infection include increased exposure in a community setting such 
as daycare, having siblings younger than 5 years old, low titers of maternal 
antibodies, premature birth, lung and heart conditions, exposure to cigarette 
smoke, and asthma (9; 45; 68; 83; 157; 165).  In addition, hospital-acquired RSV 
infection is a significant cause of RSV spread in pediatric units (89).   
 
In adults, the yearly reinfection rate for RSV is 5-10%, and up to 50% for adults 
with increased exposure, such as healthcare and daycare workers, and parents 
of small children (56-58).  In adults over 65 years of age, RSV causes an 
estimated 17,358 deaths per year in the U.S. (246).  RSV is also a significant 
cause of morbidity in patients with T-cell deficiencies and cystic fibrosis (3; 92; 
102; 176; 268). 
 
Immunopathology 
At the beginning of the infection, RSV replicates in the nasopharynx.  The virus 
has a tropism for airway and lung tissues and has been shown to preferentially 
infect ciliated cells (252; 272; 279).  RSV is not thought to cause persistent 
infection.  Primary RSV infection causes a range of symptoms including 
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rhinorhea, otitis media, fever, pneumonia and bronchiolitis, and in rare and very 
severe cases, death.  Subsequent re-infections tend to be much less severe, 
suggesting that a protective immune response comes into play.  RSV is not as 
cytopathic or invasive as influenza virus, but does cause increased shedding of 
airway cells, which leads to obstruction of bronchioles and alveoli (272; 279).  
CD4+ T cells and CD8+ T cells have both been shown to be important for viral 
clearance (77).  However, the immune response to RSV may be skewed towards 
a Th2 CD4+ T cell bias leading to airway hyper-reactivity, wheezing, and 
prolonged effects on lung function (8; 129; 215).  The humoral response to 
infection is characterized by serum and secretory antibodies to the viral fusion (F) 
and major attachment (G) glycoproteins, which are the only virus neutralization 
antigens, and titer of RSV-specific antibodies appears to correlate with protection 
from re-infection (39; 264; 265).   
 
In addition to the cellular and humoral immune response to RSV, surfactants 
have been shown to be an important early barrier to infection (5; 75; 145).  RSV 
also triggers activation of toll-like receptors (TLRs) and retinoic acid-inducible 
gene 1 (RIG-I), leading to the production of a wide range of cytokines (123; 134; 
153; 177; 217; 218; 277).  Neutrophils are recruited to the lung following infection 
and comprise the largest population of immune cells in the airway.  Neutrophils 
play a role in viral clearance, though probably at the cost of exacerbation of 
disease symptoms (55; 155; 166).  Macrophages are important to viral clearance 
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and phagocytic uptake of cellular debris and may be the primary producers of 
type I interferon (IFN) (130; 206).  However, RSV is adept at blocking the IFN 
response, in addition to inhibiting apoptosis, TNF-α and NFκB signaling, PKR 
activation and stress granule formation (70; 85; 90; 91; 96; 164; 237). 
 
Challenges to mounting an effective immune response to RSV include 
immunological immaturity in the pediatric population, and immune senescence 
and waning titers of RSV-neutralizing antibodies in the elderly population (1; 42; 
59; 94; 146; 171; 197; 225). 
 
Therapeutics and Vaccines 
Currently there are no vaccines or therapeutics approved for use against RSV.  
Ribavirin has been indicated in severe cases, but despite established antiviral 
activity against RSV in tissue culture and animal models, clinical efficacy remains 
unproven (105; 213).  Additionally, ribavirin is difficult to administer and produces 
adverse side effects, and is therefore not recommended for routine use (235).  A 
humanized monoclonal F-specific antibody prophylactic, palivizumab 
(SynagisTM), exists for use in preterm, and high-risk infants with congenital heart 
and lung defects.  Licensed in 1998, palivizumab is administered intramuscularly, 
once monthly throughout the duration of RSV season (60).  Although effective, 
palivizumab does not prevent disease, but restricts viral replication to a level that 
is manageable, and has been shown to reduce hospitalizations between 45- and 
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55-percent (86; 226).  However, the cost is prohibitive and access to monthly 
doses of palivizumab in developing countries is limited (205).  
 
Vaccine development for RSV has historically encountered many difficulties.  A 
formalin-inactivated vaccine tested in the 1960’s resulted in severe exacerbation 
of disease symptoms in vaccinees due to an unusual phenomenon called 
immunopotentiation (119; 207).  Vaccination resulted in poor induction of a 
neutralizing antibody response; the antibodies produced were not to antigenic 
epitopes (180).  However antibody-antigen complexes were still made that 
activated complement and biased a Th2 response.  This led to poor stimulation 
of natural killer cells and CD8+ T cells, which help to down regulate inflammation 
and the Th2 response upon infection with RSV (108; 191; 230; 233).  
Additionally, the process of formalin fixation generates carbonyl groups, which 
have been shown to enhance the Th2 response.  After natural infection with 
RSV, eighty percent of the trial participants were hospitalized for severe 
bronchiolitis and asthma-like symptoms and two children died (207).  
Consequently, vaccine development for RSV has proceeded slowly and with 
much caution.  However, there are several candidate vaccines entering clinical 
trials that are based on live-attenuated strains of RSV, which do not induce 
immunopotentiation (120; 273; 274).  Their efficacy remains to be seen, as none 
has yet been approved for use. 
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Several small molecule inhibitors of RSV proteins have undergone clinical trials 
including chemical compounds targeting the F and G proteins, nasally-
administered small interfering RNA (siRNAs) targeting the viral nucleoprotein (N), 
and many more compounds are being developed (50; 54; 152; 192; 224).  
Currently, there is a lot of interest in inhibitors of the RSV polymerase complex.  
The polymerase is responsible for all viral RNA synthesis and is unique from 
cellular proteins, making it an ideal target for antiviral therapeutics.  However, the 
polymerase is very large and complex, and relatively little is known about its 
function.  A greater understanding of the molecular mechanisms of RSV 
polymerase activity is important for the development of polymerase inhibitors and 
may inform rational drug design. 
 
Overview of the RSV replication cycle (Figure 3) 
Virion structure 
RSV virions are pleomorphic and consist of a mix of spherical particles, 100- 350 
nanometers (nm) in diameter, and filaments, 20- 200 nm in diameter, which can 
be up to 10 µm in length (23; 184).  The cell-derived lipid envelope is studded 
with three viral surface glycoproteins, the G protein, the F protein, and the small 
hydrophobic protein (SH).  The matrix protein (M) forms a layer on the inner side 
of the virion envelope and mediates assembly of viral components at the plasma 
membrane.  Viral RNA is packaged within the virion as a nucleocapsid.  N protein 
assembly on the genome creates a flexible, filamentous nucleocapsid structure 
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with a characteristic “herringbone” pattern (12).  The polymerase components, L, 
P and the transcription processivity factor M2-1, are associated with the 
nucleocapsid-bound RNA (Figure 1). 
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Figure 1; RSV virion structure.  Illustration of the RSV proteins that comprise 
the virion and nucleocapsid structures.  Virions have a host-derived lipid 
envelope, studded with three glycoproteins.  The ssRNA genome is 
encapsidated in N protein assembled as a helical filament, and associated with 
the RSV polymerase complex. 
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Cellular entry  
The receptor for RSV has not been satisfactorily identified, though several 
candidates have been suggested including intracellular adhesion molecule 
(ICAM)-I, RhoA, the CX3CR1 fractalkine receptor, annexin II, and nucleolin (7; 
158; 195; 242; 251).  Both G and F are also able to bind cellular 
glycosaminoglycans (GAGs).  After attachment, the F protein mediates fusion at 
the plasma membrane and the viral nucleocapsid is released into the cytoplasm 
where the replication cycle takes place (115; 231). 
 
RNA production and protein expression 
Upon entry into the cytoplasm, RSV forms large, electron-dense inclusion bodies, 
which are thought to be sites of viral replication, composed largely of viral N 
protein (24; 73) (Figure 2).  RSV encodes its own polymerase that carries out 
transcription and replication.  Transcription results in the synthesis of ten capped 
and polyadenylated mRNAs, which encode eleven proteins.  The viral mRNAs 
are translated using the host cell machinery.  RSV mRNAs and proteins can be 
detected 4-6 hours post infection (hpi) and reach peak accumulation around 15-
20 hpi.   
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Figure 2; RSV inclusions.  RSV forms dense cytoplasmic inclusion bodies, 
which are thought to be the sites of viral replication.  Cells were infected with 
RSV fixed 24 hpi, permeabilized, stained for RSV N protein (red), and visualized 
by immunofluorescence microscopy.  Image represents a single slice.  Two 
inclusions are indicated with white arrowheads.   
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Assembly and release 
Assembly of viral particles occurs at the plasma membrane associated with lipid 
rafts (18; 162).  In cell culture, progeny virions can be detected 10-12 hpi, and 
their production peaks around 24 hpi.  They are continually released up to 48 hpi 
or until cell destruction.  Unlike many other RNA viruses that hijack the 
endosomal sorting complexes required for transport (ESCRT) machinery, RSV 
commandeers cellular apical recycling endosomes (AREs) to accomplish 
budding (17; 74; 256).  Actin and profilin are involved throughout the viral life 
cycle, and actin appears to be closely involved in the formation of RSV filaments 
at the plasma membrane (4; 21; 22; 71; 111; 116; 253).  Actin may be packaged 
in the virion along with viral nucleocapsids. 
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Figure 3; Overview of the RSV replication cycle.  (1) Entry into the cell: RSV 
attaches to receptors on the apical cell surface via the F and G glycoproteins and 
enters the cell through fusion at the plasma membrane.  Nucleocapsids are 
released into the cytoplasm.  (2) Transcription: the RSV polymerase transcribes 
the genome into 10 capped and polyadenylated mRNAs.  (3) Replication: the 
polymerase also synthesizes a full-length complement of the genome, the 
antigenome, from which it synthesizes more copies of genome-sense RNA.  (4) 
Protein synthesis: the mRNAs are translated using the host cell translation 
machinery into 11 viral proteins.  Proteins are trafficked to the plasma membrane 
utilizing apical recycling endosomes.  (5) Assembly and release: nucleocapsids 
and proteins are assembled at the apical cell surface at sites enriched for lipid 
rafts.  Progeny virions bud from the plasma membrane. 
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RSV RNA synthesis 
 
Genome structure and organization 
RSV possesses a non-segmented, single stranded, negative sense RNA 
genome, which classifies it in the order Mononegavirales.  Viruses with a similar 
genome structure include the human pathogens Ebola virus (EboV), Marburg 
virus (MarV), Nipah virus (NiV), measles (MeV) and mumps (MuV).  RSV is 
further grouped into the family Paramyxoviridae, subfamily Pneumovirinae.  The 
RSV A2 strain genome is 15,222 bases long and serves as the template for both 
transcription and replication.  The genome encodes ten genes in the order, NS1, 
NS2, N, P, M, SH, F, G, M2, and L, which are separated by intergenic regions of 
varying lengths (38).  The genome is bordered by two non-coding extragenic 
regions, the 3´, 44-nucleotide leader region (Le) and the 5´, 155-nucleotide trailer 
region (Tr), which contain cis-acting sequences involved in transcription and 
replication (36; 172).  (Figure 4) 
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Figure 4; Schematic of the RSV genome.  The negative sense RNA genome of 
RSV is shown at center.  The genome is flanked by a 3´, 44- nt Le region, which 
contains the promoters for transcription and replication (indicated by the orange 
arrow) and a 5´, 155-nt Tr region.  GS signals and GE signals are shaded yellow 
and red, respectively.  The L gene accounts for almost half of the genome coding 
capacity and is therefore interrupted by dashed lines.  The viral mRNAs are 
shown at bottom.  5´-cap represented in purple, polyA tail represented in cyan.  
The positive sense antigenome is shown at top.  The Trailer complement (TrC) 
region contains the promoter for replication (orange arrow). 
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Polymerase components 
RSV encodes an RNA-dependent RNA polymerase, which is responsible for 
carrying out both viral transcription and replication.  The polymerase is composed 
of the large (L) polymerase protein and the phosphoprotein (P) cofactor (161).  
The stoichiometry of this association is still unknown and a crystal structure has 
been elusive, however early EM images indicate that the L-P complex is 
organized as a ring structure with globular appendages, similar to the 
polymerase of a related virus, vesicular stomatitis virus (VSV) (unpublished data, 
and (210)).  Multiple enzymatic domains have been predicted within the L protein 
based on homology to polymerase domains from closely related viruses (203).  
These include domains for RNA polymerization, methyltransferase activity, and 
polyribonucleotidyltransferase activity (mRNA capping), indicating the L protein is 
multifunctional (203).  This is further supported by the massive size of L, which 
accounts for close to half of the RSV genome coding capacity (232).  The P 
protein may mediate the interaction between L and the nucleocapsid (169).  
There is also some evidence that the phosphorylation status of P may influence 
promoter escape (53).  Although L and P represent the minimal polymerase 
complex necessary for RNA synthesis, the M2 ORF1 protein (M2-1) is required 
for fully processive mRNA transcription (34). 
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Transcription 
Transcription of the viral genes relies on a single promoter found at the 3´-end of 
the genome (36; 51).  Saturation mutagenesis of the Le region has shown that 
nucleotides 3, 4, 5, 8, 9, 10, 11, and 12 are critical for transcription, as 
substitution of these nucleotides ablates downstream transcription (64; 163).  
Furthermore, the first eleven nucleotides must be located proximal to the 3´-
terminus for polymerase recruitment to the template (40).  A U-rich region at the 
end of the Le is also important for transcription, as has been shown for VSV (62; 
103; 163).   
 
During transcription, the polymerase is directed by gene start (GS) and gene end 
(GE) signals, which flank each gene at their 3´- and 5´-ends, respectively.  GS 
signals in RSV are highly conserved, 9-nucleotide sequences that direct the 
polymerase to initiate transcription (33; 37; 133).  In VSV, GS signals also direct 
the polymerase to cap the nascent transcript (234).  GE sequences are semi-
conserved 12- or 13- nucleotide sequences, that signal the polymerase to 
terminate and polyadenylate the transcript (97; 132; 249).  Intergenic regions are 
gene junctions that separate the viral genes and vary in length from 1 to 52 
nucleotides (33; 114; 248).  When the polymerase reaches a gene junction and 
terminates the mRNA, it can traverse the intergenic region to find the next GS 
signal and reinitiate transcription, or it can dissociate from the template.  
However, termination can be somewhat inefficient and result in read-through 
 18 
transcription of two or more neighboring genes (38).  Because transcription relies 
on a single promoter in the Le region, transcription is obligatorily sequential.  If 
the polymerase dissociates at a gene junction it must reinitiate transcription at 
the 3´-end of the genome.  This results in a gradient of gene expression such 
that genes located closer to the 3´-end are transcribed more frequently than 
genes located nearer the 5´- end (Figure 5) (30; 38; 98; 128; 131).  The 
arrangement of genes has evolved so that genes for proteins needed in large 
amounts are located at the 3´-end, such as proteins involved in subverting 
cellular antiviral responses, and genes for proteins needed in smaller amounts 
are located near the 5´-end, such as the viral polymerase protein, L (38).   
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Figure 5; RSV transcription results in a gradient of gene expression.  Inset 
shows a close up of two viral genes separated by a gene junction.  Transcription 
is directed by a single promoter at the 3´-end of the Le (orange arrow) and is 
therefore obligatorily sequential.  Polymerases that dissociate from the template 
at the gene junction must reinitiate from the 3´-end of the genome.  This results 
in a gradient of gene expression such that genes located near the 3´-end are 
transcribed more frequently than genes located at the 5´-end. 
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The last two genes, M2 and L, are not separated by an intergenic region, but 
instead overlap, such that the L GS signal precedes the M2 GE signal by 68 
nucleotides (37).  Therefore, it was shown that for the polymerase to initiate at 
the L GS signal, it must scan backward from the M2 GE signal to locate the L GS 
signal and initiate transcription of the L gene (38; 61).  In order to generate full-
length L, the polymerase must readthrough the M2 GE signal (37).  The behavior 
of the polymerase at this unusual overlapping gene junction as well as at the 
intergenic regions provides evidence that the polymerase is capable of scanning, 
similarly to cellular proteins (260). 
 
Genome Replication 
Genome replication (hereafter referred to as replication) is also dependent on the 
promoter sequence found at the 3´-end of the Le region, as well as sequence up 
to the first 34 nucleotides of the Le (36; 163; 182; 183; 239).  Saturation 
mutagenesis of the Le indicated that in addition to the nucleotides shown to be 
critical for transcription, replication was also significantly impacted by mutations 
to nucleotides 1, 2, 6 and 7 (64).  Further, the first 13 nucleotides are sufficient 
for recruiting polymerase and initiating RNA synthesis (40; 163).  There is 
evidence that initiation from position +1 occurs in a primer-mediated fashion 
(185; 187).  Minigenome constructs with substitutions or deletions of the first two 
nucleotides of the Le or trailer complement (TrC) promoters were still able to 
generate wt products, suggesting the 5´-A-C is non-templated (185; 187).  During 
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replication, the polymerase reads through the GS and GE signals in the genome 
and generates a full-length complement called the antigenome, which then 
serves as the template for synthesis of genome sense RNA.  The TrC region at 
the 3´-end of the antigenome is highly similar to the Le region up to the first 26 
nucleotides, indicating that the two replication promoters are conserved. 
 
Both genome and antigenome are concurrently encapsidated by the viral N 
protein as they are synthesized, and do not exist as naked RNA during any part 
of the viral lifecycle.  A single N monomer binds 7 nucleotides, and assembles 
end-to-end with adjacent N monomers to form the helical nucleocapsid (12; 181; 
241).  Soluble N protein is associated with P, which may provide specificity for N 
binding to RSV RNA and bridge the interaction between the polymerase and the 
nucleocapsid (25; 43; 181).  The central region of the Le appears to be required 
for efficient encapsidation, although this sequence has not been mapped 
precisely (163).  Encapsidation is believed to protect the viral genome from 
cellular nucleases, as well as to prevent detection by pattern recognition 
receptors such as RIG-I and melanoma differentiation-associated protein (MDA)-
5.  Moreover, encapsidation has been shown to increase polymerase 
processivity during replication of SeV, suggesting that it may allow the 
polymerase to ignore GS and GE signals during replication (87; 259). 
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Scientific proposal and hypothesis 
As described earlier, both transcription and replication are directed from promoter 
sequences at the 3´-end of the Le, and carried out by the same polymerase 
protein.  The mechanism for how the polymerase is able to initiate either 
transcription or replication is poorly understood.  Elucidating the mechanism of 
transcription initiation by the polymerase would not only represent an 
advancement for molecular biology of the Mononegavirales, but may also have 
implications for therapeutic and vaccine development for RSV.  Since the RSV 
polymerase is responsible for all viral RNA synthesis, a better understanding of 
the behavior of the polymerase at the promoters may inform the rational design 
of novel therapeutics or attenuated vaccines.  Moreover, uncovering the 
mechanism of transcription initiation may illuminate how the polymerase is 
influenced by cis-acting sequences, and explain how the polymerase gains 
access to the encapsidated template and the first GS signal.  Thus, the goal of 
the following studies was to determine the mechanism of transcription initiation 
by the RSV polymerase.  Based on the following lines of evidence, (1) that Le 
sequence 1-12 is sufficient for recruitment of polymerase, and (2) that 
nucleotides within this sequence are critical for transcription, we hypothesize 
that Le nucleotides 1 through 12 contain the initiation site for transcription.   
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This thesis contains two chapters, and an appendix.  Chapter 1 describes work in 
which we identified a previously unrecognized initiation site at position +3 of the 
promoter, and characterized RNA synthesized from this site.  Chapter 2 
describes studies performed to test the model that transcription is initiated from 
position +3 of the Le promoter.  Appendix 1 describes preliminary experiments to 
examine the effect of RNA initiated from the +3 sites of the Le and TrC promoters 
on RSV replication. 
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Materials and Methods 
 
Gel recipes 
 
6% urea-acrylamide: Prepared by dissolving 92 g urea (7M) (Sigma Aldrich) in 25 
ml 10X Tris/Borate/EDTA (TBE) buffer (American Bioanalytical), 30 ml 40% (19:1 
acryl: Bis-acryl) acrylamide (National Diagnostics), and filled to 200 ml in distilled 
H2O (dH2O).  Filter sterilized. 
 
15% urea-acrylamide:  Prepared by dissolving 16.1 g urea (7M) in 3.5 ml 10X 
TBE, 13.125 ml 40% acrylamide (19:1), 7.175 ml dH2O, and syringe-filtered. 
 
20% urea-acrylamide:  Prepared by dissolving 96.6 g urea (7M) in 21 ml 10X 
TBE, 105 ml 40% acrylamide (19:1), 16.8 ml dH2O, and filter-sterilized. 
 
Gel polymerization reagents: For every 100 ml of gel mix, 1.0 ml 10% ammonium 
persulfate (APS) (Sigma Aldrich), and 100 µl 1,2-Bis(dimethylamino)ethane; 
N,N,N’,N’-Tetramethyl-1,2-diaminoethane (TEMED) (Sigma-Aldrich), was added 
and gently swirled, and gels were cast and allowed to polymerize 1-2 hours at 
room temperature. 
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1.5% Agarose-formaldehyde gels (Northern blot analysis): Gels were prepared 
by dissolving 1.5 g agarose (Sigma Aldrich) into 86.4 ml dH2O, then immediately 
adding 10 ml 10X 3-(N-morpholino)propanesulfonic acid (MOPS) buffer 
(American Bioanalytical) and 3.6 ml 36.7% formaldehyde (Sigma Aldrich). 
 
10% SDS gels:  Gels were prepared by mixing 2.87 ml dH2O, 3.75 ml 1 M Tris, 
pH 8.8 (Sigma Aldrich), 100 µl 10% sodium dodecyl sulfate (SDS) solution 
(Fisher Scientific), 3.33 ml 30% (w/v) acrylamide (37.5:1) 0.8% bis-acrylamide 
(National Diagnostics), 50 µl 10% APS, and 10 µl TEMED and cast, ~1 inch from 
the top of the gel plates, and allowed to polymerize.  A 4% stacking gel (7.3 ml 
dH2O, 1.25 ml 1 M Tris, pH 6.8, 100 µl 10% SDS, 1.33 ml 30% acrylamide, 50 µl 
10% APS, 10 µl TEMED) was cast on top of the 10% SDS gel. 
 
Cell culture 
HEp-2 cells (ATCC) were cultured in Opti-MEM Reduced Serum Media 
(Invitrogen) with 2% fetal bovine serum (FBS) (Gibco-Invitrogen), and 1% 
GlutaMAX-I Supplement (Invitrogen).  BSR-T7/5 cells (generously provided by 
the Mühlberger lab) were cultured in Glasgow Minimal Essential Media (GMEM) 
(Invitrogen) with 10% FBS, 1% GlutaMAX-1 Supplement, and 2% 50X MEM-
Amino Acids Solution (Gibco), under Geneticin (G418) (Gibco) selection.  BHK-
21 CCL-10 cells (ATCC) were cultured in GMEM with 8% FBS, 1% GlutaMAX-I 
Supplement, and 5% tryptose phosphate broth (TBP) (Sigma-Aldrich) and 
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Minimum Essential Media (MEM) (Invitrogen) with 2.5% FBS and 1% GlutaMAX-I 
Supplement.  For passaging, cell monolayers were disrupted with 0.25% Trypsin-
EDTA (Gibco-Invitrogen) and split 1:4 (HEp-2), 1:20 (BSR-T7/5), and 1:3 (BHK-
21) twice per week.  Cells were incubated at 37˚C, in 5% CO2. 
 
Plasmids 
Plasmids expressing minigenomes used in this study have all been described 
previously (64; 163; 198).  Non-replicating minigenome constructs included 46G 
(wt Le position 4G), C75Δ (Le substitution at position 4G-C), and 49G (Le 
substitutions at position 4G-C, and 7 U-G).  Replicating minigenome constructs 
used in this study were lacking the first GS sequence, and included DM138 (wt 
Le position 4G) and DM88 (Le substitution 4G-C).  A replicating minigenome 
construct with an intact GS sequence, DM66, was used as a molecular weight 
marker for sizing RNA produced from DM138 and DM88.  Plasmids required for 
minigenome expression were pTM-1 vectors that contained open reading frames 
(ORFs) of the N (HG53), P (HG60), M2-1 (C32.2) and L (pBP31) proteins, 
expressed under the control of a T7 promoter (generously provided by Peter 
Collins, NIH, and described previously- (84)).  The C75Δ plasmid (198) was used 
to synthesize the negative sense CAT riboprobe, CAT(-), and was linearized with 
XbaI (New England Biolabs).  The DM28 plasmid, derived from C75Δ (163), was 
used to synthesize the positive sense CAT riboprobe, CAT (+), and was 
linearized using PstI (New England Biolabs).  The plasmids expressing the small 
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LeC and Tr RNAs were generated by subcloning small RNA expression 
cassettes into plasmid MP28 (198), as described below. 
 
Cloning of small RNA vectors 
Plasmids were constructed to express 25-nt small RNAs corresponding to the 
LeC and Tr small RNAs initiated from position +3, that are natively expressed 
during RSV infection (Table 1).  A scrambled control was also generated based 
on scrambled LeC sequence (Table 1).  Cassettes containing a HindIII restriction 
site, T7 promoter sequence, the small RNA sequence, a hammerhead ribozyme, 
and an RsrII restriction site were generated in two rounds of polymerase chain 
reaction (PCR) using overlapping primers.  PCR reactions contained 5 µl 10X 
Thermopol buffer (New England Biolabs), 1 µl 10 mM dNTP mix (Promega), 1.5 
µl of each primer (100 µM stock, ordered from Invitrogen), 40.5 µl H2O, and 0.5 
µl Vent polymerase (New England Biolabs).  Amplification was performed over 
30 cycles with the following cycler conditions: initialization for 5 minutes at 95˚C, 
denaturation for 30 sec., 95˚C, annealing for 40 sec., between 55-65˚C, 
elongation for 45 sec. at 72˚C, and a final elongation step for 10 minutes, 72˚C.  
Round one PCR products were purified using the QIAQuick Gel Extraction Kit 
(Qiagen), and round two PCR products were purified using the MinElute PCR 
Purification Kit (Qiagen), according to manufacturer’s instructions.  Purified PCR 
products, were double-digested with HindIII (New England Biolabs) and RsrII 
(New England Biolabs) in Buffer 2 (New England Biolabs) for ~12-hours at 37˚C, 
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heat-inactivated for 10 minutes at 65˚C, and PCR purified.  PCR products were 
subcloned into the MP28 vector containing corresponding restriction sites, which 
was also double-digested and gel extracted.  PCR products were ligated with 
digested vector using the Quick Ligation Kit (New England Biolabs), according to 
manufacturer’s instructions.  Controls for specific ligation included ligation 
reactions without PCR product inserts, without the vector, and without ligase.  
Ligation reactions were transformed in MAX Efficiency® DH10B™ Competent 
Cells (Invitrogen) by heat shock at 42˚C, and selected on Lennox LB Broth with 
Agar (Sigma Aldrich) plates containing carbenicillin (100 mg/ml) (Fisher 
Scientific).  Plasmids were extracted and purified from resultant bacterial colonies 
using the QIAprep Spin Miniprep Kit (Qiagen) according to manufacturer’s 
instructions, and sequenced to confirm the proper insert. 
 
Table 1; Sequence of the small RNAs expressed by T7  
Construct Sequence (5´-3´) 
LeC nt 3-27 GCGAAAAAAUGCGUACAACAAACUU 
Tr nt 3-27 GAGAAAAAAAGUGUCAAAAACUAAU 
Scrambled (based on LeC) GGAUGACAACGACAACAUAAAUCUA 
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PAGE purification of DNA and RNA oligonucleotides 
15% urea-acrylamide gels were pre-run in 1X TBE running buffer at 10 Watts (W) 
for 10 minutes.  25 µg of DNA oligonucleotides or 75 µg RNA oligonucleotides 
were mixed 1:1 with stop buffer (1.2 ml 95% deionized formamide (Fisher 
Scientific), 20 mM UltraPure™ 0.5 M EDTA (Invitrogen), 0.1% w/v bromophenol 
blue (Sigma Aldrich), 0.1% w/v xylene cyanol (Sigma Aldrich)), boiled 5 minutes 
at 95˚C, and loaded in 20 µl aliquots in adjacent gel lanes.  Empty lanes were 
loaded with 10 µl of stop buffer and the gel was run at 10-15 W for 30-45 
minutes.  After electrophoresis, the gel was placed on saran wrap, on top of a 
TLC Plastic Sheet Cellulose screen (EMD Bioscience) in relative darkness.  
DNA/ RNA bands were visualized by UV-shadowing using a HPTLC/TLC 
Portable UV Light (EMD Bioscience) and bands of the proper size were excised 
and placed in individual microcentrifuge tubes.  Gel slices were crushed into a 
fine powder using a clean pipette tip, resuspended in 900 µl 0.3M sodium-acetate 
(NaOAc), pH 5.2 (Sigma Aldrich), and rocked overnight at 4˚C.  Samples were 
centrifuged 16.1 X g for 10 minutes at 4˚C, and split equally between two tubes 
and mixed with 8 µl glycogen (5 mg/ml) (Applied Biosystems) and 10 µl 4M NaCl 
(Sigma Aldrich).  1 ml of 100% ethanol was added and samples were vortexed 
for 30 seconds and incubated overnight at -20˚C.  For maximum recovery, the 
pelleted acrylamide from the first centrifugation was resuspended in fresh 0.3 M 
NaOAc and the elution was repeated as described.  *Note: the next step differs 
for DNA and RNA oligonucleotides.  DNA samples were centrifuged 16.1 X g for 
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30 minutes at 4˚C, supernatent was aspirated and the pellet was washed twice in 
1 ml of 70% ethanol, centrifuging 16.1 X g for 5 minutes at 4˚C.  Pellets were 
allowed to air dry briefly and were resuspended in 20 µl diethylpyrocarbonate 
(DEPC)-treated H2O (American Bioanalytical), combining pellets by transferring 
the resuspended material to the subsequent pellet.  RNA samples were 
centrifuged 16.1 X g for 30 minutes at 4˚C, supernatent was aspirated and pellet 
was washed in 70% ethanol, centrifuging 16.1 X g for 5 minutes at 4˚C.  For the 
second wash, two pellets were combined into a single tube (ex. six tubes 
becomes three tubes) and centrifugation was repeated.  For the final wash, all 
remaining pellets were combined (ex. three tubes becomes one tube), 
centrifugation was repeated, and supernatent was aspirated.  Pellet was 
resuspended in 400 µl of 2´-Deprotection Buffer (Dharmacon), vortexed for 10 
seconds, centrifuged for 10 seconds, and incubated for 30 minutes at 60˚C.  
RNA was divided into 100 µl aliquots and dried down using an automatic 
environmental SpeedVac system (Savant, AES1010), 1-hour at 60˚C.  Pellets 
were resuspended in 20 µl DEPC-treated H2O.  DNA and RNA concentrations 
were determined using a Nanodrop 2000 UV-vis Spectrophotometer (Thermo 
Fisher Scientific). 
 
Radiolabeling of oligonucleotides 
End-labeled oligonucleotides: 2 µM DNA oligonucleotides (2 µl of a 10µM stock) 
were mixed in a 10 µl total reaction volume with 1 µl 10X T4-polynucleotide 
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kinase (PNK) buffer (New England Biolabs), 3 µl DEPC-treated H2O, 1µl T4-
polynucleotide kinase (PNK) (New England Biolabs), and 3 µl 32P-γ[ATP] (3000 
Ci/mmol) (Perkin Elmer), and incubated for 20 minutes at 37˚C.  90 µl DEPC-
treated H2O was added to oligonucleotides labeled for primer extension analysis 
(100 µl total volume).  40 µl DEPC-treated H2O was added to oligonucleotides 
labeled for Northern blot analysis, and unincorporated 32P-γ[ATP] was removed 
on a GE Healthcare Illustra MicroSpin G-25 Column (Fisher Scientific) according 
to manufacturer’s instructions.  Labeled oligonucleotides were stored at -20˚C. 
 
Riboprobe synthesis:  Riboprobes were prepared by mixing 2.5 µl 100 mM 
dithiothreitol (DTT) (10 mM) (Sigma Aldrich), 5 µl 10X RNA polymerase buffer 
(New England Biolabs), 1 µl RNase inhibitor (New England Biolabs), 2.5 µl 
ribonucleotide (NTP) stock (2.5 mM ATP, 2.5 mM GTP, 2.5 mM UTP, 0.5 mM 
CTP) (Promega), 4 µl of digested plasmid (CAT+, CAT-, as described under 
“plasmids”), 2 µl T7 RNA polymerase (New England Biolabs), and 10 µl 32P-
α[CTP] (3000 Ci/mmol) (Perkin Elmer), and incubated 1-hour at 37˚C.  Reactions 
were spiked with 1 µl RNase inhibitor and 2 µl RQ1 RNase-free DNase 
(Promega), and incubated 10 minutes at 37˚C.  At the end of the incubation, 1 µl 
0.5M EDTA and 25 µl DEPC-treated H2O were added, and probes were 
extracted once in phenol (Fisher Scientific).  Probes were filtered on pre-
prepared columns constructed in 1-cc syringes (Fisher Scientific), plugged with 
Acros Organics glass wool (Fisher Scientific) and loaded up to 1-ml with G-50 
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Sephadex beads (Fisher Scientific) saturated in Tris-EDTA buffer (TE).  Columns 
were washed twice with TE prior to loading the probes.  The probes were added 
to the columns and fractions were collected in microcentrifuge tubes.  100 µl TE 
was added to the columns for nine subsequent fraction collections.  Fractions five 
through eight were typically assumed to contain labeled probe and were pooled, 
and stored at -20˚C. 
 
Labeling and alkaline hydrolysis of RNA ladder:  RNA template corresponding to 
LeC1-14 sequence was ordered from Dharmacon, and PAGE purified (as 
described in ‘PAGE purification of DNA and RNA oligonucleotides’).  To end-
label the RNA, 5 µl of RNA (100 µM stock) was mixed with 1 µl 10X T4-PNK 
buffer, 3 µl (30µCi) 32P-γ[ATP], and 1 µl T4 PNK, and incubated 20 minutes at 
37˚C.  To hydrolyze the ladder, 10 µl of the labeled RNA was mixed with 0.6 µl 
tRNA (~0.2 µg; 0.4 mg/ml) (Sigma-Aldrich), and 20 µl 1X alkaline hydrolysis 
buffer (Ambion), and the reaction was distributed into 5 µl aliquots.  The aliquots 
were incubated at 90˚C and were terminated at various time points (1, 2, 3, and 5 
minutes) with 10 µl of stop buffer.  Ladders were boiled 5 minutes at 95˚C, and 2 
µl of each ladder was loaded in a 20% urea-acrylamide gel, and migrated for 30 
minutes at 10 W.  Non-hydrolyzed, end-labeled ladder was migrated for 
comparison.  Gel was exposed to film 30-60 minutes at room temperature, and 
the ladder with the most distinct bands was selected for use as a marker in the in 
vitro RNA synthesis assay. 
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Labeling of 10 bp ladder: A 10 bp DNA ladder (Invitrogen) was used for sizing 
primer extension analysis products larger than 100 nt.  The 10 bp ladder consists 
of 33 10-bp repeats and a fragment at 1668 bp.  The ladder was labeled and 
denatured according to the manufacturer’s instructions.  Ladder stock was diluted 
tenfold in TE to a final concentration of 0.1 µg/µl.  On ice, 2-µl ladder was mixed 
with 1 µl 5X exchange reaction buffer (250 mM imidazole (Sigma-Aldrich), pH 
6.4, 60 mM MgCl2, 5 mM β-mercaptoethanol (Sigma-Aldrich), 350 µM adenosine 
diphosphate (ADP) (Sigma Aldrich)), 1 µl 32P-γ[ATP], and 1 µl T4-PNK, and 
incubated 10 minutes at 37 ˚C.  The reaction was terminated by heating for 5 
minutes at 55˚C.  An equal volume (5µl) of stop buffer was added to the labeled 
ladder and incubated for 5 minutes at 70 ˚C.  Ladder was stored at -20˚C. 
 
Virus 
Wildtype (wt) RSV was strain A2 (prepared by Robin Djang) and LeC virus 
(prepared by Laura Dickey) was based on this strain.  Modified vaccinia Ankara 
expressing T7 polymerase (MVA-T7, originally provided by Bernard Moss, NIH) 
is a highly attenuated strain of vaccinia virus which was used to provide T7 
polymerase in trans to drive expression of plasmids during transfections.  MVA-
T7 was propagated in BHK-21 cells, split 1:8 into seven Corning T-150 culture 
flasks (Fisher Scientific).  10 µl MVA-T7 was added to 190 ml MEM, and 30 ml of 
virus was added to each of six flasks (30 ml media without virus was added to 
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one flask for mock infection), and flasks were incubated for 48 hours at 37˚C.  
Cells were harvested 48-hpi by scraping into media, and collected in 50-ml tubes.  
Tubes were centrifuged in a Beckman Allegra X-15R centrifuge (Beckman 
Coulter) 1200X g, for 10 minutes at 4˚C, and supernatent was discarded.  The 
pellets were resuspended in 1 ml MEM and pooled, aliquoted into cryovials 
(Fisher Scientific), and snap-frozen on dry ice and thawed in a 37˚C water bath, 
four times.  Virus was distributed in 150 µl aliquots and stored at -80˚C. 
 
Virus titration and plaque visualization 
HEp-2 cells seeded in 24-well plates were infected at 50-60% confluence.  Serial 
dilutions of virus were prepared in Opti-MEM and a 200-µl inoculum was added 
to the cells.  Virus was allowed to adsorb for 2 hours at 37˚C, and the cells were 
overlaid with 0.8% methylcellulose (4 g methylcellulose (Sigma-Aldrich) 
autoclaved with stir bar, 500 ml Opti-MEM, 2% FBS, 1X Antibiotic-Antimycotic 
(Gibco), stirred at 4˚C for 4 days), and incubated at 37˚C, 4-5 days, until syncytia 
were visible.  Cells were fixed twice with pre-chilled 80% methanol (American 
Bioanalytical) at 4˚C for 1 hour, and overnight.  Cells were washed three times in 
dH2O by submerging in a water bath, and blocked in 5% milk powder (Shaw’s 
Supermarket) prepared in 1X phosphate-buffered saline (PBS) (Sigma Aldrich) 
for 1-hour at room temperature, with gentle shaking.  Cells were incubated with a 
monoclonal mouse antibody specific to RSV F protein (Serotec) diluted 1:200 in 
5% milk solution, 1-hour at room temperature.  Cells were washed three times 
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and incubated with goat-anti mouse immunoglobulin (Ig) G conjugated with 
horseradish peroxidase (HRP) (Abcam) diluted 1:500 in 5% milk solution, 1-hour 
at room temperature.  Cells were washed three times and plaques were 
visualized by the addition of a 1:1 mixture of 4CN (4-chloro-1-napthol) and 
peroxidase substrate solution B (KPL).  Plaques were counted from the highest 
dilution of virus, and titer was calculated using the formula:  plaque forming units 
(PFU)/ ml = [(number of plaques) X (1/ dilution factor)] / (inoculum volume in ml) 
 
Virus infections 
For analysis of total viral RNA, wt RSV stock (titer 2.0 X 107 PFU/ml) was used to 
infect HEp-2 cells 80-90% confluent in T-75 culture flasks, at a multiplicity of 
infection (MOI) of 5 PFU/ml, in a 5 ml inoculum volume.  Virus was allowed to 
adsorb for 1-hour at 37˚C, and the inoculum was aspirated and replaced with 15 
ml fresh media and serum.  Cells were harvested at 17-hpi by scraping into the 
media, cells were centrifuged 3.5 x g for 5 minutes at 4˚C, and the pellet was 
disrupted in TRIzol Reagent (Invitrogen).  TRIzol preparations were stored at -
80˚C until ready to harvest viral RNA (as described in ‘RNA isolation’).  To test 
the effect of overexpression of the small RNAs on RSV transcription and 
replication, wt RSV was used to infect 6-well plates transfected with the small 
RNA expression plasmids as described in ‘Minigenome transfections’, at an MOI 
of 3 PFU/ml, in a 500 µl inoculum volume.  Virus was allowed to adsorb 1-2 
hours at 37˚C, cells were washed with 1X PBS, and 1.5 ml Opti-MEM with 2% 
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FBS was added to the cells.  Cells were harvested 24-hpi and after 
centrifugation, cells were resuspended in 1 ml 1X PBS, and distributed for protein 
and RNA analysis.  200 µl of cell suspension was prepared for protein analysis 
(as described in ‘Western blot analysis’) and 800 µl of cell suspension was mixed 
with 1 ml TRIzol for RNA isolation.  For immunofluorescence analysis of the 
effect of the small RNAs on stress granule formation, transfected cells in 12-well 
plates were infected with LeC virus (titer 3.45 X 106 PFU/ml) at an MOI of ~1 
PFU/ml, in a 200 µl inoculum volume.  Virus was allowed to adsorb 3 hours at 
37˚C, cells were washed in 1X PBS, and 1 ml Opti-MEM with 2% FBS was 
added to the cells.  Cells were fixed at 24- and 48-hpi, as described in 
‘Immunofluorescence analysis. 
 
Fractionation analysis 
Viral RNA was fractionated as previously described (160) with modifications.  
Infections were performed as described in ‘Virus infections’.  At 17 hpi, cells were 
treated with actinomycin D (AcD) (provided as a powder from Sigma; 1 mg 
dissolved in 50 µl DMSO and 950 µl 1X PBS) for 1 hour at 37˚C, followed by an 
ice-cold 1X PBS wash.  Cells were lysed in 5 mL ice-cold 1X PBS and 250 µg L-
α-lysophosphatidylcholine (Sigma-Aldrich) by hand rocking, 1 minute on ice.  
PBS was aspirated and cells were immediately scraped into 400 µl Buffer A (50 
mM Tris-acetate, pH 8.0, 100 mM potassium-acetate, 1 mM DTT*, 2 µg/ml AcD*, 
*DTT, AcD added fresh immediately prior to the start of the experiment) and 
 37 
collected in a microcentrifuge tube.  The solution was disrupted by passaging 20 
times in a 20-gauge needle, and incubated on ice for 10 minutes.  The solution 
was centrifuged 2400X g for 10 minutes at 4˚C to generate fraction one (S1) and 
pellet one (P1).  P1 was resuspended in 200 µl Buffer B (10 mM Tris-acetate, 10 
mM potassium-acetate, 1% Triton™-X100 (Sigma-Aldrich), 1.5 mM MgCl2) and 
disrupted with a 20-gauge needle.  The solution was incubated and centrifuged 
as above to generate S2 and P2.  P2 was resuspended in 300 µl Buffer C (10 
mM Tris-acetate, 10 mM potassium-acetate, 1% Triton™-X100, 1.5 mM MgCl2, 
0.1% Tween-40 (Sigma Aldrich), 0.5% sodium deoxycholate (DOC) (Sigma-
Aldrich)).  100 µl of each fraction was mixed with 1 ml TRIzol and RNA was 
isolated as described in ‘RNA isolation’. 
 
Minigenome transfections 
Lipofectin transfection: Lipofectin Reagent (Invitrogen) was used to transfect 
HEp-2 cells according to the manufacturer’s instructions.  Cells were seeded in 
6-well polystyrene plates and transfected at 60-70% confluence.  Lipofectin (10 
µl/ well) was prepared in Opti-MEM (90 µl/ well, no additives), vortexed, and 
incubated for 30 minutes at room temperature.  Helper plasmid master mix was 
prepared by combining 0.4 µg N, 0.2 µg P, 0.1 µg M2-1, and 0.1 µg codon-
optimized L plasmids, and 8 µl of this master mix was added to 92.5 µl Opti-MEM 
(per well) in a polystyrene tube.  Master mix without L plasmid was also prepared 
for a –L control transfection.  0.2 µg of the appropriate minigenome (per well) 
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was added to each tube containing plasmid master mix.  At the end of the 30-
minute incubation, 100 µl of the lipofectin mix was added to each tube, and tubes 
were vortexed and incubated 15 minutes at room temperature.  MVA-T7 was 
prepared for coinfection to provide T7 polymerase in trans for plasmid RNA 
expression.  MVA-T7 (10 µl/ well) was mixed with Opti-MEM (900 µl/ well), 
vortexed and sonicated for 30 seconds (twice), to disrupt viral aggregates.  900 
µl MVA-T7 was added to each tube containing lipofectin and plasmids.  Tubes 
were vortexed and 1 ml of the final mixture was added to each well.  Plates were 
incubated 6 hours to overnight at 37˚C, and media was replaced with Opti-MEM 
containing 2% FBS and 1% L-glutamine.  Transfections were harvested 48-hours 
post transfection. 
 
Lipofectamine 2000 transfection:  Lipofectamine 2000 (Invitrogen) was used to 
transfect BSR-T7/5 cells according to the manufacturer’s instructions.  For small 
RNA overexpression experiments, BSR-T7/5 cells (300,000 cells/ well) were 
seeded in 6-well plates and transfected at 50-60% confluence.  For each well, 
0.5 µg of the plasmid was added to 150 µl Opti-MEM, and mixed with 108 µl 
Lipofectamine in Opti-MEM (8 µl Lipofectamine/ well, and 100 µl Opti-MEM/ well, 
vortexed and incubated for 5 minutes at room temperature).  DNA/ Lipofectamine 
mix was incubated 20 minutes at room temperature, and 263 µl was added 
dropwise to each well (washed with 1X PBS, and containing 750 µl Opti-MEM).  
For immunofluorescence assays, BSR-T7/5 cells were seeded very low (~20,000 
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cells/ well) in 12-well plates containing glass coverslips, and transfected at 30-
40% confluence.  For each well, 0.5µg of the plasmid was added to 50 µl Opti-
MEM, and mixed with 54 µl Lipofectamine in Opti-MEM (4 µl Lipofectamine/ well, 
and 50µl Opti-MEM/ well, vortexed and incubated for 5 minutes at room 
temperature).  DNA/ Lipofectamine mix was incubated for 20 minutes at room 
temperature, and 108 µl was added dropwise to each well (washed with 1X PBS, 
and containing 500 µl Opti-MEM).  All plates were incubated for a minimum of 6-
hours at 37˚C, and Opti-MEM with 6% FBS was added to all wells (500 µl/ well).   
 
Nuclease protection assay 
Cells were harvested by scraping into media, collected in a 1.5 ml 
microcentrifuge tubes and pelleted 3.5 X g for 5 minutes at 4˚C.  50 ml 
reticulocyte standard buffer (RSB)-100 (10 mM NaCl, 10 mM Tris, pH 7.5 
(Sigma-Aldrich), 1.5 mM MgCl2, 1% Triton™ X-100, 0.5% DOC) was prepared.  
Cell pellets were resuspended in 100 µl total RNA buffer (998 µl RSB-100, 1 µl 
aprotinin (Fisher Scientific), 1 mM CaCl2) or 100 µl nuclease buffer (988 µl RSB-
100, 1 µl aprotinin, 1 mM CaCl2, 1 µg Micrococcal/S1 nuclease (Thermo-Fisher)).  
Total RNA samples were mixed with 1 ml TRIzol, incubated for 5 minutes at 
room temperature, and RNA was extracted.  Nuclease-treated samples were 
incubated in a 30˚C waterbath for 1 hour, vortexing twice to resuspend the pellet.  
Following incubation, 1 ml TRIzol was added to nuclease-treated samples and 
RNA was extracted. 
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RNA isolation 
Cells were harvested by scraping into media, collected in a 1.5 ml 
microcentrifuge tube and pelleted 3.5 X g for 5 minutes at 4˚C.  Supernatent was 
aspirated and cell pellets were resuspended in 1 mL TRIzol, and incubated 5 
minutes at room temperature.  200 µl Chloroform:Isoamyl alcohol (24:1) (Sigma-
Aldrich) was added, tubes were shaken vigorously for 15 seconds and incubated 
3 minutes at room temperature, and centrifuged 12,000 X g for 15 minutes at 
4˚C.  The aqueous phase was transferred to new tube with 500 µl of isopropanol 
(American Bioanalytical), mixed by pipetting, and incubated 10 minutes at room 
temperature.  Tubes were centrifuged 12,000 X g for 10 minutes at 4˚C, and 
supernatent was carefully aspirated.  Pellet was dried briefly, resuspended in 300 
µl DEPC-treated H2O, and incubated 10 minutes at room temperature, with 
frequent vortexing to resuspend the pellet.  33 µl of 2M NaCl-Tris-EDTA (NTE) 
buffer (2M NaCl, 40 mM Tris, pH 7.4, 1 mM EDTA) was added, and tubes were 
vortexed.  330 µl phenol was added and tubes were shaken 15 seconds, and 
centrifuged 7,000 rpm for 3 minutes at 4˚C.  The aqueous phase was transferred 
to a new tube with 330 µl chloroform, shaken 15 seconds, and centrifuged 7,000-
rpm for 3 minutes at room temperature.  The aqueous phase was transferred to a 
new tube with 700 µL 100% ethanol, mixed by inverting five to six times, and 
stored at -80˚C overnight.  To precipitate RNA, tubes were centrifuged 16.1 X g 
for 20 minutes at 4˚C, and supernatent was carefully aspirated.  The pellet was 
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washed in 200 µL 70% ethanol, centrifuged 16.1 X g for 10 minutes at room 
temperature, and supernatent was carefully aspirated.  The pellet was 
resuspended in 30-50 µl DEPC-treated H2O, and RNA was snap-frozen on dry 
ice and stored at -80˚C. 
 
Exonuclease digestion 
RNA was digested with Terminator™ 5´-Phosphate-Dependent Exonuclease 
(Epicentre Biotechnologies) according to the manufacturer’s instructions.  
Terminator Exonuclease is a 5´ to 3´exonuclease that specifically digests RNA 
containing a 5´-monophosphate.  5 µl of RNA was incubated with 11.5 µl DEPC-
treated H2O, 0.5 µl RNase Inhibitor, 2µl 10X Reaction buffer A (Epicentre 
Biotechnologies), and 1 µl (1 unit) Terminator Exonuclease, in a 30 µl total 
reaction volume, for 1 hour at 30˚C.  The reaction was terminated by adding 180 
µl DEPC-treated H2O (to bring the reaction volume up to 200 µl), and RNA was 
extracted once in phenol.  The aqueous phase was placed in a new tube and 
mixed with 0.1 volume of 3M NaOAc and 2.5 volumes of 100% ethanol, and 
incubated for 30 minutes at -20˚C.  RNA was pelleted by centrifuging 16.1 X g for 
30 minutes at 4˚C.  Supernatent was aspirated, and the pellet was washed once 
with 70% ethanol by centrifuging 16.1 X g for 10 minutes at 4˚C.  RNA was 
resuspended in 30 µl of DEPC-treated H2O and stored at -80˚C. 
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Tobacco acid pyrophosphatase digestion 
Tobacco acid pyrophosphatase (TAP) (Epicentre Biotechnologies) hydrolyzes 
the phosphoric acid anhydride bonds in the triphosphate bridge of 5´-cap 
structures, leaving a 5´-monophosphate end on the decapped RNA.  RNA was 
treated with TAP according to the manufacturer’s instructions.  ~25 pmol (5 µl) of 
RNA was incubated with 5 µl 10X TAP buffer (0.5 M NaOAc, pH 6.0, 10 mM 
EDTA, 1% β-mercaptoethanol, 0.1% Triton® X-100, provided by Epicentre 
Biotechnologies), 35 µl DEPC-treated H2O, and 2.5 µl TAP (25 units), in a 50 µl 
total reaction volume, and incubated 2-hours at 37˚C.  The reaction was 
terminated by adding 150µl of DEPC-treated H2O (to bring the reaction volume 
up to 200 µl) and RNA was extracted once in phenol.  The aqueous phase was 
placed in a new tube and mixed with 0.1 volume of 3M NaOAc and 2.5 volumes 
of 100% ethanol, and incubated for 30 minutes at -20˚C.  RNA was pelleted 16.1 
X g for 30 minutes at 4˚C.  Supernatent was aspirated and the pellet was washed 
with 70% ethanol and centrifuged 16.1 X g for 10 minutes at 4˚C.  RNA was 
resuspended in 30 µl of DEPC-treated H2O and stored at -80˚C. 
 
Primer extension analysis 
Primer extension analysis, utilizing end-labeled oligonucleotides (table 2) and the 
Sensiscript RT Kit (Qiagen), was used to map the 5´-ends of RNA.  5 µl (typically 
one-fifth to one-tenth of a well or flask) of RNA was mixed with 7 µl DEPC-treated 
H2O, 2 µl 10X RT Buffer (Qiagen), 2 µl 5 mM dNTP mix (Qiagen), 2 µl 10 µM 32P-
 43 
γ[ATP]-labeled oligonucleotide, 1 µl RNase inhibitor, and 1 µl Sensiscript 
Reverse Transcriptase (Qiagen), and incubated 90 minutes at 37˚C.  Reactions 
were terminated by adding 20 µl stop buffer.  6% urea-acrylamide gels were pre-
run in 1X TBE for 30-60 minutes at 35 milliampere (mA).  Samples were boiled 5 
minutes at 95˚C, 20 µl of samples were loaded into the gel, and the gel was run 
90-120 minutes at 35 mA.  Gels were dried down onto Whatman 3MM 
Chromatography Paper (Fisher Scientific) for 2-hours at 80˚C and exposed to 
Kodak BioMax MR 8 X 10 inch film (Fisher Scientific) at -80 ˚C for various 
lengths of time (typically 24 hours to two weeks). 
Table 2; Oligonucleotides used for primer extension analysis.  
Oligonucleotides were named for the sense and nucleotide positions the primer 
corresponded to.  ‘g’= ‘genome’ sense (to detect RNA containing antigenome 
sequence) , ‘ag’= ‘antigenome’ sense (to detect RNA containing genome 
sequence). 
Oligo Sequence (5´-3´) 
g15-39 TTTGGTTTATGCAAGTTTGTTGTAC 
g45-68 ACTTATCAAATTCTTATTTGCCCC 
g24-50 TTCTCCATTCTAGAGGTTTATGCAAGT 
g56-75 AAGTGGTACTTATCAAATTC 
g91-113 TGAATTGCTGCCCATCTCTAACC 
ag13-35 TACGAGATATTAGTTTTTGAC 
ag32-55 TATATGTGTATTAACTAAATTACG 
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Northern blot analysis 
This protocol was used for analysis of RNA in the range of ~100 to ~20,000 nt.  
RNA samples were prepared (35 µl total volume) by mixing 5µl RNA (one-fifth to 
one-tenth of a well or flask) with 6 µl DEPC-treated H2O, 2 µl 10X MOPS buffer, 
7 µl 36.7% formaldehyde, and 20 µl 95% DIF, and incubated 10 minutes at 65˚C.  
Samples were mixed with 6.6 µl 6X Loading Dye Solution (Fisher Scientific) and 
migrated in 1.5% agarose-formaldehyde gels.  Gels were run at 110 Voltz (V) in 
1X MOPS buffer, approximately 2-hours, and transferred to Whatman Protran 
Nitrocellulose Blotting Membranes (Fisher Scientific) using the Whatmann 
TurboBlotter Downward Capillary Transfer System (Sigma-Aldrich) in transfer 
buffer (3M NaCl, 8 mM NaOH), overnight.  Membranes were neutralized in 6X 
SSC for 15 minutes at room temperature, dried briefly, and UV-crosslinked in a 
CL 1000 Ultra Violet Crosslinker (UVP) at 1200 Joules (J).  For hybridization with 
end-labeled probes, membranes were pre-hybridized for 1 hour at an appropriate 
hybridization temperature (see table 3) in hybridization buffer (5X Denhardt’s 
Solution (Sigma-Aldrich), 6X SSC, 0.1% SDS, 0.01% sodium pyrophosphate 
decahydrate (NaPPi) (Sigma-Aldrich)).  For hybridization with riboprobes, 
membranes were pre-hybridized for 1 hour at 65˚C in hybridization buffer (6X 
SSC, 2X Denhardt’s Soln., 0.5% SDS, and 100 µg salmon sperm DNA 
(Invitrogen) boiled for 5 minutes at 95˚C to shear DNA).  25-50 µl of radiolabeled 
probe was added to the hybridization buffer and membranes were incubated 12-
18 hours.  Blots probed with end-labeled oligonucleotides were washed twice in 
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6X SSC for 15 minutes at room temperature, and twice in 6X SSC for 10 minutes 
at the hybridization temperature.  Blots probed with riboprobes were washed in 
2X SSC and 0.1% SDS for 2 hours at 65˚C, and in 0.1X SSC and 0.1% SDS for 
15 minutes at 65˚C.  Blots were dried briefly, wrapped in saran wrap, and 
exposed to film in a cassette at -80˚C for various lengths of time (generally 24-
hours up to 2 weeks). 
 
Northern blot analysis of small RNA 
This protocol was used for the detection of small RNA in the range of ~17 to 
~1,000 nt (adapted from (263)).  6% urea-acrylamide gels were pre-run in 1X 
TBE for 30 minutes, at 200 V.  RNA samples were prepared by mixing RNA 1:1 
with stop buffer, and incubated for 20 minutes at 65˚C.  A low-range ssRNA 
ladder (New England Biolabs) was prepared by mixing 2 µl ladder (1µg) with 3 µl 
DEPC-treated H2O and 5 µl 2X RNA ladder loading buffer (New England 
Biolabs), incubated for 5 minutes at 65˚C, and chilled on ice.  A microRNA 
Marker (New England Biolabs) in ready-to-load denaturing solution was 
incubated 5 minutes at 65˚C, 5 minutes at 95˚C, and chilled on ice.  Samples 
were loaded in 6% urea-acrylamide gels and run in 1X TBE, for 20-30 minutes at 
150 V.  The ladders were cut off the gels prior to transfer and stained with 
ethidium bromide (Sigma-Aldrich) for UV-visualization.  Gels were transferred to 
Whatman Nytran Nylon positively charged 0.45 µ membranes (Fisher Scientific) 
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as described above.  Blots were neutralized in 6X SSC, UV-crosslinked, and 
hybridized as described above. 
 
Table 3; Oligonucleotides used for Northern blot analysis.  Oligonucleotides 
were named for the sense and nucleotide positions the probe corresponded to.  
‘g’= ‘genome’ sense (to detect antigenome-containing RNA) , ‘ag’= ‘antigenome’ 
sense (to detect genome-containing RNA).  Probes indicated with an asterisk 
were locked nucleic acid (LNA) probes, modified with an LNA base every third 
nucleotide.  Probes indicated with a diamond were CAT riboprobes.  Riboprobe 
sequences are not shown here because they represent long (up to 1000 nt) T7 
transcribed run-off products.  The annealing temperatures (Ta˚C) used for 
hybridization were determined by subtracting 3-5˚C from the oligonucleotide 
melting temperatures. 
Oligo Sequence (5´-3´) Ta˚C 
g7-34 * TTTATGCAAGTTTGTTGTACGCATTTTT 62 
g56-75 AAGTGGTACTTATCAAATTC 41 
g504-540 GCTAGTTGATATTAATTATAATTTATGGATTAAGATC 56 
ag5-32 * GAGATATTAGTTTTTGACACTTTTTTTC 62 
CAT (-)  CAT-specific probe to detect anti-minigenome/ mRNA 65 
CAT (+)  CAT-specific probe to detect input minigenome 65 
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Protein expression 
A codon-optimized version of the RSV (strain A2) L protein ORF was chemically 
synthesized (GeneArt), and the mutant polymerase, N812A, was generated by 
QuickChange site-directed mutagenesis (Aligent Technologies).  Wt and mutant 
polymerase proteins were cloned in the pFastBac Dual vector (Invitrogen) 
together with the P protein ORF.  The P protein was tagged with a hexahistidine 
sequence, with a tobacco etch virus (TEV) protease cleavage site between the 
ORF and the histidine tag.  Baculoviruses were recovered using the Bac-To-Bac 
system (Invitrogen) and used to infect Sf21 cells.  RSV L-P polymerase 
complexes were isolated and purified from cell lysates by affinity chromatography 
and size-exclusion, cleaved with AcTEV Protease (Invitrogen), and analyzed by 
SDS-PAGE and PageBlue protein staining as described below. 
 
SDS-PAGE and PageBlue protein staining 
Wt L-P polymerase complex and the N812A mutant L-P polymerase complex 
were mixed 1:1 with Laemmli’s Sample Buffer 2X Concentrate (BioRad) with 250 
mM DTT added, boiled 5 minutes at 95˚C, and migrated in a 10% SDS-
polyacrylamide gel with a 4% stack, 100 V for 1 hour.  The BenchMark 
Prestained Protein Ladder (Invitrogen) and the MagicMark XP Western Protein 
Standard (Invitrogen) were used to size the protein bands.  The gel was fixed in 
100 ml 40% ethanol and 10% acetic acid (Sigma-Aldrich) for 10 minutes, then 
rocked in 100 ml PageBlue Protein Staining Solution (Thermo-Fisher) for 1-2 
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hours.  Gel was washed in dH2O five times, until wash poured off clear.  Gel was 
dried down on Whatman 3MM chromatography paper at 80˚C for 2 hours. 
 
Western blot analysis 
Protein samples were prepared from cell pellets resuspended in 1 ml 1X PBS.  
200 µl of lysate was mixed 1:1 with Laemmli’s buffer 2X concentrate and 
vortexed.  Samples were boiled 5 minutes at 95˚C, and migrated in 10% SDS-
polyacrylamide gels poured with a 4% stack, 125 V in 1X SDS-PAGE running 
buffer (10X SDS-PAGE running buffer prepared by dissolving 60.6 g tris base 
(Sigma-Aldrich), 288 g glycine (Sigma-Aldrich), 20 g SDS in 2 L dH2O), for 1-2 
hours.  The PageRuler Plus Prestained Protein Ladder (Thermo-Fisher) was 
used as a molecular weight marker.  1X Western transfer buffer was prepared by 
mixing 40 ml 25X tris-glycine buffer (prepared by dissolving 18.2 g tris base (12 
mM) and 90.0 g glycine (96 mM) in 500 ml dH2O) with 200 ml methanol and 760 
ml dH2O.  Gels were transferred to nitrocellulose membranes in 1X transfer 
buffer for 2 hours at 25 V.  Membranes were blocked in 5% milk solution in PBS-
Tween (PBS-T) (1X PBS and 0.1% Tween-20 (Sigma-Aldrich)) overnight at 4˚C, 
with gentle rocking.  Membranes were washed 5 minutes in PBS-T, three times, 
and incubated with primary antibody 1-hour at room temperature.  Membranes 
were washed three times, and incubated with secondary antibody 1-hour at room 
temperature.  Membranes were washed three times and exposed to 3 ml 
Western Lightning Chemiluminescence Reagent (Perkin Elmer) for 1 minute.  
 49 
Membranes were exposed to X-Omat Blue film (Fisher Scientific) for 1, 3, and 5 
minutes. 
 
Immunofluorescence microscopy 
To examine the effect of the RSV small RNAs on stress granule formation, cells 
grown on coverslips were transfected with small RNA overexpression plasmids 
and infected with LeC virus, as described.  As a positive control for stress 
granule formation, mock-transfected/ mock-infected cells were treated with 0.5 
mM sodium arsenite (Sigma-Aldrich) for 2-hours at 37˚C, immediately prior to 
fixation.  At 48- and 72-hours post transfection, cells were washed in 1X PBS and 
2 ml of pre-chilled fixative (5% formaldehyde, 2% sucrose, in 1X PBS) was 
added to each well.  After fixing, cells were washed in 1X PBS and 1 ml 
permeabilization buffer (0.5% Igepal (Sigma-Aldrich), 10% sucrose, in 1X PBS) 
was added for 20 minutes at room temperature, with gentle shaking.  Coverslips 
were blocked in 1X PBS with 5% FBS for 1-hour at room temperature, and 
primary antibody cocktail (anti-RSV N protein (Serotec) diluted 1:500, and anti-
eIF3 (Santa Cruz) diluted 1:100) was prepared in 1X PBS.  Coverslips were 
incubated with primary antibodies for 1-hour at room temperature in a humid 
chamber, and washed 5 minutes in 1X PBS with 5% FBS, three times.  Isotype-
specific secondary antibodies labeled with AlexaFluor 488 and AlexaFluor 568 
(Invitrogen, diluted 1:1,000) were mixed with 0.1 µg 4,6-diamidino-2-phenylindole 
(DAPI) (Sigma-Aldrich) in 1X PBS, and cells were incubated 1-hour at room 
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temperature in the humid chamber, in darkness.  Cells were washed 5 minutes in 
1X PBS with 5% FBS, three times, mounted on slides with VectaShield Mounting 
Medium for Fluorescence (Fisher Scientific), and visualized by fluorescence 
microscopy. 
 
In vitro RNA synthesis assay 
RNA oligonucleotides corresponding to nt 1-14 of the Le promoter, the LeC, and 
a mutant Le (position 2G-A) (Dharmacon) were PAGE purified as described.  For 
radiolabel incorporation reactions, 10 µl of 10 µM RNA template was combined 
with 5µl 10X RNA synthesis buffer (500 mM Tris HCl pH 7.4, 500 mM NaCl, 50 
mM MgCl2, 50 mM DTT), 20 µl 1 mM NTP mix (containing all four NTPs, 10mM 
stock concentrations, New England Biolabs), 12 µl DEPC-treated H2O, and 1µl 
(10µCi) 32P-α[GTP] (3000 Ci/mmol) (Perkin Elmer).  End-labeling reactions were 
identical to incorporation reactions, except that the cold GTP or ATP 
concentration was reduced to 10 µM in the NTP mix for reactions labeled with 
32P-γ[GTP] or 32P-γ[ATP], respectively.  For –UTP experiments, DEPC-treated 
H2O was added to the NTP mix in place of UTP.  Reactions were mixed by 
pipetting and 1 µl of the purified L/P polymerase complex (containing ~100 ng of 
L protein) was added (without mixing), in a final volume of 50 µl.  Reactions were 
incubated for 3-hours at 30˚C, followed by incubation for 3 minutes at 90˚C to 
inactivate the polymerase, and cooled on ice.  For reactions containing 32P-
α[GTP], 1 µl calf intestinal phosphatase (CIP) (New England Biolabs) was added 
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and reactions were incubated for 1-hour at 37˚C.  For reactions containing 32P-
γ[GTP] or 32P-γ[ATP], 7.5 µl 10% SDS, 0.5 µl 100 mM Tris, pH 7.4, 0.5 µl 500 
mM EDTA and 0.5 µl Proteinase K (New England Biolabs) was added, and 
reactions were incubated for 45 minutes at 45˚C.  Reactions were extracted once 
by adding 200 µl H2O and 5 µl 10% SDS, with 250 µl UltraPure 
Phenol:Chloroform:Isoamyl alcohol (25:24:1) (Invitrogen) and vortexing for 30 
seconds.  Reactions were incubated 5 minutes on ice and centrifuged full speed 
for 5 minutes at room temperature.  The aqueous phase was transferred to a 
new tube containing 10 µl 4M NaCl and 1 µl GlycoBlue Coprecipitant (Applied 
Biosystems).  500 µl 100% ethanol was added and tubes were shaken to mix, 
and incubated overnight at -20˚C.  The RNA was precipitated by centrifuging full 
speed for 30 minutes at 4˚C, and the pellet was washed in 800 µl 70% ethanol, 
briefly air-dried, and resuspended in 30 µl DEPC-treated H2O.  The RNA was 
combined 1:1 with stop buffer, boiled 5 minutes at 95˚C, and analyzed by 
electrophoresis on a 20% urea-acrylamide gel.  Gels were exposed to film and 
the nucleotide lengths of the RNA products were determined by comparison with 
a LeC molecular weight ladder generated by alkaline hydrolysis as described. 
 
Quantitation and statistical analysis 
All experiments were performed with consistent results three times, unless 
otherwise indicated.  For quantitation, phosphorimager analysis was performed 
on a Personal Molecular Imager (PMI) System (BioRad) using Quantity One 1-D 
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Analysis Software (BioRad).  Data are presented as the mean ± standard error 
pooled from three replicates. 
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Chapter 1:  Additional initiation sites in the RSV promoters  
Note that some figures and text in this chapter have appeared in print previously;  
Copyright © 2013, American Society for Microbiology [Journal of Virology, 87, 
2013, 3196-3207, DOI: 10.1128/JVI.02862-12] All Rights Reserved. 
Introduction 
 
Cis-acting sequences involved in transcription. 
Since transcription and replication are both initiated from a promoter sequence at 
the 3´-end of the Le, this raises the question of how two distinct RNA synthesis 
processes are initiated from the same or overlapping promoters.  Sequence from 
positions 1 to 13 has been shown to be sufficient for recruitment of both 
transcription- and replication-competent polymerases (40).  Furthermore, 
saturation mutagenesis of the Le implicated many of the same nucleotides (nt 3, 
5, 8, 9, 10 and 11) as being critical for both transcription and replication (64).  
However, mutations to nucleotides 4 and 12 appeared to specifically affect 
transcription (64).  Additionally, transcription required a uridine-rich region at the 
end of the Le, as well as the first GS signal (40; 163).  A schematic of the cis-
acting elements involved in transcription is shown in Figure 6. 
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Figure 6; Schematic of the Le sequence elements involved in transcription.  
The sequence of the 44-nt Le region and NS1 GS (blue) is shown.  Nucleotides 
critical for transcription indicated in bold.  Note that positions 4 and 12 (red) can 
be substituted with little effect on replication, while having a great effect on 
transcription, indicating these positions are optimized for transcription.  U-rich 
region at the end of the Le indicated in bold.  Transcription initiates from position 
+45 at the first nucleotide of the NS1 GS sequence.  Adapted from Cowton et al, 
2006, J Gen Virol (41) 
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Sequence comparison of the viral promoters and the L GS signal. 
Upon closer inspection of the sequences at the 3´- end of the Le and Tr 
complement promoters, we noticed that the sequences are highly similar to a GS 
sequence, specifically the L GS sequence.  RSV GS sequences are highly 
conserved; 9 are identical, and the L GS signal differs from the others by two 
nucleotides (33; 37).  Regardless of the sequence differences, the L GS signal 
functions like the other GS signals (37).  The sequences from position 3 to 11 of 
the Le and TrC promoters can be aligned with the L GS sequence, and 
correspond in 8 out of 10 nucleotides, and 7 out of 10 nucleotides, respectively 
(Figure 7).  This intriguing observation led us to ask if RNA synthesis initiation 
could occur at this site, as it does at an authentic GS signal. 
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Figure 7; Nucleotides 3-12 of the Le and TrC promoters contain a gene 
start-like sequence.  The sequences of the canonical RSV GS signal (GS), the 
L gene start signal (L GS), the leader promoter (Le) and the TrC promoter (TrC) 
are written from 3´to 5´, and aligned from the first ‘C’ residue of the GS and 
position +3 of the Le and TrC.  The sequences in the Le and TrC promoters and 
the L GS that align are underlined.  The Le shares 8 out of 10 nucleotides with 
the L GS, while the TrC shares 7 out of 10 nucleotides.   
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Evidence for an additional initiation site at position +3 of the Le and TrC 
promoters in the minigenome system. 
It is generally accepted that initiation at position +1 of the Le promoter 
corresponds to synthesis of full-length antigenome, and from the TrC promoter, 
genome sense RNA.  During the course of experiments studying the mechanism 
of RSV replication using the minigenome system, primer extension analysis 
using primers that hybridize close to the 5´- end of RNA synthesis products 
revealed that in addition to the position +1 initiation site in the Le and TrC 
promoters, there was an additional site for RNA synthesis initiation in both 
promoters at nucleotide position 3 (Figure 8, panel A) (185; 187).  No other 
initiation sites were identified.  Identification of RNA initiated from position +3 was 
a surprising finding; until recently (220; 280), additional initiation sites had not 
been reported for RSV or related viruses.   
 
In the minigenome system, initiation at position +3 of either promoter in a 
wildtype (wt) template appears to be a minor event.  However, a 1U to A 
substitution in the TrC template results in nearly 9-fold more initiation from 
position +3 than from position +1 (Figure 8, panel A (ii), compare lanes 5 and 6).  
This result likely reflects the polymerase preference to initiate at a pyrimidine.  To 
determine whether RNA initiated from position +3 was elongated to the end of 
the template, we performed primer extension analysis on the RNA initiated from 
position +3 of wt and 1U-A minigenomes using two primers that hybridized 
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further downstream of the initiation site.  Analysis with these primers showed that 
RNA initiated from position +1 was elongated, as expected.  But no products 
were detected that migrated faster than +1 initiated products, suggesting that the 
RNA initiated from position +3 was not efficiently extended beyond 50 and 100 
nucleotides (Figure 8, panel B (i) and (ii), lanes 2 and 3.  Note that the faint band 
detected in lane 2 migrates at the same size as the RNA initiated from position 
+1 in lane 3).  Thus, these data show that the polymerase is capable of initiating 
RNA synthesis at the gene start-like sequence in the viral promoters, and RNA 
initiated from this site is not efficiently extended. 
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Figure 8; Evidence for an additional initiation site at position +3 of the Le 
and TrC promoters in the minigenome system.  (A) (i) Primer extension 
analysis of RNA synthesized from the Le promoter using a primer hybridizing to 
LeC positions 24-50, (ii) and from the TrC promoter using a primer hybridizing to 
Tr positions 24-48.  Molecular weight markers representing initiation at position 
+3, +2 and +1, present in lanes 1, 2, and 3, respectively.  Panel (i): Wt Le-
containing minigenome (lane 4) compared to –L control (lane 5).  Panel (ii): Wt 
TrC promoter (lane 6) compared to 1U-A substitution mutant (lane 5).  –L control 
(lane 4).  +1 and +3 initiations are indicated.  (B) Primer extension analysis of the 
same RNA samples in panel A (ii), using primers that hybridized from positions 
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74-100 (i) or 124-148 (ii) of Tr, to examine extension of the RNA initiated at 
position +3.  Panel A (i) adapted from Noton and Fearns, 2011 (187). Panel A (ii) 
and Panel B adapted from Noton et al, 2010 (185).  Sarah Noton performed 
experiments shown in Panel A.  I performed the experiments in Panel B. 
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In the following studies, we examined RNA isolated from wt RSV infections with 
the goal of determining whether the polymerase uses this additional initiation site 
during viral infection.  We also characterized the length and properties of the 
RNA initiated from position +3. 
 
Results 
 
1.1  The +3 initiation site is used during RSV infection, and the RNA 
initiated from position +3 is not efficiently extended. 
To determine if RNA synthesis initiation from position +3 also occurs during viral 
infection, intracellular RNA from RSV-infected cells was examined by primer 
extension analysis using a genome sense primer that corresponded to 
nucleotides 15 to 39 of the Le sequence (genome (g)15-39), and an antigenome 
sense primer that corresponded to nucleotides 13 to 35 (antigenome (ag)13-35) 
of the TrC sequence.  By using primers that hybridized so close the 5´ends of the 
LeC and Tr RNAs, the initiation sites of RNA products from the 3´ends of the Le 
and TrC promoters could be determined precisely.  A schematic of the positions 
that the primers correspond to on the genome is shown in Figure 9 (panel A). 
 
Primer extension analysis using the g15-39 primer indicated that RNA was 
initiated from two sites within the Le promoters, the +1 initiation site, which is the 
expected initiation site for antigenome synthesis, and position +3 (Figure 9, panel 
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B, (i)).  Surprisingly, significantly more RNA initiated at position +3 could be 
detected from the Le than RNA initiated from position +1.  It is not possible to 
determine the absolute frequency of initiation at +1 versus +3 based on levels of 
intracellular RNA because of the potential differences in RNA stability in the 
cellular environment.  However, antigenome initiated at +1 would be expected to 
be very stable due to encapsidation, therefore, this finding indicates that the RSV 
polymerase could initiate at the +3 site relatively frequently during infection.   
 
Primer extension analysis with the ag13-35 primer also detected RNA initiated 
from both position +1 and +3 of the TrC promoter (Figure 9, Panel B, (iii)).  
However, in contrast to the results for the Le promoter, the levels of +3 initiation 
from the TrC promoter were lower than the levels of +1 initiation.  It is important 
to point out however, that if the RNA initiated from position +3 is not 
encapsidated it may be underrepresented in this assay, and may actually be 
much more abundant.  These analyses showed that RNA synthesis initiation 
occurs relatively frequently at position +3 from both the Le and TrC promoters 
during RSV infection. 
 
To determine whether the RNA initiated from position +3 was extended, primers 
that hybridized further downstream of the Le and TrC promoters were used for 
analysis.  Using a primer that corresponds to genome positions 45-68 of the Le, 
and antigenome positions 32-55 of the TrC, RNA initiated from position +1 was 
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still readily detected, as expected (panel B, ii and iv).  However, normalizing to 
RNA initiated from position +1, there was a 7.8-fold decrease in the level of RNA 
initiated at position +3 of the Le promoter, and RNA initiated from position +3 of 
the TrC promoter was no longer detectable, demonstrating that these RNAs were 
not efficiently elongated (Panel B, (ii) and (iv), quantitation in Panel C).  Thus, 
this result shows that RNA synthesis can be initiated from position +3 of the Le 
and TrC promoters, and the bulk of this RNA is terminated within a short distance 
of the initiation site. 
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Figure 9; Evidence for initiation at position +3 of the Le and TrC promoters 
in RSV-infected cells.  (A) Schematic diagram showing the hybridization 
positions of the primers relative to genome (purple bars, below) and antigenome 
(blue bars, above).  (B) Primer extension analysis of viral RNA using negative 
sense primers corresponding to genome positions 15-39 (i) and antigenome 
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positions 13-35 (iii).  Primer extension analysis of the same RNA using primers 
that hybridized further downstream at genome positions 45-68 (ii) and 
antigenome positions 32-55 (iv).  RNA isolated from mock-infected cells was 
used as a negative control (lane 1).  End-labeled oligonucleotides corresponding 
to initiations at positions 1, 2 and 3 were used as markers (not shown).  Asterisk 
indicates background band (ii).  (C) Quantification of the RNA detected from the 
position +3 initiation site (white bars), as determined by quantification of 
replicates of the experiment shown in panel B, (i) and (ii).  For each primer the 
data were normalized to the RNA initiated from position +1 at 100% (black bars).  
The bars show the means of three experiments, with standard errors indicated. 
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1.2  RNAs initiated from position +3 do not contain 5´-monophosphate 
ends. 
One possible explanation for the observance of RNA corresponding to initiation 
from position +3 could be that RNA initiated from position +1 is cleaved or 
processed to generate this RNA.  There is precedence for cleavage of viral 
genomic RNA, as Borna disease virus is known to cleave its 5´- triphosphate 
ends in order to avoid detection by RIG-I (88).  If RNA initiated from position +1 
was cleaved to generate the RNA detected from +3, it would be expected to 
contain a 5´-monophosphate end.  To determine if this was the case, RSV RNA 
was treated with an exonuclease that digests RNA containing a 5´-
monophosphate, but is unable to digest 5´-tri- and di-phosphorylated RNA, RNA 
containing a 5´-cap, or RNA containing a 5´-hydroxyl group.  As an internal 
control for exonuclease digestion, ribosomal RNA (rRNA), which possesses a 5´-
monophosphate, was visualized by 0.8% agarose gel with ethidium bromide.  
The rRNA was largely digested by treatment with exonuclease, although the 
rRNA from the mock-infected cell samples was not digested as completely as the 
rRNA from RSV-infected cell sample (Figure 10, panel A, lanes 2 and 3).  Next, 
primer extension analysis was performed to determine the effect of exonuclease 
treatment on the RNA initiated from position +1 and +3 of the Le and TrC 
promoters.  Analysis with the g15-39 primer showed no change in the levels of 
+3 initiation from the Le, suggesting that this RNA does not contain a 5´-
monophosphate end (panel B, i, compare lanes 2 and 4).  The RNA initiated from 
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position +3 of the TrC promoter was also examined.  Analysis with primer ag13-
35 showed no change in the levels of +3 initiations from the TrC promoter, 
indicating that this RNAs also does not contain a 5´-monophosphate end (panel 
B, ii, compare lanes 2 and 4).  While these results do not determine the structure 
of the 5´-ends of the RNA initiated from position +3, they do rule out the 
possibility that these RNAs contain a 5´-monophosphate, and therefore strongly 
suggests that these RNAs are initiated from position +3.   
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Figure 10; RNA initiated from +3 does not have a 5´- monophosphate. (A) 
0.8% agarose gel stained with ethidium bromide to visualize ribosomal RNA.  
Exonuclease-treated RNA is migrated in lanes 3 and 4.  28S and 18S rRNA 
bands are indicated.  (B) Primer extension analysis of exonuclease-treated RNA 
to determine if there is an effect on +1 and +3 initiations.  RNA was analyzed 
using a primer that corresponded to genome positions 15-39 (i) and antigenome 
positions 13-35 (ii). Initiations from +1 and +3 are indicated. 
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1.3  Small RNAs are generated from the Le and TrC promoters. 
To further characterize the RNAs generated from position +3 of the Le and TrC 
promoters, RNA isolated from RSV-infected cells was analyzed by Northern blot.  
A negative sense probe specific to genome positions 7-34 was used to detect 
LeC-containing RNA (antigenome), while a positive sense probe specific to 
antigenome positions 5-32 was used to detect Tr-containing RNA (genome).  A 
negative sense probe specific to genome positions 504-540 was also used to 
detect NS1 mRNA (for sequences, refer to table 3).  The Northern blot analysis 
was performed using two different electrophoresis conditions; formaldehyde-
agarose gel electrophoresis, designed to detect RNAs in the range of ~100- 
~20,000 nucleotides in length (Figure 11, panel B), and polyacrylamide gel 
electrophoresis, to allow resolution of small RNAs in the range of 17 to 500 
nucleotides in length (panel C).  Northern blot analysis of larger RNAs using 
agarose gels showed that the probes bound to the expected RNA species.  The 
g7-34 probe bound to a high-molecular-weight band corresponding to 
antigenome RNA, and the NS1 probe identified bands of appropriate sizes to be 
NS1 and NS1-NS2 readthrough mRNAs (panel B, i and iii).  Long exposures 
were required to detect antigenome RNA with this probe reflecting the relative 
scarcity of antigenome RNA compare to NS1 mRNA (panel B, iv).  The ag5-32 
probe bound to a high-molecular-weight band corresponding to genome RNA 
(Panel B, ii). 
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Analysis of the same RNA samples using polyacrylamide gel electrophoresis 
showed that the g7-34 probe was also able to detect a band of small RNAs that 
were somewhat heterogeneous in size but predominantly ~25 nucleotides, with 
some transcripts detectable as a faint smear, extending up to ~50 nucleotides in 
length (Panel C, i).  The ag5-32 probe also detected heterogeneous RNAs of 
similar size, as well as a much less abundant RNA ~60 nucleotides in length 
(Panel C, ii).  These are the only small RNAs detectable with these probes.  
Under these conditions the NS1 probe detected full-length NS1 mRNA (532 nt 
excluding the poly(A) tail) near the top of the gel, as well as some prematurely 
terminated NS1 RNAs that could be detected with a probe that hybridizes closer 
to the 5´end of NS1 mRNA (Panel C, iii and iv).  However, no ~25 nt RNA 
species were detected with the NS1 probes, indicating that the small RNAs 
detected with the Le and Tr probes were not antigenome and genome that had 
become degraded during the RNA purification procedure.  These results show 
that small transcripts predominantly 25 nucleotides in length are generated from 
the Le and TrC promoters during RSV infection. 
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Figure 11; Small RNAs are generated from the Le and TrC promoters. (A) 
Schematic diagram showing the positions primers correspond to on the genome 
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(below, purple) and antigenome (above, blue).  (B) RNA migrated on 1.5% 
agarose-formaldehyde gels was probed with oligonucleotides corresponding to 
genome positions 7-34, to detect antigenome and LeC-containing RNA (panel i), 
antigenome positions 5-32, to detect genome and Tr-containing RNA (panel ii), 
and genome positions 504-540, to detect NS1 mRNA (panel iii).  Panel (iv) is a 
longer exposure of panel (iii) showing antigenome levels compared to NS1 
mRNA.  Antigenome, genome, NS1, NS1/ NS2 and NS1/ NS2/ N readthrough 
mRNA are indicated.  (C) RNA migrated on 6% urea-acrylamide gels was probed 
as above to detect small RNA in the range 17- 1000 nts (i, ii and iii).  Probe 
corresponding to genome positions 56-75 was also used to detect small RNA 
generated from the NS1 GS (iv). RNA from mock-infected cells was used as a 
negative control (lanes 1, 3, 5, and 7 for both panels). 
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1.4  RNA initiated from position +3 of the Le fractionates with subgenomic 
mRNAs during RSV infection. 
Taken together, the primer extension and Northern blot data described above are 
consistent with a model in which RNA initiated at the +1 site is elongated into 
antigenome RNA, whereas RNA initiated at +3 is truncated at ~25 nt.  However, 
the data do not exclude the possibility that some RNA initiated at +1 is also 
truncated, or that some RNA initiated at position +3 is elongated to the end of the 
genome, similarly to antigenome RNA.  Therefore, to further investigate the 
relationship between +1 and +3 initiated RNA, it was of interest to separate the 
products of the +1 and +3 initiation sites and determine their lengths.  To 
accomplish this, RSV-infected cell extracts were fractionated using a modified 
version of the method described by Mason and colleagues (160), which we had 
found is able to separate nucleocapsids from cytoplasmic mRNAs (Noton and 
Fearns, unpublished data).  Briefly, mock- or RSV-infected cells were harvested 
and treated with a series of increasingly stringent buffers to generate two 
supernatant fractions (S1 and S2) and one pellet fraction (P2) (Figure 12).   
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Figure 12; Schematic of modified fractionation analysis.  The original 
protocol involved centrifugation of resuspended P2 to generate fractions S3 and 
P3 (160), however, we combined the final two fractions into resuspended P2 to 
concentrate genome and antigenome RNA.  
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RNA was isolated from each fraction and was analyzed by formaldehyde-
agarose gel electrophoresis and Northern blotting to determine if genome and 
antigenome RNAs had been separated from mRNA.  Analysis with probe ag5-32 
to detect genome RNA revealed that genome fractionated predominantly in the 
P2 fraction, with small amounts detectable in S1 and S2 (Figure 13, panel i), and 
analysis with the g7-34 probe to detect antigenome RNA showed antigenome 
fractionated exclusively in P2 (panel ii).  In contrast, an NS1 specific probe, 
detected NS1 and NS1-NS2 read through mRNAs primarily in the S1 fraction, 
with some RNA detected in fraction S2 (panel iii).  No RNAs were detected in 
mock-infected fractionated controls (lanes 1, 2 and 3).  These data demonstrate 
that this method can be used to largely separate subgenomic mRNA from 
genome and antigenome. 
 76 
   
Figure 13; RSV mRNA can be separated from genome and antigenome by 
fractionation analysis.  RNA was isolated from fractionated mock- and RSV-
infected cells, and was migrated on 1.5% agarose-formaldehyde gels and 
Northern blotted, and probed with ag5-32 to detect genome (i), g7-34 to detect 
antigenome (ii), and g504-540 to detect NS1 mRNA (iii).  Fractions from mock 
infections were used as negative controls (lanes 1, 2, and 3).  Genome, 
antigenome, NS1 and NS1-NS2 readthrough mRNA are indicated.  Note that 
each fraction is not equally concentrated; the S1 fraction is resuspended in 300 
µl of buffer, S2 is resuspended in 100 µl of buffer, and P2 is resuspended in 200 
µl of buffer, but an equal volume of each fraction was taken for RNA extraction.  
Thus, the RNA in fraction P2 is 1.5 times more concentrated than RNA in fraction 
S1.  This means that RNA in fraction P2 is overrepresented compared to RNA in 
fraction S1.  Therefore, it is not appropriate to compare quantities between lanes. 
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The same RNA fractions were then subjected to primer extension analysis to 
examine which fractions contained RNA initiated at +1 or +3.  Primer extension 
analysis was performed using primer g45-68.  Analysis with this primer revealed 
RNA initiated from position +3 fractionated predominantly in the S1 fraction, with 
only small amounts detectable in fractions S2 and P2.  Conversely, RNA initiated 
from position +1 fractionated primarily into fraction P2, with very little in fractions 
S1 and S2 (Figure 14, panel A, i). 
 
Small RNA Northern blot analysis of the RNA fractions showed that the ~25 nt 
RNA fractionated predominantly in the S1 fraction, but a significant amount was 
also detectable in P2 (panel A, ii).  As a control, small RNA Northern blot analysis 
of NS1 supports the finding that mRNA fractionates into S1 (panel iii).  Based on 
these results it can be concluded that initiation from position +3 of the Le region 
usually results in synthesis of a ~25 nt RNA that could be detected in fraction S1, 
consistent with the primer extension results shown in panel (i).  In contrast, 
initiation at +1 can result in synthesis of full-length antigenome RNA that could be 
detected in P2.  However, the data also show a relatively high level of ~25 nt 
length RNA in P2, despite a relatively low level of RNA initiated at +3 in this 
fraction. This result indicates that at least some of the ~25 nt RNA that can be 
detected is initiated at +1.  In summary, these data show that the dominant 
product of the Le +3 initiation site is ~25 nt in length whereas initiation at Le +1 
can yield either full-length antigenome or small RNAs ~25 nt in length. 
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Fractionation analysis of the RNA generated from the TrC promoter was 
somewhat less conclusive.  Primer extension was performed using the primer 
that hybridized from positions 13-35 to examine RNA initiated from position +1 
and +3 of the TrC promoter.  Despite detection of genome RNA in the insoluble 
fraction by Northern blot (Figure 13, panel i) it was difficult to detect RNA initiated 
from position +1 of the TrC promoter in this fraction by primer extension (Figure 
14, panel B, i; see lane 6).  Indeed, RNAs initiated at +1 and +3 are both 
detected in the S1 fraction predominantly (compare lanes 4 and 6).  Primer 
extension analysis of the Tr containing RNA with alternative primers was not 
performed due to time constraints. 
 
Small RNA Northern blot analysis of the small Tr RNAs showed they were 
detected largely in the S1 fraction, in good agreement with the primer extension 
analysis (Figure 14, panel B, ii).  Very low levels of the ~25 nucleotide RNA were 
also detected in the S2 and P2 fractions.  No RNA was detected from mock-
infected controls (lanes 1, 2, and 3).   
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Figure 14; Fractionation analysis of the small LeC and Tr RNA.  (A) Primer 
extension analysis using a primer hybridizing to genome positions 45-68 to 
detect initiation from positions +1 and +3 from the Le promoter (i). Asterisk 
indicates a background band.  Panels (ii) and (iii) are urea-acrylamide Northern 
blots probed with g7-34 (ii) and g504-540 (iii) to detect the small LeC RNA and 
NS1, as indicated. (B) Primer extension analysis using a primer hybridizing to 
antigenome positions 32-55 to detect initiation from positions +1 and +3 from the 
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TrC promoter (i).  Panel (ii) is a urea-acrylamide Northern blot probed with ag5-
32 for the detection of small Tr RNA, as indicated.  RNA isolated from mock-
infected fractionated cells was used as negative controls in lanes 1-3.  Note that 
the type of analysis, primer extension (PE) or Northern blot (NB), and the probe/ 
primer used is indicated in bold on the left side of each panel. 
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In summary, these data show that the bulk of RSV mRNA can be separated from 
genome and antigenome by fractionation.  RNA initiated from position +3 of the 
Le fractionates predominantly into fraction S1 with subgenomic mRNAs, while 
RNA initiated from position +1 fractionates almost exclusively into fraction P2, as 
expected, with genome and antigenome.  The small LeC RNA fractionates 
primarily in the S1 fraction, indicating that initiation from position +3 is 
responsible for the generation of at least some of the small RNA, since the only 
initiation event detected is from position +3.  However, some of the small LeC 
RNA is also detected in P1.  Therefore, this result does not rule out the possibility 
that some of the small LeC RNA is also generated from position +1.  In contrast, 
RNA initiated from positions +1 and +3 of the TrC promoter were largely detected 
in fraction S1, which corresponds with detection of the small Tr-containing RNAs 
predominantly in fraction S1 as well.  
 
1.5  Small RNA initiated from position +3 of the Le is partially encapsidated. 
The small RNA may either be encapsidated in N protein, or unencapsidated.  To 
determine the encapsidation status of the small RNA, mock- and RSV-infected 
cell lysates were treated with nuclease to digest unencapsidated RNA prior to 
RNA isolation, and the RNA was analyzed by Northern blot.  As expected, 
genome and antigenome were resistant to degradation by nuclease because 
they are encapsidated in N protein, while NS1 mRNA, which is not encapsidated, 
was digested by nuclease treatment (Figure 15, panel A, compare lanes 2 and 
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4).  Nuclease-treated RNAs were then analyzed by urea acrylamide gel 
electrophoresis to detect the small LeC RNA as well as NS1 mRNA.  Analysis 
with probe g56-75 showed that the NS1 mRNA was efficiently digested (panel B, 
ii).  Analysis with probe g7-34 showed that nuclease treatment resulted in a 
reduction in the level of the ~25 nucleotide RNA (panel B, i).  However, the 
nuclease treatment did not completely ablate the small LeC RNA, indicating that 
either the nuclease digestion of this very small RNA was incomplete, or that the 
~25 nucleotide RNA that could be detected was comprised of a mixture of 
encapsidated and unencapsidated RNA.  Additionally, the nuclease treated RNA 
was also analyzed by primer extension with the g45-68 primer to examine the 
effect of nuclease on the RNA initiated from position +3 of the Le promoter (panel 
C).  RNA initiated from position +1 appeared to be protected.  RNA initiated from 
position +3 was no longer detected, suggesting it was digested by nuclease 
treatment, although some shorter RNA was detected (lane 4, shorter RNA 
indicated with an ellipse).  It is not possible to determine from this result whether 
the shorter RNA represents partial digestion of +3-initiated RNA or +1-initiated 
RNA, since some of the ~25 nt RNA appeared to be initiated from position +1, 
and may also be unencapsidated. 
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Figure 15; Nuclease treatment of RSV RNA. (A) Agarose-formaldehyde 
Northern blots probed with g7-34 to detect antigenome (i), ag5-32 to detect 
genome (ii), and g504-540 to detect NS1 mRNA (iii).  Nuclease-treated RNA is 
migrated in lanes 3 and 4.  RNA from mock-infected cells was used as negative 
controls (lanes 1 and 3).  Antigenome, genome, NS1 and NS1-NS2 readthrough 
mRNA are indicated.  (B) Urea-acrylamide Northern blots for the detection of 
small RNA were probed with g7-34 to detect LeC containing RNA (i) and g504-
540 to detect NS1 mRNA (ii).  (C) Primer extension analysis of the same RNA 
using a primer that hybridizes to positions 45-68 of the genome.  Initiations at 
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positions +1 and +3 are indicated.  Partially digested RNA (lane 4) is indicated by 
an ellipse.  Background bands are indicated by an asterisk.  Note that the results 
in panels B and C are representative of two experiments. 
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Discussion 
 
Summary of Results 
We have shown that the RSV polymerase is able to use an previously 
undescribed site for RNA synthesis initiation within the Le and TrC promoters 
during infection.  Initiation at position +3 resulted in an RNA that was not 
efficiently elongated, yielding the small LeC and Tr containing RNAs.  The RNA 
initiated from position +3 of the Le was very abundant, and represented the 
dominant initiation event in the Le region.  The small LeC RNA predominantly 
fractionated with viral subgenomic mRNA, and was also partially degraded by 
nuclease indicating some of it is unencapsidated.  This is the first demonstration 
of an additional initiation site within the viral promoters being used during viral 
infection, and challenges the dogma that RNA synthesis initiation only occurs 
opposite the first nucleotide of the genome or antigenome.   
 
Elucidating the structure of the 5´-ends of the small RNAs 
The exonuclease digestions showed that the small RNAs do not contain 5´- 
monophosphate ends, suggesting that the RNAs are not cleaved from RNA 
initiated from position +1.  However, these experiments did not exclude the 
possibilities that the RNAs contain 5´- di- or tri-phosphate moieties, or 5´- cap 
structures.  Since capping is known to stabilize the elongation complex during 
transcription, it seems unlikely that RNA initiated from +3 would be capped since 
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it is not efficiently extended.  Moreover, in another NNS virus, VSV, mRNAs are 
not capped until they are 31 nt in length, thus the RNA initiated from position +3 
in RSV may not be long enough to be capped (243).  It is therefore most likely 
that the small RNA initiated from position +3 contains a 5´-di- or tri-phosphate.  In 
good agreement with a predicted triphosphate, LeC RNA isolated from RSV-
infected cells and stripped of viral N protein, has been shown to be a ligand for 
RIG-I, leading to the activation of IFN-β in A549 cells (13).  Since RIG-I is 
activated in response to detection of tri-phosphorylated viral RNA, this strongly 
suggests that the LeC RNA contains a 5´- triphosphate. 
 
Truncation of the small RNAs 
Based on the results of the primer extension and Northern blots, RNA initiated 
from position +1 is efficiently elongated, whereas RNA initiated from position +3 
is not and is only ~25 nt in length.  Since mRNAs initiated from GS sequences 
are typically extended many hundreds of nucleotides, this raises the question of 
why RNA initiated from position +3 at a sequence highly similar to a GS are not 
extended.  Despite the sequence similarity of nucleotides 3-12 of the Le and TrC 
promoters to a GS signal, there is no sequence downstream that resembles a 
GE signal.  Moreover, the sequence from nucleotides 23-27 of Le and TrC, 
where the small RNAs are terminated, do not share obvious sequence similarity, 
suggesting that the sequence of the template is not responsible for the 
polymerase terminating RNA synthesis.  In addition, the small RNAs are 
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heterogenous in size, which argues against a termination signal.  Therefore, 
termination of the small RNA is likely in response to the polymerase reaching a 
checkpoint for RNA synthesis.  One potential checkpoint may be failure to 
concurrently encapsidate nascent RNA.  In Sendai virus (SeV) it has been shown 
that concurrent encapsidation results in greater processivity of the polymerase 
during replication (87).  Thus, in this model, RNA that fails to become 
encapsidated within synthesis of ~25 nucleotides may be aborted.  Failure of the 
RNA initiated at position +3 to become encapsidated may therefore explain why 
the RNA is prematurely terminated, as at least some of the RNA was digested by 
nuclease treatment, indicating that it was not protein bound.   
 
Importantly, these assays cannot distinguish if some RNA initiated at +1 was also 
terminated prematurely; the small LeC RNA may contain RNA initiated from 
position +1 as well as RNA initiated at +3.  Small LeC RNA can be detected in 
the insoluble fraction by Northern blot with genome and antigenome RNA, 
suggesting that at least some of the small LeC RNA was generated from position 
+1.  Moreover, the primer extension analysis of fractionated Tr-containing RNA 
failed to clearly detect RNA initiated from position +1 in the insoluble fraction, but 
detected a high level of +1 RNA in the S1 fraction.  This further suggests there 
may be a lot of small RNA initiated from position +1.  This RNA may represent 
abortive replication product that did not become encapsidated with N protein, and 
was therefore released within the Le region. 
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While the nuclease treatment indicates that some of the small LeC RNA is 
protected, this experiment does not determine whether or not the RNA is bound 
by N protein or another cellular protein.  Another group has shown that La 
autoantigen, an ~50 kiloDalton (kDa) cellular protein, binds to RSV LeC-
containing RNA to subvert activation of RIG-I (13).  Interestingly, they show that 
the majority of early LeC transcripts are bound by La protein, and that over time 
as viral N protein accumulates, LeC RNA is predominantly bound by N protein.  
However, LeC RNA appears to be specifically bound either by La or by N, and 
not by both proteins, for reasons unclear at this time.  La has been shown to act 
as a chaperone in the biogenesis of small eukaryotic RNAs, and aids in 
assembly of small RNAs into functional ribonucleoprotein complexes (RNPs) (15; 
167; 193; 275).  It is exciting to consider the possibility that La is behaving 
analogously to its cellular function with regards to the LeC small RNA.  Thus, La 
may not only serve to subvert the activation of RIG-I by this RNA, but may also 
serve to direct the assembly of the small RNA into a higher order viral or cellular 
complex, where it then influences viral replication or the cellular response to 
infection. 
 
Future Directions 
It would be interesting to determine if the small RNA initiated from position +3 of 
the Le is bound with cellular La protein.  LeC RNA in the form of RNPs could be 
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affinity purified on Sepharose beads coupled to antibody against La or N protein, 
and deproteinized to release naked LeC RNA, as described previously (13).  
Primer extension could then be performed on this RNA to determine whether 
RNA initiated from position +3 is associated with La-containing RNPs, viral N 
protein, or both.  It would be remarkable if +3 RNA is only associated with La 
protein, while +1 initiated RNA is only associated with N protein.  If this were the 
case, then it would be important to understand what is responsible for the 
recruitment of N protein specifically to +1 initiated viral RNA.  There is some 
evidence that the first two initiating nucleotides (5´- AC) may be part of an 
encapsidation signal required to recruit N to the RNA, which would not be 
present in an RNA initiated from position +3 (64; 163).  The experiments 
proposed above may provide support for this idea. 
 
In conclusion, this work presents the novel finding of an previously undescribed 
RNA synthesis initiation site at position +3 of the viral promoters, leading to the 
generation of small RNAs.  This of course raises the question as to why the RSV 
polymerase generates these small RNAs, and how the polymerase engages with 
two closely spaced sites during infection.  The role of the +3 initiation site within 
the Le promoter is explored in more detail in Chapter 2. 
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Chapter 2:  Transcription can initiate from position +3 of the Le promoter  
Note that some figures and text in this chapter have appeared in print previously;  
Copyright © 2013, American Society for Microbiology [Journal of Virology, 87, 
2013, 3196-3207, DOI: 10.1128/JVI.02862-12] All Rights Reserved. 
 
Introduction 
 
Prevailing models of transcription initiation in the non-segmented negative 
sense RNA viruses. 
For more than two decades, the mechanisms of viral replication and transcription 
employed by non-segmented negative sense (NNS) RNA viruses have been in 
contention.  Two models that are well supported by data derived from studies on 
VSV and SeV have been proposed and are generally accepted.  The first model, 
based on studies with VSV, posits that there are two pools of polymerase, a 
transcriptase and a replicase, which consist of a basic L-P complex but are 
associated with different viral and cellular proteins, and initiate at two different 
sites on the genome (Figure 16).  Two distinct polymerases have been purified 
and shown to be functional in vitro, in support of this model (209).  The 
transcriptase is bound with cellular cofactors and is capable of initiating 
transcription directly at the first GS signal without first transcribing the Le region.  
In contrast, the replicase is not bound by cellular cofactors but instead is 
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complexed with viral N protein, and initiates replication opposite the first 
nucleotide of the genome.  The idea that prior Le synthesis is not required for 
transcription is consistent with the results of experiments on the VSV polR1 
mutant, which produces a molar excess of N mRNA over Le RNA (31; 32).  
Additionally, evidence that the transcriptase enters directly at the first GS signal 
is supported by experiments in which UV treatment of VSV genomes to introduce 
lesions randomly throughout the Le, which would block the movement of the 
polymerase, showed that mRNA synthesis was independent of the number of UV 
cross linkages in the Le (267).  However, the inverse was true for UV-treated 
VSV templates tested in vitro, and transcription was dependent on prior Le RNA 
synthesis (267).  This disparity between in vivo and in vitro data has not been 
satisfactorily explained. 
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Figure 16; Model of transcription initiation for VSV.  Two distinct polymerase 
complexes carry out transcription and replication.  The transcriptase is 
associated with cellular cofactors and enters the template directly at the first GS 
sequence, where transcription is then initiated and the transcriptase caps the 
mRNA.  There is no requirement for prior Le RNA synthesis for transcription to 
occur.  The replicase is associated with viral N protein and enters at the 3´-end of 
the template, and generates antigenome that is concurrently encapsidated. 
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The second model has been proposed based on studies done with SeV.  This 
model suggests that there is a single polymerase composed of L and P, which is 
responsible for carrying out both replication and transcription, always enters the 
template at the 3´-end of the genome.  When the polymerase is in transcription 
mode, it initiates opposite the first nucleotide of the Le, and generates a positive 
sense Le transcript (Le+), releases the nascent Le+ RNA, and reinitiates 
transcription at the first GS signal.  Upon sufficient accumulation of N protein, 
replication can be initiated opposite position +1 and the RNA is concurrently 
encapsidated (Figure 17).  This model is supported by substitution analyses of 
SeV demonstrating that promoter sequence can impact initiation at the GS 
signal, and that there is competition between these sites for polymerase (138; 
261; 262).  This model hinges on the idea that transcription is dependent on prior 
initiation from the Le.   
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Figure 17; Model for transcription initiation for SeV.  The same polymerase is 
responsible for carrying out both transcription and replication.  The polymerase 
always enters the template at the 3´-end of the genome and transcribes the Le.  
Upon reaching the end of the Le, the polymerase stops and scans to locate the 
first GS signal, where it reinitiates transcription.  During replication, the 
polymerase is influenced by the levels of N protein and generates encapsidated 
antigenome. 
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It is possible that transcription initiation is different for rhabdoviruses and 
paramyxoviruses, a possibility supported by the observation that the promoter 
regions of these viruses appear to be organized differently (149; 163; 266).  A 
unified model was proposed to explain the disparate results obtained for VSV 
and SeV, in which the polymerase always enters at the 3´-end of the template, 
but does not always initiate RNA synthesis (46).  This model suggests that during 
transcription the polymerase scans the Le region to locate the first GS signal, 
and implies that N protein is sequentially displaced as the polymerase traverses 
the Le, allowing recognition of the first GS signal (46; 124).   
 
While elements of both models may apply to transcription initiation by the RSV 
polymerase, neither model entirely explains the findings for RSV.  One tenet of 
the SeV model is that N protein is an important factor regulating the switch from 
transcription to replication.  However, in RSV it has been shown that increasing 
the amount of N protein in the minigenome system does not result in a decrease 
in the levels of transcription, although replication was augmented (63).  The fact 
that sequence within the first 12 nucleotides of the RSV Le have been shown to 
be critical for transcription argues against the VSV model of direct initiation at the 
first GS signal (64).  In addition, NNS virus genomes are completely 
encapsidated in N protein and therefore the GS should not be directly accessible 
(2; 78).  Thus, the VSV model raises several questions about how the 
polymerase identifies and accesses the first GS signal.  Addressing the idea that 
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the polymerase does not always initiate in the Le but can scan to the first GS 
signal, scanning of the Le region of RSV (or any NNS virus) has not been directly 
demonstrated.  The RSV polymerase has been shown to be capable of scanning 
at gene junctions, which range from 1 to 56 nucleotides in length (33; 114; 248), 
and at the unusual M2/L overlapping gene junction, where the polymerase must 
scan backwards 68 nucleotides from the M2 GE signal to locate the L GS signal 
(37; 61).  Therefore, scanning within the Le region, which is 44-nucleotides long 
for RSV, is not implausible.  But unlike a polymerase that encounters a gene 
junction and can freely diffuse along the template, a polymerase that is bound to 
a promoter at the 3´-end of the Le would require energy to break promoter 
contacts.  Thus it seems unlikely that any NNS virus polymerase can scan 
directly from the Le. 
 
Reconstitution of RSV RNA synthesis in vitro 
Until recently, studying RSV polymerase activity in promoter regions was 
hindered by a lack of an in vitro assay that utilized an artificial template and 
purified components to examine individual stages of RNA synthesis.  Intracellular 
assays only allow you to study stable end products of RNA synthesis; it is 
impossible to manipulate the cellular environment or to study unstable 
intermediates of transcription in a viral infection.  Therefore, we developed an in 
vitro RNA synthesis assay in which RSV RNA synthesis could be reconstituted 
utilizing a defined RNA template and purified polymerase (186).  The assay was 
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developed using an RNA template representing the TrC promoter.  Although the 
template was naked RNA, the polymerase demonstrated specificity for TrC 
promoter in the absence of N protein.  Additionally, the results of this assay 
recapitulated RNA synthesis events observed in RSV-infected cells, such as 
initiation at position +3 (186).  In this chapter, we used this assay to study RNA 
synthesis events at the Le promoter.   
 
The goal of the following studies was to elucidate the mechanism of transcription 
initiation by the RSV polymerase.  Because of the similarity of the Le 3-12 
sequence to the L GS, and our data showing RNA synthesis initiation from 
position +3 of the Le (Chapter 1), we hypothesized that position +3 may be the 
start site of transcription (Model, figure 18).  We set out to test this model by 
determining whether the +3 initiation site could be accessed directly by the 
polymerase, or if initiation from position +3 was dependent on prior initiation at 
position +1.  This would indicate whether all RNA synthesis initiates from position 
+1 and initiation from +3 is a secondary event, or if position +3 is a bona fide 
initiation site.  We also tested the effect of mutations in the GS-like sequence on 
mRNA initiation from the first GS signal at position 45. 
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Figure 18; Proposed model for transcription initiation by the RSV 
polymerase.  Transcription initiates from position +3 of the RSV Le region at a 
sequence that is highly similar to a GS sequence.  A small LeC RNA is 
generated and this RNA is terminated after synthesis of ~25 nt.  The polymerase 
reinitiates mRNA transcription at position +45 at the first GS signal. 
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Results 
 
2.1 RNA produced in the in vitro RNA synthesis assay is RSV polymerase 
dependent and Le promoter specific. 
We wanted to be able to test whether the polymerase could access the position 
+3 initiation site directly, or if this was a secondary event to initiation at position 
+1.  To determine whether the in vitro RNA synthesis assay would be useful for 
examining initiation events at the Le promoter, it was important first to verify that 
RNA synthesis was both dependent on the presence of the RSV polymerase and 
specific to the Le promoter.  The RNA synthesis assay was performed using an 
RNA template corresponding to nucleotides 1 through 14 of the wt Le promoter, 
and RNA synthesis on this template was tested with two forms of the L-P 
polymerase complex, either a wt or mutant polymerase.  The mutant polymerase 
contains an amino acid substitution in the catalytic GDNQ motif of the L protein 
(N812A), which inhibits RNA synthesis.  The purified polymerase complexes are 
shown in Figure 19. 
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Figure 19; Analysis of isolated RSV polymerase complexes.  PageBlue 
stained SDS-polyacrylamide gel of two RSV polymerases showing wt L/P (lane 
1) and mutant LN812A/P (lane 2) complexes.  The bands corresponding to the 
expected migration patterns for L (250 kDa) and P (27 kDa) are indicated.  Mass 
spectrometry of a representative gel showed that the band indicated with the 
asterisk contained L-specific polypeptides, while the bands indicated with the dot 
contained P-specific polypeptides.  Hsp70 also purifies with the L-P complexes 
(as indicated).  Polymerase purification procedure was developed by Laure 
Deflubé (186) and purified polymerase was provided to me for the following 
experiments. 
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The Le RNA was incubated with the purified polymerase complexes in a reaction 
mixture containing ATP, CTP, UTP and GTP, supplemented with [α-32P]GTP.  
Following the reaction, the RNA products containing incorporated [α-32P]GTP 
were analyzed by denaturing gel electrophoresis.  Analysis of the RNA generated 
in the reaction containing wt polymerase yielded products ranging from 7 to 12 nt 
in length.  These products were not detected in reactions containing no 
polymerase or mutant polymerase, indicating they were generated by the purified 
RSV polymerase (Figure 20, compare lanes 2, 3, and 4).  Similarly, no products 
were detected in a reaction containing a template RNA representing the LeC 
sequence 1-14, confirming that the polymerase had template specificity for the 
Le promoter (lane 5).  These results were similar to those obtained previously in 
studies of the RSV TrC promoter sequence and show that the isolated RSV 
polymerase was functional and had specificity for RSV promoter sequence (186). 
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Figure 20; In vitro RNA synthesis is both RSV polymerase dependent and 
Le promoter specific.  (A) Sequences of the RNA templates tested in this 
assay.  Wt Le 1-14 represented the Le promoter, while LeC 1-14 was used as a 
control for polymerase specificity for the promoter sequence. (B) RNA synthesis 
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reactions were migrated on 20% urea-acrylamide gels alongside a ladder 
generated by alkaline hydrolysis of a LeC 1-14 RNA template to size the RNA 
products (lane 1).  Le RNA was incubated without polymerase (lane 2) or with 
mutant polymerase (lane 4) as negative controls for RNA synthesis.  The 
reactions were performed with all 1 mM each of all four NTPs, supplemented with 
[α-32P]GTP to allow detection of RNA products made from the Le RNA template.  
Sarah Noton generously helped with all of the RNA synthesis reactions by adding 
radiolabled GTP to the reactions and running the gels. 
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Since the Le template is 14-nts long, the 12-nt product could represent RNA 
initiated from position +1 that was terminated prematurely, or it could also 
represent RNA initiated from position +3 and extended to the end of the template.  
The following experiments were performed to determine which of these 
possibilities was more likely. 
 
2.2 RNA products are the appropriate size to have been initiated from 
position +3. 
To determine whether the 12-nt product was initiated from position +1 and 
prematurely terminated, or from position +3 and elongated to the end of the 
template, a mutant template with a substitution intended to block +1 initiation was 
utilized.  This mutant template contained a substitution at position 2 from a wt ‘G’ 
residue to an ‘A’ residue (2A Le).  This substitution was selected based on 
previous results in the minigenome system indicating that a 2 G-A mutation in the 
Le reduced +1 initiation, but had no effect on initiation from position +3 (187).  Wt 
Le and 2A Le 1-14 RNA templates were incubated with wt or mutant polymerase 
complexes in a reaction containing all four NTPs, supplemented with [α-32P]GTP.  
Reactions with both the wt Le and 2A Le templates generated the same pattern 
of products, suggesting the products were all generated from position +3 (Figure 
21, compare lanes 4 and 5).  This result indicated that the polymerase could 
access the +3 site directly.  However it was still possible that the polymerase was 
first initiating at position +1, generating 2-3 nt products, which cannot be easily 
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distinguished on this gel, and then reinitiating at the +3 site.  To rule out this 
possibility, duplicate reactions were performed without UTP in the reaction 
mixture.  The first site of UTP incorporation in the wt Le is at position 12, 
therefore products initiated from position +1 would be expected to be 11 
nucleotides, while products initiated from position +3 would be 9 nucleotides.  In 
contrast, the first site of UTP incorporation in the 2A Le template is at position 2, 
thus omission of UTP would be expected to block any initiation from position +1.  
If the +3 initiation site could be accessed independently by the polymerase, 
products generated from position +3 should not be affected, and would still be 
expected to be 9 nucleotides.  In wt Le reactions omitting UTP, products of 8 and 
9 nt were detected, but no 11 nt band indicative of initiation from position +1 was 
detected (lane 7).  The products generated from reactions containing 2A Le 
without UTP were 8 and 9 nt long, and appear to be generated at the same level 
as the products generated from the wt Le template (lane 8).  These data strongly 
suggest that the +3 initiation site can be accessed directly by the RSV 
polymerase, independent of initiation at position +1. 
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Figure 21; The RNA products detected were initiated from position +3.  (A) 
Wt Le 1-14 template was compared to a 2A mutant template.  Sites of UTP 
incorporation in the product are underlined.  (B) Wt Le RNA was incubated with 
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no polymerase (lane 2) or mutant polymerase (lanes 3 and 6) as negative 
controls for RNA synthesis.  Reactions in lanes 1-5 were performed with 1 mM 
each of all four NTPs, supplemented with [α-32P]GTP.  UTP was omitted from 
duplicate reactions in lanes 6, 7 and 8 to halt RNA synthesis at the first site of 
UTP incorporation.  Credit to Sarah Noton for help with the radioactivity and 
running the gel. 
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2.3  End-labeling of in vitro RNA products indicates all detectable products 
are initiated from position +3. 
As a final confirmation that the detectable products were initiated from position 
+3, wt Le or 2A Le 1-14 RNA templates were incubated with wt or mutant 
polymerase complexes, in reactions containing gamma-labeled radionucleotide.  
[γ-32P]NTPs can only be incorporated at the 5´-end of RNA, allowing 
determination of the initiating nucleotide.  In reactions performed with [γ-32P]GTP, 
only RNA products with a 5´- ‘G’ residue would be labeled, eliminating detection 
of RNA initiated with a 5´- ‘A’ residue (for example, opposite position +1).  In 
these reactions, the largest product detected from both the wt Le and 2A RNA 
templates was 12 nt, and the banding pattern was similar to the reactions 
containing [α-32P]GTP (Figure 22, lanes 3 and 5).  In reactions omitting UTP, 
bands of 8 and 9 nt were predominantly detected, and again the pattern was 
similar to the reaction containing [α-32P]GTP, suggesting all detectable products 
were initiated from position 3 (lanes 7 and 9).  This experiment was repeated 
using [γ-32P]ATP in an attempt to label RNA initiated from position +1.  No 
products were detected, confirming that initiation from position +1 is not favored 
in this assay (Figure 23).  Note that the 14 nt band (indicated by an ellipse), 
which is visible in all lanes including reactions containing mutant polymerase, 
likely represents phosphorylated template and is not a product of RNA synthesis. 
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Figure 22; Products of RNA synthesis were initiated with a 5´- ‘G’ residue. 
Wt Le and 2A Le 1-14 RNA templates were incubated with 1mM each ATP, UTP, 
CTP, and 10µM GTP, supplemented with [γ-32P]GTP to detect only RNA initiated 
with a 5´-‘G’ residue (lanes 3-5).  Duplicate reactions were performed omitting 
UTP (lanes 7-9).  Wt Le was incubated with all four NTPs and [α-32P]GTP as in 
previous experiments, as a control.  Wt Le RNA was incubated with mutant 
polymerase as a negative control for RNA synthesis (lanes 4 and 8).  Credit to 
Sarah Noton for help with the radioactivity and running the gel. 
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Figure 23; No initiation is detected from position +1.  Wt Le and 2A Le 1-14 
RNA templates were incubated with 1mM each GTP, UTP, CTP, and 10µM ATP, 
supplemented with [γ-32P]ATP to detect RNA initiated with a 5´-‘A’ residue (lanes 
3-5).  Duplicate reactions were performed omitting UTP (lanes 7-9).  Wt Le was 
incubated with all four NTPs and [α-32P]GTP as in previous experiments, as a 
control.  Wt Le RNA was incubated with mutant polymerase (lanes 4 and 8), and 
incubated without polymerase (lane 10) as negative controls for RNA synthesis.  
Credit to Sarah Noton for help with the radioactivity and running the gel. 
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Collectively, these data show that the RNA generated from the Le promoter 
under these reaction conditions was initiated from position +3, and that initiation 
from position +1 was not detectable.  Importantly, these data demonstrate that 
the polymerase is able to initiate RNA synthesis at position +3 independently of 
initiation at position +1, confirming that the position +3 is a bona fide initiation 
site, consistent with the model illustrated in Figure 18. 
 
2.4 Mutations that make Le3-12 identical to the L GS signal result in 
extension of the RNA initiated at position +3, and decreased initiation at 
position +45 at the first gene start. 
The results presented thus far show that the RSV polymerase can generate short 
transcripts from a sequence resembling the L GS sequence at nucleotides 3 to 
12 of the Le region.  This is consistent with previous findings that showed that nt 
3, 4, 5, 8, 9, 10, 11 and 12 are required for transcription initiation (64).  However, 
these findings raise the question of why RNA initiated at position +3 is terminated 
after synthesis of only ~25 nucleotides, whereas the L mRNA can be extended 
several hundred nucleotides.  One possible explanation is that initiation 
sequence may impact polymerase processivity; there is a two-nucleotide 
difference between Le nucleotides 3 to 12 and the L GS signal.  To investigate if 
the sequence at Le 3-12 can alter elongation of RNA initiated at position +3, 
experiments were carried out using the minigenome system to study Le 
substitution mutants.  The minigenome system is a cell-based assay that allows 
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for the investigation of cis-acting sequences involved in transcription and 
replication, enabling the study of mutations to the promoter regions that would 
otherwise be lethal in the virus.  A minigenome plasmid typically contains one or 
two reporter genes flanked by GS and GE signals, and bordered by 3´- Le and 
5´- Tr regions.  The minigenome is expressed from a T7 promoter at its 5´-end, 
and the 3´-end is generated by a ribozyme.  Minigenome plasmids are 
transfected into cells along with “helper” plasmids, which express N, P, M2-1, 
and L proteins, and T7 polymerase is provided in trans by coinfection with a 
modified vaccinia Ankara virus engineered to express T7 (MVA-T7).   
 
In the following experiments, two mutant minigenomes with nucleotide 
substitutions in Le 3 to 12 that increase similarity to the L GS signal were utilized.  
The first minigenome contained a substitution at position 4 from G to C (“4C”), 
increasing identity of the Le to L GS sequence to 9 out of 10 nucleotides, while 
the second minigenome contained both the 4C substitution and a substitution at 
position 7 from U to G (“4C7G”), effectively recreating the L GS sequence from 
positions 3 to 12 of the Le (Figure 24, panel A).  The minigenomes contained a 
chloramphenicol acetyltransferase gene (CAT) split into two cistrons by the N-P 
gene junction, and flanked by the NS1 GS and the L GE sequences.  These 
minigenomes also possessed a mutation in the Tr region rendering them 
replication incompetent to ensure that the effect of mutations on the levels of 
replication could not influence transcription (64).  Wt (4G), and the 4C and 4C7G 
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minigenomes, were transfected into cells and total intracellular RNA was isolated 
for analysis.  RNA from transfection of wt minigenome without the L plasmid (-L) 
was used as a negative control for RNA synthesis. 
 
Primer extension analysis of RNA isolated from transfections with the mutant 
minigenomes was performed using primers that correspond to genome positions 
15-39, 45-68 and 56-75.  The first two primers were used to detect initiation from 
positions +1 and +3, while the third primer was used to detect initiation at the first 
GS signal at position +45.  Primer extension analysis with g15-39 shows RNA 
initiated from position +3 could be detected from the wt (4G) and mutant 
minigenomes (Figure 24, panel B, i).  Interestingly, the ratio of +3 to +1 initiation 
in the 4C mutant was higher than the wt, suggesting the +3 site is used with 
greater frequency in this mutant, or that the RNA that is made is more stable 
(panel B (i), lane 3, and panel C).  It should be noted that initiation at position +1 
(replication) is also increased in the 4C mutant, a finding that has been 
recognized in previous studies (35; 64; 84).  It is not currently understood why 
this is the case, and the present study does not attempt to address this 
phenomenon.  No RNA initiated from position +1 was detected from the 4C7G 
minigenome, consistent with previous studies showing this mutation strongly 
reduces replication (64), but levels of +3 initiation were still high (panel B (i), lane 
4).  Analysis with the g45-68 primer showed that initiation from position +1 was 
still detectable from wt and the 4C mutant.  However, while initiation at position 
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+3 decreased in the wt, the relative levels of RNA initiated from +3 detected from 
the 4C and 4C7G mutants were similar to those detected with the g15-39 primer.  
This result indicated that while the RNA initiated at +3 on the wt template was 
terminated prior to the GS signal, the RNA initiated at +3 of the mutant 
minigenomes was efficiently elongated beyond the first GS signal (panel B (ii), 
lanes 2, 3 and 4).   
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Figure 24; Single nucleotide substitutions of the Le promoter allowed RNA 
initiated from position +3 to be efficiently extended past the first GS.  (A) 
Minigenome constructs containing substitutions in the Le promoter.  Mutations 
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made were to position 4 G-C and position 7 U-G.  These mutants were compared 
to a minigenome containing a wt 4G Le sequence.  Minigenomes contained a 2 
C-G substitution in the Tr region rendering them non-replicating.  Genome 
positions the primer corresponded to are shown in purple.  Le1-12 sequences of 
the wt and mutants compared to the L GS are shown below.  Substituted nt are 
bold and italic.  (B) Primer extension analysis of RNA isolated from transfections 
with wt (4G) and mutant minigenomes.  The RNA was analyzed using primers 
g15-39 (i) and g45-68 (ii) to assess extension of RNA initiated from positions +1 
and +3, as indicated.  Lane 1 in each panel contains a negative control of RNA 
from cells transfected with wt minigenome, but lack the L plasmid.  The asterisk 
in panel (i) indicates a non-specific background band. (C) Quantification of 
replicates of these experiments, showing RNA initiated from +3 (black bars), 
compared to RNA initiated from +1 from wt normalized to 100% (white bars).  
Bars show the mean of three experiments, with standard error indicated. 
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Because the RNA initiated from position +3 of the mutant minigenomes was 
extended into the first GS signal, we wanted to determine if transcription initiation 
at position +45 was impacted.  Primer extension analysis with primer g56-75 
showed an almost 2-fold reduction in initiation at the first GS signal for the 4C 
and 4C7G mutants as compared to wt (Figure 25, panel B (i), and C).  Longer 
exposures of the same primer extension gel allow for direct comparison of the 
levels of initiation at the GS and initiation from position +1 and +3 (panel B, ii).  
While transcription initiation at position +45 was clearly impacted by mutations 
that affect elongation of the RNA initiated at position +3, the RNA initiated from 
+45 was still much more abundant than the RNA initiated from within the Le.  
This indicates either that transcription initiation occurs more frequently than 
initiation at position +3, or that the RNA generated at the first GS is more stable.  
Remarkably, this result demonstrates that mutation of the initiation sequence in 
the Le has an affect on initiation nearly 40 nt downstream at the first GS signal.   
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Figure 25; Mutation of the Le sequence impacts transcription initiation at 
position +45.  (A) Position of genome the primer corresponded to is shown in 
purple.  (B) Primer extension analysis of RNA isolated from wt and mutant 
minigenome transfections, analyzed with primer g56-75, to examine initiation at 
the first GS signal at position +45.  Panel (ii) is a longer exposure of panel (i).  
Although we did not use markers corresponding to +1 and +3 initiated RNA, we 
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can infer that the products at the top of the gel are initiations from position +1 and 
+3 based on the banding pattern.  This allows for direct comparison with 
initiations from +45 (bottom). (C) Quantification of initiations at positions +45 
determined from replicates of panel (i).  The data are normalized to the level of 
RNA from wt minigenome at 100%. 
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To determine how far RNA initiated from position +3 was extended, the RNA 
generated from the Le mutants was further analyzed by Northern blot.  Using a 
probe to detect RNA initiated from within the Le region (g7-34), antigenome but 
no other LeC-containing RNA was detected from the wt minigenome, as 
expected (Figure 26, panel B).  However, in addition to antigenome, LeC-
containing RNA that was the appropriate size to be LeC-CAT 1 read through 
mRNA was detected from both the 4C and 4C7G mutants.  Additionally, both 
mutants generated a heterogeneous smear of LeC-containing RNA, ~200 
nucleotides in length (lanes 3 and 4).  Blots were also probed for positive sense 
RNA using a negative-sense CAT-specific RNA probe, to compare levels of 
antigenome, CAT1 mRNA and CAT2 mRNA.  Both the 4C and 4C7G mutants 
produced lower levels of CAT1 and CAT2 mRNA compared to wt, consistent with 
the primer extension analysis (panel C) and previously published data (64).  As a 
control, a positive-sense CAT specific probe was used to detect levels of input 
minigenome, confirming the same amount of minigenome was transfected for 
each condition (panel D). 
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Figure 26; Substitutions within the Le promoter result in the generation of a 
Le-CAT 1 readthrough mRNA.  (A) Minigenome schematic showing 
hybridization positions of the Le-specific oligo and (-) sense CAT riboprobe 
(bottom, purple), and the (+) sense CAT riboprobe (top, blue).  RNA isolated from 
minigenome transfections was migrated on 1.5% agarose-formaldehyde gels.  
(B) Blot probed with g7-34 to detect antigenome and LeC-containing RNA.  
Antigenome, Le-CAT 1 mRNA and truncated LeC are indicated.  Note that a 
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background band that comigrates with antigenome is visible in the –L control 
(lane 1).  (C) Blot was probed with a negative-sense CAT-specific riboprobe to 
detect antigenome and mRNA (as indicated).  (D) Blot was probed with a 
positive-sense CAT riboprobe to detect input minigenome, as a transfection 
control.  Lane 1 in all blots is negative control of RNA from cells transfected with 
wt minigenome without the L plasmid. 
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Taken together, these results show that mutation to the sequence at positions 3-
12 of the Le can alter polymerase processivity and result in efficient elongation of 
the RNA initiated from position +3.  Additionally, these mutations had an impact 
on transcription initiation at the first GS signal, indicating that events at the 
promoter can affect events downstream. 
 
2.5 The polymerase that initiates within the Le is capable of sequential 
downstream transcription of gene 2. 
Because a single 4C substitution resulted in elongation of the RNA initiated from 
position +3 beyond the first GS signal, we wanted to determine if the polymerase 
could engage in downstream transcription after releasing the RNA initiated from 
+3.  To facilitate analysis of the RNA initiated from +3, the first GS signal of 
mutant minigenomes containing either a wt Le (4G) or the 4C substitution was 
deleted to ablate production of CAT 1 mRNA (Figure 27, panel A).  These 
minigenomes also contained a wt Tr region and were capable of multi-cycle 
replication, to enhance the signal from CAT 2.  A wt minigenome with an intact 
CAT 1 GS was used to size the RNA generated from the mutant minigenome. 
 
Northern blot analysis of RNA from the mutant minigenomes recapitulated the 
result from Figure 25, in that the 4C mutant generated a LeC-CAT 1 read through 
mRNA, and was the appropriate size to have been terminated at the first GE 
signal (Figure 27, panel B, compare lane 3 to lane 2).  This RNA was not 
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detected from the wt minigenome (lane 4).  Moreover, CAT 2 mRNA could be 
detected at ~50% of wt levels from the 4C minigenome, indicating that the 
polymerase that initiated at position +3 was capable of sequential downstream 
transcription (panel B, and quantitation in panel C).  The RNA was also treated 
with nuclease to determine the encapsidation status of the RNA initiated within 
the Le.  As expected, antigenome was not degraded by nuclease treatment, but 
the LeC-CAT 1 read through mRNA was ablated, indicating that this RNA was 
not encapsidated (panel B, lanes 5-8).  Finally, primer extension analysis of 
these minigenomes using a primer corresponding to genome positions 24-50 
detected a doublet at position +3 (panel D, doublet indicated with an ellipse).  
The reverse transcriptase tends to fall off the RNA when it encounters a 5´-cap, 
resulting in two cDNAs that migrate as a doublet (208; 223).  Thus, this result can 
be taken as evidence that the RNA initiated from position +3 of the 4C 
minigenome was capped. 
 
Taken together, these data suggest that polymerase processivity from position 
+3 can be influenced by the initiation sequence.  More significantly, mutations at 
positions 4 and 7 can have an effect on initiation further downstream.  When the 
sequence is highly identical to a GS signal, the polymerase can cap and extend 
the RNA initiated from position +3, and respond to downstream transcription 
signals, which fits with a model in which the transcribing polymerase must initiate 
at position +3 (Figure 18).   
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Figure 27; The polymerase that initiates from position +3 of the Le is 
capable of downstream transcription.  (A) Replicating minigenomes containing 
either a ‘G’ or ‘C’ residue at position 4 of the Le, and with the first GS sequence 
deleted to ablate production of CAT 1 mRNA (-GS).  A wt 4G minigenome with 
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an intact GS sequence was used as a size marker for RNA produced from the 
mutant minigenome (+GS).  Hybridization positions of probes and primers are 
indicated.  (B) Northern blot analysis of RNA isolated from transfected cells.  
RNA was prepared in duplicate, such that RNA in lanes 5-8 was treated with 
nuclease to digest unencapsidated RNA.  RNA isolated from transfections with a 
wt minigenome with an intact GS signal was migrated as a size marker (+GS, 
lanes 2 and 6).  RNA isolated from transfections with wt minigenome without L 
plasmid was used as a negative control (lanes 1 and 5).  (C) Quantification of the 
CAT 1 and CAT 2 mRNAs normalized to the level of CAT 1 mRNA from +GS 
minigenome.  Data is represented as the mean of three experiments and 
standard error bars are indicated.  (D) Primer extension analysis of the 4C and 
4G (wt) minigenomes lacking the first GS signal.  The primer hybridized from 
positions 24-50 of the LeC.  Initiations from positions +1 and +3 are indicated 
(markers not shown), and doublet representing capped +3 product is indicated 
with a dot (lane 2).  RNA from a wt minigenome transfection without the L 
plasmid was used as a negative control (lane 1). 
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Discussion 
 
Summary of Results 
We have been able to reconstitute Le RNA synthesis in vitro using purified RSV 
polymerase and an RNA template corresponding to Le nucleotides 1 to 14.  RNA 
synthesis was both polymerase dependent and promoter specific, and all 
detectable RNA products were initiated from position +3.  No initiation from 
position +1 was observed.  Mutation of the Le sequence to increase its similarity 
to the L GS signal resulted in elongation of RNA initiated from position +3 beyond 
the Le region, and a decrease in initiation at position +45 at the first GS signal.  
The resulting RNA was apparently terminated at the first GE signal, was not 
encapsidated, and the polymerase that initiated at position +3 was able to 
reinitiate transcription downstream at the next GS signal.  These results suggest 
that transcribing polymerase is able to initiate at the 3´-end of the genome and is 
not constrained to initiate at the first GS signal.  Additionally, the results of the 
minigenome experiments show that a single nucleotide substitution is sufficient to 
increase elongation of the RNA initiated from position +3 and impact the level of 
downstream initiation, indicating that the sequence of the initiation signal may 
play a role in polymerase processivity. 
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Capping as a checkpoint for RNA elongation 
The results presented here demonstrate that the sequence of the template can 
influence polymerase activity.  Substitution of Le position 4G to C results in 
stable elongation of RNA initiated from position +3, and the results of primer 
extension analysis and nuclease treatment suggest that the RNA is a product of 
a transcriptase, in that it is unencapsidated and potentially capped.  This result 
raises the question of why the +3 RNA initiated from the wt Le sequence is not 
efficiently extended beyond 25 nucleotides.  Due to the heterogeneous size of 
the small RNA, it is most likely that the polymerase generating the RNA reaches 
a checkpoint in RNA synthesis, rather than a defined termination signal.  As 
previously discussed in Chapter 1, failure to become encapsidated by N protein 
is one possible checkpoint.  Another checkpoint could be the failure of the 
nascent RNA to become capped, although these checkpoints are not mutually 
exclusive.  Capping of viral mRNA is required for mRNA stability and allows the 
mRNA to be translated on the ribosome.  Previous studies of an RSV capping 
inhibitor showed that an mRNA that does not become capped is terminated after 
synthesis of less than 50 nucleotides (152).  It is known for VSV that initiation of 
RNA synthesis and capping of the nascent RNA are both directed by separable 
elements within the GS sequence (234).  In the VSV study, mutation of 
nucleotides 1 or 3 of the GS sequence inhibited transcription, while mutation of 
nucleotide 2 did not inhibit RNA synthesis, but prevented capping and 
polyadenylation of the RNA (234).  Similarly, the wt sequence from 3-12 of the Le 
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may be sufficient for directing the polymerase to initiate RNA synthesis at this 
site, but the two-nucleotide difference could ablate the signal for capping.  This 
idea is supported by the minigenome data presented here, in that a single 
nucleotide substitution at position 4 results in elongation of the +3 RNA, and the 
primer extension data suggests this RNA is capped.  During wt RSV infection, 
initiation at this site would serve to allow the polymerase to gain access to the 
first GS signal.  In this model, elongation of this RNA due to capping would be 
detrimental to downstream transcription, and therefore does not occur from a wt 
promoter sequence. 
 
In VSV, RNA is capped after synthesis of 31 nucleotides (243).  It is thought that 
this is the minimum length necessary to allow the 5´- end of the RNA to be 
extruded from the polymerase active site and contact the putative capping 
domain (243).  In RSV, experiments with a polymerase mutant that is defective 
for capping show that failure of mRNA transcripts to become capped result in 
mRNA being truncated around 45 to 50 nucleotides ((48), also see Appendix 2).  
No 25 nucleotide RNA was detected, in contrast to the Le studies.  However, it is 
difficult to determine whether the RNA made from the Le is aborted because it 
fails to become capped, or if it fails to become capped because it is not 
elongated far enough for the 5´-end of the RNA to contact the polymerase 
capping domain.  While the result with the L capping mutant may suggest that 
the checkpoint in the Le is therefore not capping, it may also indicate that there 
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are differences in the elongation abilities between a polymerase that initiates 
near the 3´-end of a template and one that initiates at the GS signal.   
 
Failure to detect initiation from position +1 in vitro 
It is worth commenting on the failure of the in vitro RNA synthesis assay to detect 
initiation from position +1.  It is possible that +1 initiation was occurring but at 
levels too low to be detected.  Primer extension analysis of RNA initiated from 
the Le in wt RSV infection show there is a much higher level of RNA initiated 
from position +3 than from position +1.  Another possibility is that +1 initiation is 
not occurring in this assay because it requires the presence of N protein to 
become concurrently encapsidated.  This would be simple to test if it were 
possible to purify soluble N protein.  This has proven technically difficult as N 
protein tends to self-aggregate when not in the presence of P protein (12; 181).  
However, an N protein mutant exists that is unable to self-assemble, and may be 
useful to discern whether association of N with the L-P complex has a 
fundamental impact on whether the polymerase acts as a replicase.  Additionally, 
sequence beyond Le1-14 may be required for initiation at position +1 (163).  
Longer Le templates could be tested in the in vitro assay, however the difficulty 
with this is that longer RNA templates may adopt secondary structures and 
therefore be unsuitable in this assay.  But the ability to use encapsidated 
templates in the assay may present a solution to this problem.  Finally, in the 
minigenome system, substitutions or deletions of the template at positions 1 and 
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2 are largely corrected back to wt sequence in the product, suggesting that 
replication may be initiated with an A-C dinucleotide primer in a non-templated 
manner (185).  A similar mechanism for non-templated replication initiation using 
a self-generated primer has been demonstrated in Dengue virus as well (220).  
Thus, it is possible that under the conditions tested here, an A-C dinucleotide 
primer could not be synthesized or scavenged from the cellular milieu.  The idea 
that replication initiation from position +1 requires a non-templated A-C 
dinucleotide fits nicely with the idea that transcription initiates de novo from 
position +3.  This theory is explored in more detail in the Concluding Remarks. 
 
Modified model of transcription initiation by the RSV polymerase 
At the beginning of this chapter we proposed a simplified model for transcription 
initiation by the RSV polymerase (Figure 18).  The data presented here support 
our hypothesis that the +3 initiation site is a bona fide initiation site used by the 
transcribing polymerase.  The results of the in vitro RNA synthesis assay indicate 
that the polymerase can initiate at position +3 independently of initiation at 
position +1.  The minigenome studies showed that the polymerase that initiates 
at position +3 is capable of downstream transcription in the absence of the first 
GS signal, and that the Le initiation sequence has an affect on downstream 
transcription initiation events.  Putting these results together with results from 
Chapter 1, we offer the following expanded model for transcription initiation by 
the RSV polymerase:  The polymerase enters the genome at the 3´-end of the 
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template and binds to nucleotides 3 to 12 of the Le.  De novo RNA synthesis is 
initiated opposite position +3 and the polymerase moves past the promoter.  After 
the synthesis of approximately 25 nucleotides, the polymerase reaches a 
checkpoint and aborts synthesis of the RNA.  The polymerase is now poised to 
scan the template to locate the first GS signal at position +45 and reinitiate RNA 
synthesis.  The polymerase that reinitiates RNA synthesis at position +45 
becomes committed to sequential mRNA transcription (Figure 28, panel A).  
Transcription might also be performed by a polymerase that initiates at position 
+1 and generates a transcript that fails to become encapsidated before the 
checkpoint at ~25 nucleotides.  RNA replication occurs if the polymerase initiates 
at +1 and the RNA becomes encapsidated with N protein before the ~25 
nucleotide checkpoint.  Initiation at position +1 may require an A-C dinucleotide 
primer (panel B). 
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Figure 28; Modified model for transcription initiation by the RSV 
polymerase. (A) The polymerase enters the template at the 3´-end of the 
genome and binds to a promoter within the first 12 nucleotides of Le.  
Transcription is initiated opposite position +3 (1).  The polymerase reaches a 
checkpoint in RNA synthesis at ~25 nucleotides and aborts the nascent RNA (2).  
The polymerase scans the rest of the Le region and reinitiates transcription at 
position +45 (3).  (B) During replication, the polymerase initiates opposite position 
+1 of the Le.  In some cases, the polymerase aborts synthesis of the RNA at ~25 
nucleotides, possibly due to failure of the RNA to become encapsidated (4).  
Replication of full-length antigenome occurs from +1 in the presence of sufficient 
N protein (5). 
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Critique of the model 
A possible criticism of this model is that even when a sequence that is identical to 
the L GS sequence was recreated at positions 3-12, and the RNA initiated at 
position +3 was efficiently elongated, transcription initiation at position +45 was 
not completely inhibited.  In fact, as demonstrated in figure 24, initiation at 
position +45 is only about 2-fold lower than in the wt minigenome.  There are 
several potential explanations for this apparent discrepancy.  First, re-initiation at 
position +45 may be accomplished by polymerase that initiates at position +1 but 
terminates within the Le region due to failure of the RNA to become 
encapsidated, essentially an aborted replication attempt.  A second possibility is 
polymerase that initiates at position +3 but releases the RNA prior to capping, 
and scans the Le to the first GS signal.  Third, polymerase that initiates at 
position +3 and caps the nascent RNA may still terminate RNA synthesis within 
the first gene, as evidenced by the ~200 nt LeC-containing RNA detected by 
Northern blot (Figure 26).  This polymerase could potentially scan backward to 
the first GS signal and initiation transcription.   
 
Another possible explanation of this result, which is perhaps the most exciting, is 
the idea that both the +3 initiation site and the +45 initiation site are used to 
initiate transcription in a temporal manner.  The primary initiation event on a 
given nucleocapsid may occur at position +3, and then once the N protein has 
been displaced along the Le region, all subsequent initiations on that template 
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are able to occur at position +45.  In this model, the 3´-end of the genome may 
fold into a secondary structure upon N protein being locally removed, bringing the 
polymerase binding within the Le into close proximity with the first GS sequence, 
allowing initiation to occur directly at position +45.  This model is appealing 
because it may also provide an explanation for the disparate results obtained for 
VSV concerning whether transcription at the GS signal required prior 
transcription of the Le, discussed in the introduction to this chapter (267).  In 
those studies, UV mapping was performed on VSV nucleocapsids isolated from 
virions in vitro, and showed that Le synthesis was required for downstream 
transcription.  However, nucleocapsids isolated from virus infected cells behaved 
differently, and UV mapping showed that Le synthesis was not required (267).  
The critical difference between these two experiments is the origin of the 
nucleocapsids.  Virion-derived nucleocapsids are freshly synthesized and 
packaged into nascent virus particles and have not yet been used as a template 
for RNA synthesis, whereas nucleocapsids isolated from infected cells represent 
a population of templates that are in various stages of use by the viral 
polymerase.  This idea suggests that for a given template, there may be a 
fundamentally different series of events occurring depending on what point that 
template is at in the replication cycle. 
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Does the polymerase direct transcription from the replication promoter? 
Notably, initiation from position +3 leading to the generation of a small RNA is not 
exclusive to the Le promoter.  As shown in Chapter 1, RNA synthesis is initiated 
at the +3 site and an ~25 nt RNA is generated from the TrC promoter in the 
antigenome as well.  This is not surprising considering the sequence similarity 
between the Le and TrC promoters.  However, this finding suggests the exciting 
possibility that both promoters can direct initiation of transcription.  While only the 
Le promoter with downstream genes is capable of directing mRNA synthesis, the 
TrC promoter can synthesize a short RNA.  This may suggest that the small 
RNAs are not just generated as a byproduct of RNA synthesis initiation and 
promoter escape, but may possess a viral or cellular function.  This idea will be 
explored in Appendix 1. 
 
Future Directions 
It would be interesting to determine whether failure of the polymerase to cap the 
RNA is responsible for termination within the Le.  One of the problems with the 
minigenome experiments is that the transfections were carried out with 
coinfection with MVA-T7 to drive expression of the minigenome and helper 
plasmids.  The vaccinia polymerase has been shown to possess promiscuous 
capping activity and therefore it is impossible to determine whether capping can 
be attributed to the RSV polymerase.  To negate the effects of coinfection with 
MVA-T7, these experiments could be repeated using BSR-T7/5 cells, baby 
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hamster kidney cells that stably express the T7 polymerase.  We did attempt to 
perform tobacco acid pyrophosphatase (TAP) digestion of RNA from RSV 
infection followed by primer extension analysis to determine whether RNA 
initiated from position +3 was capped, however these experiments were 
unsuccessful and will require optimization (see Appendix 3).  It would also be 
useful to develop a trans-capping assay similar to the one used for VSV, which 
would allow us to examine the template sequence requirements that influence 
capping by the RSV polymerase (148; 188).  The trans-capping assay is a 
minimalist assay that would utilize purified RSV polymerase and an artificial 
template to distill the study of the RSV polymerase capping function to its most 
basic components. 
 
Another interesting direction this work could take would be to test the model 
concerning temporal regulation of transcription on a given nucleocapsid.  
Nucleocapsids isolated from virions, and from various timepoints during RSV 
infection could be tested in an in vitro transcription assay to determine whether 
transcription is dependent on prior Le synthesis, similar to the studies done for 
VSV (267).  Other experiments that could be done to test this idea would be to 
reexamine previously described non-replicating minigenome mutants that have 
substitutions at positions within the Le that are critical for downstream 
transcription (64).  Primer extension analysis could be performed on RNA 
isolated from transfections with these mutants to determine whether they are 
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unable to utilize the position +3 initiation site.  If downstream transcription were 
dependent on the primary initiation event occurring within the Le, then we would 
predict that these mutants might be unable to initiate at position +3. 
 
In conclusion, the data presented in this chapter indicate that the +3 initiation site 
is accessed by the RSV polymerase independently of the +1 initiation site, and 
polymerase processivity from this site is influenced by the initiation sequence.  
These data, in conjunction with the findings of Chapter 1 have led us to propose 
a model for transcription initiation whereby the RSV polymerase initiates at 
position +3 of the Le, generates a small RNA, scans to the first GS signal and 
becomes committed to transcription.   
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Concluding Remarks 
 
Summary of Results 
The mechanism of transcription initiation by the non-segmented negative sense 
RNA viruses has been debated for several decades.  Models proposed for 
related viruses were not sufficient to explain the mechanism for RSV, thus we set 
out to explore the behavior of the RSV polymerase at the promoter regions.  We 
hypothesized that the sequence from Le nucleotides 3-12 serves as a 
recruitment site for the transcribing polymerase.  This hypothesis was supported 
by saturation mutagenesis indicating the importance of nucleotides within this 
sequence for downstream transcription (64), and strong sequence similarity of Le 
nucleotides 3-12 with the L GS sequence (8 out of 10 nt identity).  Furthermore, 
there was evidence for initiation from position +3 demonstrated in the 
minigenome system (185; 187).  In Chapter 1, we were able to show that the 
RSV polymerase initiated RNA synthesis at position +3 of the Le and TrC 
promoters during virus infection.  Surprisingly, RNA initiated from position +3 of 
the Le promoter was more abundant than RNA initiated from position +1, 
suggesting this site is frequently used during infection.  RNA synthesis initiation 
at position +3 resulted in the generation of a short ~25 nucleotide RNA that was 
partially unencapsidated, and this RNA fractionated with subgenomic viral 
mRNA.  These data allowed us to propose a model for transcription initiation, 
whereby the transcribing polymerase enters the Le region at the 3´-end of the 
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genome and initiates RNA synthesis from position +3, synthesizes a short RNA, 
and reinitiates mRNA transcription at the first GS signal.  This is the first 
demonstration of an additional RNA initiation site that is used during RSV 
infection. 
 
In Chapter 2, we tested the model that transcription is initiated from position +3 of 
the Le.  We showed that initiation from position +3 was reproducible in the in vitro 
RNA synthesis assay using a Le RNA 1-14 template and purified polymerase.  
Moreover, we demonstrated that initiation from position +3 occurred 
independently of initiation from position +1, a finding that is consistent with 
previous studies in the minigenome system showing that deletion or substitution 
of nucleotides 1 and 2 did not affect initiation from position +3 (185; 187).  This 
finding suggests the polymerase accesses the +3 initiation site directly, and that 
initiation at position +3 is not dependent on prior initiation from position +1.  As 
mentioned earlier, the sequence from Le positions 3-12 shares eight out of ten 
nucleotide identity with the L GS sequence, thus we wanted to determine 
whether the two nucleotide difference could explain why mRNA initiated from the 
L GS is extended many hundreds of nucleotides, while RNA initiated from 
position +3 is terminated around 25 nucleotides.  A single nucleotide substitution 
of the Le sequence (Le4C) that increased similarity to the L GS sequence altered 
polymerase processivity within the Le region, resulting in stable elongation of the 
transcripts initiated from position +3 through the first gene.  The polymerase that 
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initiated at position +3 was able to engage in downstream transcription of the 
next gene.  This substitution also had the effect of reducing transcription initiation 
at the first GS signal at position +45, indicating that the initiation sequence can 
affect transcription of downstream genes. 
 
Significance 
The significance of the data presented here is two-fold.  First, from a basic 
science standpoint, the results suggesting that transcription initiates at position 
+3 adds to the discussion on how NNS RNA viruses initiate RNA synthesis.  As 
demonstrated by primer extension analysis (Chapter 1) and the in vitro RNA 
synthesis assay (Chapter 2), initiation from position +3 is the dominant initiation 
event in the Le, suggesting the polymerase is adept at initiating internally.  Thus, 
defining the mechanism of RNA synthesis initiation is important because the viral 
polymerase must faithfully replicate the genome ends, and therefore must have 
evolved a way to initiate right at the 3´-end of the template (at position +1).  
Second, understanding the behavior of the polymerase at the promoters may 
expose novel stages in RSV infection that could be targeted by rational drug 
design, and inform vaccine development.  Each of these ideas is explored in 
more detail below. 
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RSV RNA synthesis initiation; challenging the paradigm 
RNA-dependent RNA polymerases are known to initiate RNA synthesis 
predominantly by two mechanisms.  The first mechanism is primer-mediated 
initiation, in which RNA synthesis occurs in a template independent manner and 
requires a protein or nucleic acid primer to initiate.  Examples of this include VPg 
protein-primed transcription of picornaviruses (196) and cap snatching by 
influenza virus (202).  The second mechanism of RNA synthesis initiation is de 
novo initiation, or primer-independent initiation.  De novo initiation is facilitated 
through the formation of a phosphodiester bond between the initiating NTP and 
the second NTP, which are both specified by the template.  The hepatitis C virus 
and rotavirus polymerases initiate de novo (29; 117; 118; 281).  In some 
instances, de novo RNA synthesis can result in the generation of a primer, either 
through abortive initiation or a prime and realign mechanism.  Turnip crinkle 
carmovirus generates short 4-8 nucleotide abortive products de novo that then 
act as primers for synthesis of negative strand RNAs (99).  And some 
arenaviruses and bunyaviruses use a prime-realign mechanism, whereby de 
novo initiation first occurs internally.  Then the nascent RNA primer is shifted 
back such that it aligns with the 3´-end of the template (72; 127). 
 
Some viruses appear to utilize a combination of initiation mechanisms.  For 
example, influenza virus replication has been shown to initiate internally de novo 
and synthesize a dinucleotide primer, which is then realigned to prime replication 
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(49; 280).  Similarly, the polymerase of Dengue virus is able to self-generate a 
dinucleotide primer, which it then uses to initiate from the +1 site (220).  Until 
recently, it was believed that the polymerases of the NNS RNA viruses initiate all 
RNA synthesis by a de novo mechanism.  However, our studies suggest that for 
RSV, transcription initiates de novo at position +3 (186; 250), while replication is 
mediated through a dinucleotide primer corresponding to positions 1 and 2 in a 
nontemplated manner (185). 
 
Primer synthesis: a possible function for the small LeC RNA 
How the dinucleotide primer is generated is still under investigation.  But it is 
possible that the small LeC RNA that is synthesized de novo serves as the 
template for the generation of an A-C dinucleotide.  A sequence element at 
positions 15 and 16 of the LeC RNA could direct synthesis of a dinucleotide 
primer (5´-AC- 3´) for initiation from position +1 (Figure 29).  This scenario might 
represent an adaptation of the prime-realign mechanism utilized by other viral 
polymerases as described earlier, in that the RSV polymerase might synthesize 
the primer from the LeC RNA, instead of from a sequence near the 3´-end of the 
genome (note that there are no sequence elements close to the 3´-end that could 
encode an A-C dinucleotide).  If the small LeC RNA were necessary to generate 
an A-C dinucleotide primer, this could explain why initiation from position +1 was 
not detected in the in vitro RNA synthesis assay.  The template used in the assay 
corresponded to Le nucleotides 1-14; the sequence element that can generate 
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the primer is found just beyond nucleotide 14, thus the primer would not be 
generated and initiation from position +1 would not be reconstituted. 
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Figure 29; Schematic for the generation of a replication primer from the 
LeC small RNA.  The first 27 nucleotides of the Le sequence from the 3´-end of 
the genome are shown at top.  The polymerase initiates RNA synthesis de novo 
from position +3 and generates an ~25 nt RNA (middle).  The sequence element 
at positions 15 and 16 that could encode a di-nucleotide A-C primer is underlined 
and in bold.  The first 27 nucleotides of the LeC sequence at the 5´-end of the 
antigenome is at the bottom, showing incorporation of the primer from position 
+1. 
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RSV as a model for other NNS viruses 
Whether or not the mechanism of transcription initiation utilized by the RSV 
polymerase will serve as a new paradigm for other negative strand RNA viruses 
is still unclear.  Studies carried out for VSV in the in vitro RNA synthesis assay 
failed to turn up evidence for internal initiation or non-templated initiation (173).  
This may simply suggest that the mechanism used by paramyxoviruses is distinct 
from that of rhabdoviruses and other NNS RNA virus families.  However, the 
model may still hold for other members of the paramyxovirus family.  It is 
interesting to note that all the viruses in the paramyxovirus family possess a 5´-
AC at the genome and antigenome termini, suggesting they may all exploit a 
common mechanism for replication initiation (185).  Consequently, we compared 
the Le sequences of other paramyxoviruses, including SeV, MuV, Newcastle 
disease virus (NDV), NiV, MeV, parainfluenza virus 5 (PIV5), parainfluenza virus 
3 (PIV3), and human metapneumovirus (hMPV), to their conserved or consensus 
GS sequences to look for evidence of internal GS-like motifs in the Le region 
(Table 4).  In some instances, internal sequences similar to GS sequences could 
be identified, particularly for NDV and hMPV, however none aligned as strongly 
as the RSV sequences (shown at the top for comparison).  For some viruses, no 
internal alignment could be identified between the Le and GS sequences (SeV, 
MeV, and PIV3).  Interestingly, a GS-like element can be aligned from position +4 
of the VSV (Rhabdoviridae) Le region (bottom), despite a lack of evidence for 
internal initiation in vitro (173).  It would be worthwhile carrying out primer 
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extension analyses on viral RNA isolated from infections with these and other 
viruses, to look for evidence of alternate initiation events. 
 
Table 4; Sequence alignments of paramyxovirus Le and GS sequences.  
Conserved nucleotides are written in uppercase, while for non-conserved 
sequences, the most common nucleotide found at a given position is written in 
lowercase.  ‘N’ represents any nt, ‘Y’ is a pyrimidine (C or U), ‘K’ is ‘U’ or ‘G’.  
The sequence in the Le that can be partially aligned with GS sequences is 
underlined, and the nt that align in the GS are underlined.  (Note that VSV is a 
rhabdovirus) 
RSV  
Le 3´-UGCGCUUUUUUACGCAUGUU… 
GS (L) 3´-  CCCUGUUUUA 
 
SeV  
Le 3´-UGGUUUGUUCUCUUGUUUGA… 
GS 3´-UCCCANUUUC 
 
MuV  
Le 3´-UGGUUCCCCUUUUACUUCUA… 
GS 3´-        UYCKKNYYU 
 
NDV  
Le 3´-UGGUUUGUCUCUUAGGCAUU… 
GS 3´-     UGCCCAUC 
 
NiV  
Le 3´-UGGUUUGUUCCCUCUUAUAC… 
GS 3´-        UCCUngGU 
 
MeV  
Le 3´-UGGUUUGUUUCAACCCAUUC… 
GS 3´-UCCcnggU 
 
 148 
PIV5 
Le 
 
3´-UGGUUCCCCUUUUACUUCAC… 
GS 3´-   UcCgggCa 
 
 
PIV3 
 
Le 3´-UGGUUUGUUCUCUUCUCUGA… 
GS 3´-UCCUNNUUUC 
 
hMPV  
Le 3´-UGCGCUUUUUUUGCGCAUAU… 
GS 3´-  CCCUGUUCA 
 
VSV  
Le 3´-UGCUUCUGUUUGUUUGGUAA… 
GS 3´-   UUGUCNNUAG 
 
 
Other possible functions for the small LeC and Tr RNAs 
As discussed, the small RNAs may serve as a template for primer generation for 
initiation from position +1.  However, these RNAs may also have other functions 
(discussed extensively in Appendix 1).  It has recently been shown that small 
viral RNAs synthesized by influenza virus bind the viral polymerase and influence 
a switch from transcription to replication (199; 200).  Similarly, we have 
preliminary data suggesting the small LeC and Tr RNAs may enhance genome 
replication (See Appendix 1).  The small RNAs may also play a role in the cellular 
response to RSV infection.  The SeV Tr sequence has been shown to bind TIAR, 
a component of stress granules, and block the stress granule response to SeV 
infection (110).  Correspondingly, it has been shown previously that RSV blocks 
the stress granule response to infection, and that the Tr region may play a role 
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(96).  Additionally, virally-encoded microRNAs (miRNAs) and other small RNAs 
have been shown to play diverse roles in virus infection from establishing latency 
to evading the immune response.  It is unclear whether the small RNAs 
generated from the Le and TrC promoters might function as miRNAs.  Despite 
the fact that the ~25 nt RNAs are roughly the size of a fully-processed miRNA, 
they are synthesized de novo from the genome and antigenome, and do not 
appear to be processed in a canonical miRNA fashion.  Typically miRNAs are 
cleaved from larger precursors in the nucleus by an endonuclease called Drosha, 
thus it was believed that cytoplasmic RNA viruses could not synthesize miRNAs.  
However, noncanonical synthesis of a viral miRNA that occurs in the cytoplasm, 
independent of Drosha processing has recently been described (222; 258).  
Additionally, it would be important to ascertain whether or not the LeC and Tr 
RNAs become associated with Argonaute (Ago) proteins to form a functional 
RNA-induced silencing complex (RISC).  To that end, it would be interesting to 
investigate whether the small LeC and Tr RNAs have cellular or viral RNA 
targets.  The small RNAs may also hijack cellular factors and form higher order 
ribonucleoprotein complexes to benefit viral infection.  For example, Epstein-Barr 
virus encodes two small RNAs, EBER1 and EBER2, that are highly abundant, 
form ribonucleoprotein complexes with many host proteins, most intriguingly, La 
autoantigen (144), and are thought to be involved in transformation and 
oncogenesis of the host cell (125; 276).  Such a relationship between the RSV 
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small RNAs and cellular proteins should be explored, since it has been shown 
that RSV LeC RNA also binds La protein (13). 
 
Could the small RNAs play a role in polymerase regulation? 
Taking into consideration the possible functions of the small RNAs, we can 
speculate on the larger question of how the polymerase is regulated between 
transcription and replication.  The results presented in Chapters 1 and 2 allowed 
us to propose a modified model for transcription initiation by the RSV 
polymerase, in which the polymerase enters the encapsidated genome at the 3´-
end of the template and binds to a recruitment site found from positions 3 to 12 of 
the Le.  RNA synthesis is initiated de novo from position +3, and the polymerase 
escapes the promoter and synthesizes approximately 25 nucleotides of LeC 
RNA, before terminating synthesis.  We surmised that the small RNA is not 
terminated at a specific stop sequence but rather that the polymerase aborts 
synthesis after failing a checkpoint for RNA elongation.  Possible checkpoints 
include failure to cap the nascent RNA, or failure of the RNA to become 
encapsidated in viral N protein, and these may both come into play.  The small 
LeC RNA, which likely bears a 5´-triphosphate, becomes bound either in N 
protein or cellular La protein to mask it from pattern-recognition receptors like 
RIG-I (13).  After terminating synthesis of the small RNA, the polymerase is 
poised to scan the rest of the Le region to the first GS signal at position +45, 
where it reinitiates RNA synthesis and becomes committed to a transcription 
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program.    For replication to occur, the polymerase must initiate opposite the first 
nucleotide of the template, and previous studies have indicated that the first two 
nucleotides may be non-templated (185).  Thus, the small LeC RNA might serve 
as a template for the synthesis of the first two initiating NTPs, 5´-A-C.  The 
polymerase may become preloaded in its active site with the A-C dinucleotide 
primer, and would then be able to synthesize full-length antigenome RNA from 
position +1 that is concurrently encapsidated, and which then serves as the 
template for synthesis of genome-sense RNA.  Alternatively, the LeC RNA may 
physically associate with the polymerase and cause a change in the polymerase 
complex structure, altering its function, or it may act as an indicator or feedback 
molecule corresponding to levels of transcription.  All of these possibilities may 
influence the polymerase behavior between transcription and replication.  In 
addition, the polymerase can also initiate at position +3 of the TrC promoter and 
generate the small Tr RNA, which may function similarly to the LeC RNA.  The 
small Tr RNA may also play a role in the cellular stress granule response to 
infection, which could affect viral fitness.  While this is all speculation and the 
function of the small RNAs still needs to be investigated, based on the available 
data for RSV and other viruses (185-187; 199; 200; 220; 280) these scenarios 
are plausible (See figure 30). 
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Figure 30.  The small RNAs might influence polymerase behavior during 
infection.  Schematic showing the production of the ~25 nt RNAs from the Le 
and TrC promoters of the genome and antigenome (shown in gray), respectively.  
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The polymerase is represented as a green oval.  The small LeC RNA might 
serve as the template for the generation of A-C dinucleotide primers needed for 
replication from position +1.  It might also physically bind the polymerase 
complex and influence its behavior.  Both activities might lead to a shift from 
transcription to replication.  The small Tr RNA might function similarly, and might 
also play a role in the stress granule response.  Both RNAs might have other 
cellular or viral roles that should be explored (indicated by the question mark).  
Not to scale. 
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Application of these studies towards the development of treatments and 
vaccines for RSV infection 
As a final note, there is a demonstrated need for RSV antiviral compounds, as 
treatment of severe RSV infection is currently limited to supportive care.  The 
RSV RNA-dependent RNA polymerase is responsible for carrying out both 
transcription and replication from the same or overlapping promoter regions in 
the Le.  Thus, inhibiting the RSV polymerase or blocking the interaction between 
the polymerase and the promoter would effectively arrest the viral replication 
cycle, making it an excellent target for the development of novel therapeutics.  
The studies presented here have improved our knowledge of how the 
polymerase initiates RNA synthesis and becomes committed to transcription, and 
could inform rational drug design.  This knowledge could be applied to a couple 
of different novel strategies.  Antisense oligodeoxynucleotides (AS-ODNs) are 
small molecules, 15-20 nucleotides in length that are designed to target viral 
sequences (201; 278).  When targeted against translational regulatory 
sequences of NS1 and NS2 mRNAs, AS-ODNs were shown to be effective in 
inhibiting translation of these proteins (US patent 5 831 069).  They can also be 
coupled with 2´, 5´-oligoA-dependent RNase L, which recruits RNase L to the 
RNA:DNA duplex, resulting in degradation of the target RNA (139).  An AS-ODN 
designed to be complementary to the LeC or Tr small RNAs may have a potent 
effect RSV replication, as preliminary data suggests the small RNAs play a role 
in influencing replication (Appendix 1).  A molecule representing the Le or TrC 
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promoter region may also function secondarily as competitor for polymerase 
complex, greatly reducing the pool of available polymerase for transcription and 
replication.   
 
A clearer understanding of polymerase behavior at the promoters could be 
applied to the development of live-attenuated vaccines for RSV.  Live-attenuated 
vaccines do not induce vaccine-enhanced disease like their killed vaccine 
counterparts, and are therefore a promising avenue for vaccine development 
(179).  However, it is difficult to balance sufficient attenuation of the virus for 
vaccine safety and a robust ability to elicit a protective immune response.  
Engineering a recombinant virus with mutations to the Le promoter that promote 
transcription over replication may result in a vaccine strain that is strongly 
antigenic but is greatly impaired in viral replication.  In Chapter 2, we showed that 
a mutation at position 4 from wt ‘G’ to ‘C’ results in elongation of RNA initiated 
from position +3 to the first GE signal, and reduces the level of mRNA 
transcription initiation at the first GS signal.  A recombinant RSV with a 4C Le 
sequence has been rescued and has also arisen naturally through cold-passage 
in cell culture (67).  This virus was shown to have a small plaque phenotype, and 
replicates to a lower titer than a wt 4G clone.  However pathogenicity and 
virulence was not reduced in chimpanzees (112; 270).  Whether this mutation 
alters the balance between transcription and replication has not been reported.  If 
the RNA initiated from position +3 of the Le is elongated in a 4C virus, we would 
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expect the transcription gradient of the viral genes to be impacted, since there 
was a measurable decrease in initiation from position +45 in the minigenome 
system.  The first viral gene is NS1, which plays a role in inhibiting the induction 
and signaling of type I and type III IFN.  It is known that replication of a delta-NS1 
RSV is attenuated in IFN-responsive cells (113; 229; 244; 245; 269).  It would be 
interesting to determine the effect of a reduction in NS1 transcription, via 
generation of a Le-NS1 read through RNA, on RSV fitness and the immune 
response to infection, to evaluate whether this virus would be a good candidate 
for an attenuated vaccine. 
 
In conclusion, we have shown that the RSV polymerase initiates RNA synthesis 
frequently from an additional site in the Le region during infection.  Initiation from 
this site is independent of initiation at position +1 and may provide the 
polymerase with a mechanism to access the first GS signal and become 
committed to transcription.  Additionally, small RNAs are generated from both the 
Le and TrC promoters in association with initiation at position +3.  This is the first 
demonstration of an previously undescribed initiation site being used during NNS 
RNA virus infection, and challenges the dogma that all RNA synthesis is initiation 
from position +1.   
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Appendix 1:  Functional analysis of the small RNAs generated from the 
viral promoters 
 
Introduction 
 
The interesting finding that RSV generates small non-coding RNAs from both the 
Le and TrC promoters (Chapter 1) led us to question whether these RNAs play a 
role in viral replication or the host response to infection.  The following is a review 
of what is known about virally encoded small RNAs. 
 
Virus-derived microRNAs 
MicroRNAs (miRNAs) are small, non-coding RNAs approximately 22 nucleotides 
in length that play a regulatory role in gene expression in plants and animals 
(reviewed in (6)).  MiRNAs are highly conserved and are likely to be involved in 
nearly every process in the cell (135; 137; 141).  Dysregulation of miRNAs has 
now been implicated in many disorders including cancer (100; 174; 175), obesity 
(214; 282; 283), heart disease (240; 247; 257), heritable diseases (47; 106; 170), 
and schizophrenia (10; 11; 65).  Canonical miRNAs originate from RNA 
polymerase II transcripts called primary miRNAs (pri-miRNAs).  Pri-miRNAs are 
capped, polyadenylated and spliced RNA stem-loop structures, several hundred 
nucleotides in length.  Pri-miRNAs are processed in the nucleus by the 
endonuclease Drosha in concert with a double-stranded RNA binding protein, 
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DGCR8 (together called the “Microprocessor”), to generate 70-80 nucleotide 
stem-loop precursor miRNAs (pre-miRNAs), which are then exported from the 
nucleus (79).  In the cytoplasm, pre-miRNAs are cleaved by the enzyme Dicer, 
which generates an approximately 22 nucleotide imperfect miRNA:miRNA* 
duplex (156).  The passenger strand (miRNA*) is typically degraded, while the 
guide strand is loaded into an RNA induced silencing complex (RISC).  
Argonaute (Ago) proteins are part of the RISC complex and serve to direct the 
guide strand to a target mRNA (211; 219).  In cases of perfect complementarity 
between the miRNA and the mRNA target, some Ago proteins such as Ago2 can 
directly degrade the target mRNA (16; 151; 168; 190).  When the base pairing 
between the miRNA and the target mRNA is imperfect, silencing of the mRNA is 
mediated through translational repression instead of cleavage (142; 150; 271).  
Recognition of a target mRNA can be achieved with only 6-8-nucleotide identity, 
in a region known as the “seed region” found at the 5´-end of a miRNA from 
nucleotides 2 through 7. (For overview, see Figure A1). 
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Figure A1; miRNA biogenesis pathway.  Illustration showing the canonical 
pathway of miRNA processing.   
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Since miRNAs are such potent tools for the manipulation of the cellular 
environment, it is unsurprising that some viruses have evolved to encode their 
own miRNAs.  The majority of viral miRNAs that have been identified thus far 
have been shown to be involved in inhibiting the cellular antiviral response to 
infection, or in downregulating the expression of certain viral proteins to establish 
viral latency (reviewed in (254)).  Currently there is little data to support the 
hypothesis that virus-encoded miRNAs play a role in pathogenesis or replication 
of the virus, although studies in this area are ongoing (236).  Table A1 lists all the 
currently known viruses that generate miRNAs.  
Table A1; Viruses known to express viral miRNAs (adapted from Kincaid and 
Sullivan, 2012 (122), and updated from miRBase (80-82; 126)) 
Virus Family/ 
Subfamily Virus species 
α-herpesviruses Herpes Simplex Virus 1 
 Herpes Simplex Virus-2 
 Herpes B virus 
 Herpesvirus of turkeys 
 Infectious laryngotracheitis virus 
 Duck enteritis virus 
 Bovine herpesvirus 1 
 Marek’s disease virus type 1 
 Marek’s disease virus type 2 
 Pseudorabies virus 
β-herpesviruses Human cytomegalovirus 
 Mouse cytomegalovirus 
 Human herpesvirus 6B 
γ-herpesviruses Epstein-Barr virus 
 Rhesus lymphocryptovirus 
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 Kaposi’s sarcoma-associated herpesvirus 
 Rhesus monkey rhadinovirus 
 Herpesvirus saimiri strain A11 
 Mouse gamma herpesvirus 68 
Polyomaviruses Simian virus 40 
 JC polyoma virus 
 BK polyoma virus 
 Mouse polyoma virus 
 Merkel cell polyoma virus 
 SA12 
Retroviruses Bovine leukemia virus 
 Human immunodeficiency virus 1 
Iridoviruses Singapore Grouper Iridovirus 
Ascoviruses Heliothis virescens ascovirus 
Baculoviruses Bombyx mori nucleopolyhedrosis virus 
Adenoviruses Human adenovirus types 2 and 5 
Unclassified Bandicoot papillomatosis carcinomatosis virus type 1 
 Bandicoot papillomatosis carcinomatosis virus type 2 
 Heliothis zea nudivirus-1 
 
Currently, virally encoded miRNAs have only been observed in DNA viruses or 
viruses that have a DNA stage in their lifecycle, such as the retroviruses.  
Therefore it has been theorized that RNA viruses do not generate miRNAs for 
two reasons; first, that many RNA viruses replicate in the cytoplasm and would 
not have access to the nuclear Microprocessor, and second, because miRNA 
processing would be detrimental to RNA virus genome and viral mRNA integrity 
(44; 104).  However, a miRNA-like small RNA has recently been described for 
West Nile virus (WNV) that appears to upregulate a cellular mRNA that is 
important to WNV replication (107).  Furthermore, nuclear and cytoplasmic RNA 
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viruses have been successfully engineered to express functional miRNAs with 
little or no negative consequence to viral replication (136; 216; 222; 258).  Two 
cytoplasmic RNA viruses, Tick-borne encephalitis virus (TBEV) and Sindbis virus 
(SINV), were engineered to produce miRNAs that were processed in a non-
canonical fashion (216; 222).  These miRNAs were dependent on Drosha and 
Dicer, but independent of the Microprocessor (216; 222).  This work suggested 
an alternative mechanism for Drosha activity such that it becomes partially 
localized to the cytoplasm, and two phosphorylation sites have now been 
identified that putatively regulate Drosha localization (221; 238).  Influenza virus, 
an RNA virus that replicates in the nucleus, was modified to express cellular 
microRNA-124 (miR-124).  A 500-nucleotide sequence encoding the pri-miR-124 
hairpin was inserted into the viral genome.  Viral replication was unaffected, and 
virus-generated miR-124 was completely functional (258).  Additionally, the 
hairpin in the context of the influenza genome was not a target for cleavage by 
the Microprocessor, possibly due to encapsidation of the genome (258).  These 
studies cast doubt on the theory that RNA viruses do not generate miRNAs due 
to deleterious effects on replication, and lack of access to nuclear enzymes.  
Instead, these results suggest that RNA viruses may not generate miRNAs 
because there is no significant evolutionary advantage to doing so. 
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Other virally-derived small RNAs 
Despite the dearth of RNA virus-derived miRNAs, many other small non-coding 
RNAs have been identified.  Deep sequencing of cells infected with influenza 
virus, hepatitis C virus, poliovirus, dengue virus, VSV or WNV has uncovered 
large populations of small RNAs ranging from 10 to 60 nucleotides in length, and 
from low to high abundance (194).  In particular, the small RNAs identified from 
influenza virus are unusual in that they correspond to the 5´-ends of each of the 
eight viral gene segments and range in size from 18-27 nucleotides (199; 255).  
These RNAs possess a 5´-triphosphate instead of a 5´-monophosphate like a 
miRNA, and associate with the viral polymerase complex rather than an Ago 
complex (200).  In the study that first described the influenza virus small viral 
RNAs (svRNA), the authors posit that the segment-specific svRNAs may serve to 
regulate the switch between transcription and replication during viral infection 
(199).  Accordingly, the authors showed that the peak of svRNA production 
corresponds with a dramatic shift to replication, and that the svRNAs physically 
associate with the complete influenza virus polymerase (199).  They suggest a 
model wherein the svRNA binds the polymerase and either serves to reconstitute 
a double stranded promoter on the viral RNA segment, or by binding the 
polymerase, alters the replication activity of the complex (199; 200). 
 
Virally-encoded small RNAs have also been implicated in interfering with the 
cellular antiviral response to infection.  In response to various forms of 
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environmental stress including viral infection, the cell initiates the formation of 
dense cytoplasmic aggregates called stress granules, which are sites of mRNA 
triage.  SeV is known to synthesize RNA from its Tr region (143).  It has been 
demonstrated that a mimetic of the SeV Tr region binds a cellular stress granule 
component, TIAR, and potentially sequesters it, preventing stress granule 
formation in response to SeV infection (110). 
 
Hypothesized functions for the RSV LeC and Tr small RNAs 
Similarly to the influenza virus model, it is possible that either of the small LeC or 
Tr RNAs may bind the RSV polymerase and behave as feedback molecules to 
influence the switch from transcription to replication.  In addition, the small Tr 
RNA may also behave similarly to the Tr RNA of SeV in the context of stress 
granule formation.  Previously it has been shown that wt RSV subverts or blocks 
the cellular stress granule response to infection (96).  However, infection with a 
mutant virus that contains the 44-nt LeC region in place of the Tr region (LeC 
virus) leads to the formation of stress granules (96).  This finding implicates the 
Tr region and possibly the small Tr RNA in the subversion of the stress granule 
response by RSV. 
 
In the following pilot studies we set out to characterize the structure and function 
of the small LeC and Tr RNAs.  We examined whether overexpression of the 
small RNAs has an effect on RSV transcription and replication.  We also sought 
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to determine whether expression of the small Tr RNA could block stress granule 
formation induced by infection with LeC virus. 
 
Results 
 
A1.1  The small LeC and Tr RNAs can be expressed under the control of a 
T7 promoter  in BSR-T7/5 cells. 
To test whether the small LeC and Tr RNAs play a role in RSV infection, 
plasmids were designed to express these RNAs under the control of a T7 
promoter.  Le and TrC sequences from positions 3 to 27 were cloned into a 
plasmid between a T7 promoter and a Hammerhead ribozyme to generate the 
3´-ends of the RNA, to express 25-nucleotide LeC and Tr RNAs.  A scrambled 
sequence based on Le was cloned as a control (Sequences shown in Table 1, 
Materials and Methods).  The plasmids were transfected into BSR-T7/5 cells, 
baby hamster kidney cells (BHK) stably expressing T7 polymerase (19), and the 
cells were coinfected with RSV or mock-infected 24 hours later.  RNA was 
isolated 24 hpi and analyzed by urea-acrylamide Northern blot.  Using probe g7-
34 to detect LeC-containing RNA, the small ~25 nt LeC RNA was detected from 
mock-transfected and RSV-infected control cells (Figure A2, B, panel i, lane 2).  
When cells were transfected with the LeC overexpression plasmid and mock-
infected, LeC RNA of the appropriate size was generated (compare lane 4 to 
lane 2).  When cells were transfected with the LeC overexpression plasmid and 
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infected with RSV, the levels of the LeC RNA appeared to be increased, 
confirming overexpression of the small RNA (lane 5).  RNA isolated from cells 
transfected with a scrambled control plasmid shows no effect on the native 
expression of LeC RNA from RSV (lane 3).  No LeC RNA was detected from 
mock treated cells (lane 1).  The same set of RNA samples was also probed with 
ag5-32 to detect Tr-containing RNA (panel ii).  The ~25 nt Tr RNA was detected 
from mock-transfected/ RSV-infected cells (lane 2).  Transfection with the 
scrambled control did not have an effect on the native expression of the Tr RNA 
in RSV-infected cells (lane 3).  In cells transfected with the Tr overexpression 
plasmid and mock-infected, a Tr-containing RNA of the appropriate size was 
detected at high levels (lane 4), and overexpression of the Tr RNA was 
confirmed in the context of RSV infection (lane 5).  These results verify that we 
are able to overexpress the small LeC and Tr RNAs in the context of RSV 
infection.  Therefore we can use these overexpression plasmids to explore the 
effect of these small RNAs on virus and host. 
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Figure A2; The small LeC and Tr RNAs can be overexpressed in BSR-T7/5 
cells.  RNA isolated from cells transfected with the overexpression plasmids and 
mock or RSV-infected (as indicated by - /+) was analyzed by urea-acrylamide 
Northern blot.  (i) Blot was probed with g7-34 to detect LeC-containing RNA.  (ii) 
Blot was probed with ag5-32 to detect Tr-containing RNA.  RNA isolated from 
mock-transfected, RSV-infected cells was migrated as a control for native 
expression of the small RNAs (lane 2).  RNA from cells transfected with the 
scrambled control plasmid (scr) and infected with RSV is shown in lane 3.  Lanes 
4 and 5 show expression of the small RNAs from plasmid alone and in the 
context of RSV infection, respectively. 
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A1.2  Expression of the small RNAs does not have a noticeable effect on 
cytopathic effect induced by coinfection with wildtype RSV. 
Having confirmed that we can overexpress the small RNAs in BSR-T7/5 cells, we 
wanted to test whether overexpression of the small RNAs alone had an effect on 
cell morphology, or altered the cytopathic effect (CPE) induced by RSV infection.  
RSV spreads in culture via fusion to adjacent cells, forming large clusters of 
multinucleate cells called syncytia.  This process is mediated by the RSV F 
glycoprotein, which is expressed on the surface of the budding viral particle.  
BSR-T7/5 cells were transfected with the overexpression plasmids (~60% 
transfection efficiency) and coinfected with wt virus 24 hours post transfection, 
and cell morphology was observed 24 hpi.  Mock-transfected/ mock-infected cells 
are shown as a control demonstrating the normal morphology of the cells (panel 
i, left).  Examples of syncytia are indicated with arrowheads in mock-transfected/ 
RSV-infected cells (Figure A3, panel i, right).  If overexpression of the small 
RNAs had an effect on CPE, a difference in the size or number of syncytia would 
be observed.  Transfection alone appears to have a deleterious effect on the 
cells, as cell rounding and thinning of the monolayer is observed (compare left 
panels ii and iii with panel i).  However, no changes in syncytia formation were 
visible in infected cells overexpressing the LeC and Tr small RNAs, as compared 
to mock-transfected cells (compare right panels (ii) and (iii) to panel i).  
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Figure A3; Effect of overexpression of LeC and Tr RNAs on cell 
morphology and RSV syncytia formation.  BSR-T7/5 cells were transfected 
with overexpression plasmids and either mock-infected or infected with RSV at 
an MOI of 3, 24 hours post transfection.  Cell morphology was observed by light 
microscopy and imaged 24 hpi with the 20X objective.  Cells in left panel were 
mock-infected, while cells in the right panel were infected with wt RSV.  Black 
arrowheads indicate examples of RSV syncytium formation.  (i) Mock-transfected 
cells (ii) Cells transfected with the plasmid overexpressing the LeC RNA (iii) Cells 
transfected with the plasmid overexpressing the Tr RNA (iv) Cells transfected 
with the scrambled control plasmid. 
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A1.3  Overexpression of the small RNAs impacts RSV RNA and protein 
expression. 
After observing CPE, the cells were harvested and total cell lysates were 
collected for protein and RNA analysis.  RNA was extracted and migrated on 
agarose-formaldehyde gels and probed for genome, antigenome and NS1 
mRNA.  Note that there was no loading control for these blots, however, all the 
gels were run at the same time using the same RNA samples, therefore it is 
possible to compare the relative levels of RNA expression between blots.  
Overexpression of the LeC sRNA resulted in an increase in antigenome 
compared to the scrambled control (Figure A4, panels i and ii, compare lane 5 to 
lane 3).  In contrast, LeC sRNA did not have a similar effect on the relative levels 
of genome and NS1 mRNA compared to the scrambled control (panels ii and iii, 
compare lane 5 to lane 3).  Overexpression of the Tr sRNA did not result in an 
obvious increase in the levels of antigenome (panels i and ii, compare lane 7 to 
lanes 3), and also did not have an impact on the levels of genome and NS1 
mRNA (panels ii and iii, compare lanes 7 and 3).  Unfortunately, transfection with 
the scrambled control plasmid reduced the levels of genome, antigenome and 
NS1 mRNA as compared to the mock-transfected, RSV-infected controls 
(compare lane 3 to lane 2, all panels).  Therefore these results must be 
interpreted with caution because the negative control was unreliable.  
Additionally, the T7 polymerase produces extraneous RNA from the expression 
vectors, as indicated by high levels of background detected throughout the lane 
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(panel i, lanes 4 and 5; panel ii, lanes 6 and 7), which may alter RSV infection 
kinetics or otherwise impact the cellular response to infection, possibly skewing 
the results.  Therefore, it is impossible to make any firm conclusions about the 
data. 
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Figure A4; Overexpression of the LeC and Tr RNAs appears to alter the 
levels of RSV transcription and replication.  RNA isolated from cells 
transfected with the overexpression plasmids and mock-infected or infected with 
RSV at an MOI of 3 was analyzed by agarose-formaldehyde Northern blot.  (i) 
Blot probed with g7-34 to detect antigenome sense RNA. (ii) Blot probed with 
ag5-32 to detect genome sense RNA. (iii) Blot probed with g504-540 to detect 
NS1 mRNA.  Antigenome, genome and NS1 mRNA are indicated.  Note that 
lanes 6 and 7 were run on the same gel for each blot.  Background bands are 
indicated by asterisks. 
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Protein was extracted from the cell lysates and subjected to Western blot 
analysis to determine whether overexpression of the small RNAs had an effect 
on RSV protein expression.  Blots were probed with a polyclonal anti-RSV 
antibody, which detects the full complement of RSV proteins.  As a loading 
control, blots were stripped and reprobed for alpha-tubulin.  RSV protein 
expression from mock-transfected cells infected with RSV is shown in lane 2 
(Figure A5, both panels).  Overexpression of the LeC RNA did not have a notable 
effect on RSV protein expression (panel i, lane 5).  Note that although there is a 
decrease in RSV proteins, there is a corresponding decrease in tubulin.  
However, overexpression of the Tr RNA does appear to increase RSV protein 
expression, which is most easily discerned by comparing the band indicated with 
the dot in lanes 5 and 2 (panel ii).  As above, interpretation of these results is 
hindered by lack of a good control, as transfection with the scrambled control 
plasmid also appears to increase RSV protein expression, although in this 
instance the tubulin levels also appear to be increased (panels i and ii, lane 3). 
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Figure A5; Overexpression of the Tr RNA appears to increase RSV protein 
expression.  Protein was extracted from cells transfected with overexpression 
plasmids and infected with RSV at an MOI of 3.  Protein samples were subjected 
to 10% SDS-PAGE and analyzed by Western blot.  Blots were probed with a 
polyclonal RSV antibody to detect viral proteins, and reprobed with an antibody 
to alpha-tubulin as a loading control.  Controls included protein extracted from 
mock-transfected, mock-infected cells (lane 1), mock-transfected, RSV-infected 
cells (lane 2), and cells transfected with the scrambled control plasmid and RSV-
infected (lane 3).  (i) Protein extracted from cells overexpressing LeC RNA and 
either mock (lane 4) or RSV-infected (lane 5).  (ii) Protein extracted from cells 
overexpressing Tr RNA and either mock (lane 4) or RSV-infected (lane 5).   
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A1.4  LeC virus does not appear to induce stress granules in BSR-T7/5 
cells. 
Previously it was shown that wt RSV blocks the stress granule response during 
infection.  A mutant virus containing LeC sequence in place of the Tr region (LeC 
virus) was shown to have a reduced ability to subvert the stress granule 
response compared to wt RSV (96).  Additionally, the Tr sequence of SeV has 
been shown to be able to bind to TIAR, a stress granule protein, and block stress 
granule formation (110).  Therefore, we wanted to explore the relationship 
between the small Tr RNA and the cellular stress response by testing whether 
overexpression of the Tr RNA could rescue the LeC virus’ ability to block stress 
granule formation.  These experiments were performed in BSR-T7/5 cells 
because we already showed that the Tr RNA could be overexpressed in these 
cells without the need for coinfection with MVA-T7, as vaccinia virus has been 
shown to induce antiviral granules (227).  The cells were either mock-treated or 
infected with LeC virus at an MOI of ~1, fixed at 24- and 48-hpi, permeabilized, 
and stained for eIF3, a stress granule marker, RSV N protein to detect infected 
cells, and a nuclear stain, DAPI.  As a control for stress granule formation, one 
well of mock-infected cells was treated with sodium arsenite prior to fixation to 
induce oxidative stress.  Unfortunately, 2-hour arsenite treatment causes 
significant cell death and rounding, while inducing eIF3-containing granules 
(Figure A6, panel ii).  A shorter, 30-minute arsenite treatment was also tested, 
however, while the cells still maintained a healthy morphology, no eIF3-
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containing granules were observed (data not shown).  Normal diffuse 
cytoplasmic distribution of eIF3 is observed in mock treated cells (panel i).  
Unexpectedly, virtually no stress granules could be detected in LeC virus-
infected cells at either time point (24 hpi- panels iii and iv, 48 hpi- panel v).  Some 
punctate eIF3 staining can be observed in panel (iv), however it is unclear if 
these are stress granules or a different type of antiviral granule. 
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Figure A6; LeC virus does not induce eIF3-containing stress granules in 
BSR-T7/5 cells.  Cells were mock-treated or infected with LeC virus at an MOI of 
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~1.  Cells were fixed at 24- and 48- hpi, permeabilized, and stained with an anti-
eIF3 antibody (green), and an anti-RSV N antibody for RSV infection (red).  Cells 
were incubated with a fluorescent secondary antibody cocktail containing DAPI to 
stain the nucleus (blue). (i) Mock treated cells showing the diffuse cytoplasmic 
distribution of eIF3. (ii) Cells treated with 0.5 mM sodium arsenite for 2 hours 
prior to fixation, showing punctate staining of eIF3. (iii) LeC virus infected cells 
showing RSV N-containing viral inclusion bodies (bright aggregates), 24 hpi, first 
field, and (iv) second field. (v) LeC virus infected cells, fixed 48 hpi.  Images are 
individual slices taken on a Zeiss Axiovert fluorescence microscope using the 
40X objective with oil immersion. 
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Discussion 
 
Summary of Results 
In these preliminary experiments, we demonstrated that it is possible to 
overexpress the small LeC and Tr RNAs under the control of T7 in BSR-T7/5 
cells.  Overexpression of these RNAs did not have a significant impact on RSV 
syncytium formation, eliminating CPE as an easily observable phenotype to 
discern the effect of these RNAs on RSV infection.  However, we showed that 
the LeC and Tr RNAs might have an effect on levels of RSV replication and 
protein expression.  Unfortunately, we were unable to explore the relationship 
between the Tr RNA and stress granule formation since the LeC virus failed to 
induce stress granules in BSR-T7/5 cells.   
 
The effect of the LeC small RNA on transcription and replication 
One possible model for the function of the LeC small RNA is that it functions as a 
feedback molecule that binds the polymerase and influences the switch between 
transcription and replication, similar to the model proposed for influenza virus 
small RNAs (199).  If this model is correct, overexpression of the LeC RNA in the 
context of RSV infection would be expected to result in an increase in replication, 
as measured by the level of antigenome and correspondingly, genome, while the 
levels of transcription might remain unchanged or even decrease.  As compared 
to the scrambled control, an increase in antigenome was detected, as well as a 
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modest increase in genome.  No appreciable change in the level of transcription 
was observed (panel iii).  One explanation for this is that the RNA was isolated at 
24 hpi; at this time point in infection transcription products will be saturated.  
Moreover, during infection transcription is the dominant event, thus a minor 
decrease in the level of transcription may not be distinguishable.  Alternatively, 
rather than influence a switch between transcription and replication, the LeC 
RNA may somehow interact with a nonviable replicase, allowing it to become 
active.  If this was the case, then the level of transcription would not be affected, 
but the level of replication would increase.  Silencing the LeC RNA may therefore 
be expected to drastically reduce levels of genome.  This could be pursued by 
transfecting in an LNA/DNA oligonucleotide that is complementary to the LeC 
RNA in order to bind and block native expression of the RNA during infection.   
 
The effect of the small Tr RNA on stress granule formation 
Concerning the hypothesized role of the Tr RNA in the stress response, 
unfortunately, we were unable to test whether the Tr RNA is involved in 
subverting the stress granule formation.  Despite documented eIF3-containing 
granule formation in response to LeC virus infection in HEp-2 cells (96), we were 
unable to recapitulate this effect in BSR-T7/5 cells.  This disparity may point to a 
host-specific response to infection.  In addition, it has not been demonstrated that 
BSR-T7/5 cells are able to form stress granules, although they are derived from 
BHK cells, which are known to form stress granules.  Another possibility is that 
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the LeC virus phenotype reverted to wt, a phenomenon observed due to 
instability of the LeC phenotype, and accomplished by a single substitution at 
position 12 relative to the 5´-end of the genome, from ‘A’ to ‘U’ (96).   
 
Future Directions 
 
Because we were unable to confirm whether the BSR-T7/5 cells were able to 
mount a stress response, it is important to repeat the experiments performed 
here in a cell line that is known to form stress granules.  The A549 human airway 
cell line is more authentic than the BSR-T7/5 cells with regards to RSV infection.  
This would necessitate recreating the small RNA expression vectors under the 
control of a different promoter, such as the cytomegalovirus (CMV) promoter.  In 
addition, because of the toxicity of lipofectamine transfection, it would be 
important to perform a transfection time course for small RNA expression to 
determine the best time to subsequently infect the cells, to minimize the length of 
time the cells are in culture.  The peak of sRNA expression may fall within 12-18 
hours, thus cells could be infected much earlier.  Additionally, the infection could 
be halted and the cells fixed between 12 and 18 hpi, as stress granules have 
been shown to form within this time frame (96).  The sodium arsenite treatment 
must also be optimized such that stress granules are induced but the cells still 
maintain a normal morphology.  Increasing the concentration of sodium arsenite 
and decreasing the length of time of the treatment may achieve this.  
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Implementing these controls may aid in providing a clearer picture of the Tr 
region’s relationship to stress granule formation. 
 
Remaking the small RNA vectors under the control of a CMV promoter may also 
subvert some of the problems that arose from T7 expression of these RNAs.  As 
noted in the results, in addition to the small LeC and Tr RNAs, extraneous RNA 
products are generated.  These RNAs are likely T7 transcripts that are not 
efficiently cleaved by the ribozyme.  The T7 polymerase also requires a ‘GGG’ 
motif to efficiently initiate, and will therefore add sequence at the 5´-end of the 
small RNAs that are expressed.  Another solution to these problems would be to 
generate PCR products using a primer that corresponds to the exact 3´-end of 
the small RNA, and a primer corresponding to the 5´-end with a T7 promoter 
sequence added, that overlap.  The ‘GGG’ motif of the T7 promoter can be 
removed which will reduce efficiency of the promoter (109), however, a high 
concentration of the PCR product could be transfected, ensuring expression of a 
precise small RNA. 
 
It is disconcerting that the scrambled control plasmid had an effect on RSV RNA 
and protein expression, thus a better control must be identified.  A greater 
number of scrambled plasmids could be tested to discover one that has no effect 
on RSV RNA and protein expression.  An empty vector control should also be 
included to control for the effect of DNA transfection.  In general, it would also be 
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important to confirm that expression of the small RNAs are not activating an IFN 
response, which would then impact RSV infection.  This could be tested by 
probing Western blots of protein samples from cells overexpressing the small 
RNAs for phosphorylated IRF-3 or phosphorylated-PKR.  
 
Going forward there are several experiments that could be performed to better 
understand the role of the small LeC and Tr RNAs in RSV infection.  It would be 
interesting to examine the kinetics of viral small RNA production as well as 
precise determination of the sequences of these RNAs.  A timecourse of infection 
should be carried out to determine the peak of expression of the small RNAs, as 
it compares to RSV transcription and replication, and protein expression.  
Additionally, assumptions were made about the RNA length and sequence in 
order to proceed with the experiments described within this chapter.  We 
postulated that the RNA was predominantly 25 nucleotides and initiated from 
position +3, with a 5´-triphosphate end.  These assumptions were based on the 
data from the primer extension analysis and small RNA Northern blot analysis 
(Chapter 1).  However the sequence could be determined with more accuracy 
using a method commonly used to clone miRNAs (107; 154).  Briefly, the small 
RNAs could be migrated on high percentage urea-acrylamide gels, the bands 
could be extracted, and the RNA isolated and polyadenylated.  The 
polyadenylated RNA would then be subjected to first strand cDNA synthesis 
using a poly(dT) primer.  The resulting cDNA would be amplified by PCR using a 
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forward primer designed to sit within the predicted small RNA sequence and 
oligo(dT) as a reverse primer.  PCR products would then be cloned and 
sequenced.  It is likely that the 3´-ends of the RNAs are heterogeneous, 
however, it would be informative to confirm whether the RNAs are initiated from 
position +3 or position +1.  
 
Since the model posits that LeC RNA binds the polymerase and acts as a 
feedback molecule for transcription, it is important to pursue whether the RSV 
polymerase contains a binding site for the small LeC RNA.  This could be done 
similarly to the studies on influenza (199; 200) by cotransfecting tagged L-P and 
a small LeC RNA mimetic into cells, and then coimmunoprecipitating for the tag, 
followed by small RNA Northern blot to detect the LeC RNA.  This would confirm 
that the polymerase does in fact bind the small RNA.  If these studies are borne 
out, then they could be repeated using L truncation mutants to narrow down the 
domain, and single amino acid substitutions to narrow down the residues that are 
directly involved in binding the RNA.   
 
In the event that the LeC RNA does not bind the RSV polymerase, then we could 
pursue whether the RNA has other cellular or viral binding partners that may 
implicate its function in transcription and replication.  It would also be interesting 
to identify cellular binding partners of the Tr small RNA.  One approach that has 
been used for West Nile virus (107) is to conduct a “fishing experiment” using 
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DNA oligonucleotides representing the small RNAs to fish out cellular sequences 
from mock and infected cell extracts.  Reverse transcription polymerase chain 
reaction (RT-PCR) would be carried out on total cell extracts from mock and 
RSV-infected A549 cells using a Tr oligonucleotide that contains restriction sites 
for cloning.  This will amplify any sequence the Tr RNA binds to.  The cDNA 
generated would be purified, tailed, cloned, and sequenced, and sequencing hits 
would be analyzed using BLAST (NCBI).  To identify RNA-protein binding 
interactions, an approach that has been used successfully for Helicobacter pylori 
(212) is aptamer-tagging of the small RNAs followed by affinity chromatography 
and mass spectrometry.  A small tag could be added to the 3´-ends of small RNA 
mimetics, which would then be incubated with A549 cell extracts.  Lysates would 
be purified on a column to bind the aptamer, RNA-protein complexes eluted, and 
the proteins would be migrated on a gel and analyzed by mass spectrometry.  
These techniques could potentially provide a reasonable list of cellular binding 
partners for both the Tr and LeC RNAs, whose function during RSV infection 
could then be fully explored. 
 
In conclusion, the data presented in this appendix suggests that the small LeC 
and Tr RNAs play a role in RSV replication, by potentially influencing the activity 
of the polymerase.  More work needs to be done to confirm and expand on these 
findings, and the mechanism of how these RNAs function needs to be elucidated.  
However, the prospect that RSV generates small RNAs that behave in a 
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regulatory fashion is novel in the field of single stranded, negative sense RNA 
viruses and should be investigated. 
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Appendix 2: Polymerase capping mutants terminate mRNA synthesis at 
~40 nucleotides 
As noted in the introduction, the RSV L protein is thought to contain all the 
enzymatic domains necessary for viral transcription and replication.  Capping is 
an important activity of the polymerase that is essential to transcription.  Studies 
in VSV have demonstrated that capping is necessary for elongation of transcripts 
(148; 234).  Additionally, studies of an RSV capping inhibitor showed that failure 
of transcripts to become capped resulted in termination of mRNA synthesis at 
~50 nucleotides (152).  Sequence alignment of the RSV L protein with other NNS 
virus L proteins suggests that capping activity resides within a domain called 
conserved region V (20; 66; 147; 159; 178; 228).  To identify the amino acid 
residues in conserved region V that are critical for polymerase capping activity, 
single alanine substitutions were made at six different residues thought to be 
important based on conservation of these residues in other NNS viruses (69; 
148; 189; 204).  These mutants were tested for RNA synthesis in the 
minigenome system using a non-replicating, wt minigenome construct (Figure 
A7, panel A).  RNA from transfections with these mutants was isolated and 
migrated on urea-acrylamide Northern blots.  The blots were probed with an end-
labeled oligonucleotide corresponding to positions 12-31 of the first reporter gene 
to detect mRNA initiated from the first GS signal. 
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The majority of the products synthesized by a wt polymerase in this assay were 
larger than 150 nt, with a dominant band between 500 and 1000 nt, 
corresponding to polyadenylated CAT 1 mRNA (lane 1).  As a negative control 
for RNA synthesis, RNA was isolated from transfections with the polymerase that 
has a mutation in the catalytic RNA synthesis domain (N812A, lane 2).  All of the 
mutants displayed a varying degree of deficiency in generating full-length mRNA 
as compared to the wt (compare lanes 3-8 to lane 1).  However, the mutants that 
were most noticeably deficient generated a short transcript, ~40 nt in length 
(lanes 3, 7, and 8).  Low levels of this short RNA were also detected from wt, as 
well as the mutants that were still able to produce longer RNAs (lanes 1, 4, 5, 
and 6).  Thus, this result indicates that polymerase mutants that are unable to 
efficiently cap mRNA synthesized from the GS signal terminate RNA synthesis at 
~40 nt.  This contrasts with the results presented in Chapter 1 indicating that 
RNA initiated from the +3 initiation site in the Le is terminated after synthesis of 
~25 nt, suggesting failure to cap the nascent transcript from position +3 may not 
be the checkpoint that causes the polymerase to terminate RNA synthesis.  
Alternatively, this result may indicate that there is a fundamental difference in 
polymerase initiation within the Le region and polymerase initiation from a GS 
signal. 
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Figure A7; Determination of the size of prematurely terminated RNA 
initiated from a GS signal.  Adapted from Deflube et al, 2014 (48) (A) 
Minigenome schematic showing the hybridization position of the probe used for 
this Northern blot analysis.  (B) Urea-acrylamide Northern blot analysis of RNA 
isolated from minigenome transfections with polymerase mutants containing 
substitutions in the putative capping domain.  Gel lanes containing the markers 
were removed and stained with ethidium bromide, and realigned with the blot for 
sizing.  Laure Deflubé generated the polymerase mutants and performed the 
minigenome transfections and RNA isolations.  I performed the Northern blot 
analysis.   
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Appendix 3: Development of an assay to determine RNA 5´-end structures 
To test the possibility that RNA initiated from position +3 is capped, we attempted 
to digest the RNA with tobacco acid pyrophosphatase (TAP), which is an enzyme 
that digests 5´-cap structures, leaving a 5´-monophosphate on the RNA.  If the 
RNA initiated from position +3 were capped, treatment with TAP, followed by 
treatment with exonuclease, which digests 5´-monophosphorylated RNA, should 
ablate the RNA (Figure A8, panel A).  To test the efficacy of these enzymatic 
treatments, primer extension analysis was performed on mRNA initiated from the 
NS1 GS signal, which is capped.  As explained in Chapter 2, primer extension 
analysis of capped RNA often results in the detection of a doublet due to 
inefficient cDNA extension through the cap by the reverse transcriptase.  
Treatment of the mRNA with TAP would therefore be expected to ablate the 
upper band of the doublet (representing capped RNA), and further treatment of 
the RNA with exonuclease should digest the remaining RNA.  As expected, 
mock-treated RNA migrates as a doublet (panel B, lane 2, indicated with a blue 
ellipse).  TAP treatment reduced the upper band of the doublet, however overall 
levels of RNA were also reduced (compare lane 4 to lane 2).  Further treatment 
with exonuclease did not completely ablate the RNA, suggesting that either 
decapping by TAP was inefficient, or exonuclease digestion was incomplete 
(lane 6).  Because levels of RNA were very low post-treatment, and because 
digestion of decapped mRNA was incomplete, we were unable to use this 
approach to examine RNA initiated from position +3.  Time did not permit 
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optimization of this technique, however measures could be taken to increase 
RNA recovery after each enzymatic treatment, which may facilitate proper 
analysis of treated RNA.  Moreover, both TAP and exonuclease treatments can 
be optimized to ensure efficient digestion of RNA.  
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Figure A8; TAP and Exonuclease digestion is inefficient on a known 
capped mRNA.  (A) Enzymatic digestion scheme showing four RNAs with 
different ends and how these RNAs would be expected to be affected by 
treatment.  Digestion of RNA is indicated by a dashed line.  (B) Primer extension 
analysis of RNA isolated from RSV-infected cells, treated with TAP and 
Exonuclease.  RNA was mock-treated (lanes 1 and 2), treated with TAP (lanes 3 
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and 4), or treated with Exonuclease following treatment with TAP (lanes 5 and 6) 
and analyzed by primer extension using a primer that corresponded to genome 
positions 91-113 to detect initiations from the first GS at +45.  Doublet band 
representing the cap structure is indicated with a blue ellipse (lane 2). 
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